ANNUAL REPORT 2008-09 - parliament.qld.gov.au · ANNUAL REPORT 2008-09 300 Herston Road, Herston...

ANNUAL REPORT

2008-09300 Herston Road, Herston QLD 4006, Australia

P: (+61) 7 3362 0222 F: (+61) 7 3362 0111 www.qimr.edu.au [email protected]

ANNUAL REPORT

2008-09

QIM

R A

NN

UA

L RE

PO

RT 2008-09

QIMR - Annual Report 2008-2009 QIMR - Annual Report 2008-2009

AbOUT UsQIMR is one of Australia’s largest and most successful medical research institutes. Our researchers are investigating the genetic and environmental causes of more than 40 diseases as well as developing new diagnostics, better treatments and prevention strategies. The Institute’s diverse research program extends from tropical diseases to cancers to Indigenous health, mental health, obesity, HIV and asthma.

OUR VIsION better health through medical research.

OUR MIssION To prevent and cure disease through research.

OUR PHILOsOPHy QIMR supports scientists who perform world-class ethical medical research aimed at improving the health and well-being of all people.

OUR LOgO The QIMR logo is comprised of superimposed benzene rings which symbolise one of the fundamental molecular arrangements of the chemicals which make up living things.

Director – Professor Michael good AO

Deputy Director – Professor Adèle green AC

www.qimr.edu.au | [email protected]

1800 993 000

Cover Image: Close up of neuron network

Inside Cover Image: Rebekah Brennan, PhD student Cellular Immunology Laboratory - Immunology Division

300 Herston Road, Herston QLD 4006, AustraliaT: 1800 993 000 E: [email protected] www.qimr.edu.au

Project Manager sarah Tennant

Compilation Jann O’Keefe Editing sarah-Jane Matthews

Design Rowland

Graphic Support Mimi Kersting

Photography Heather Matthews Tony Phillips

Published October 2009

Copies can be obtained by phoning 1800 993 000 or [email protected]

Online version available at www.qimr.edu.au

QIMR - Annual Report 2008-2009 • 1

World-class

ethical medical

research aimed

at improving

the health and

well-being of

all people

CONTENTS

Organisational structure 2

QIMR at a glance 4

Research highlights 6

Chairman’s report 9

Members of Council 10

Director’s report 12

Patron’s message 15

Research Divisions 16

Genetics and Population Health 18

Immunology 34

Cancer and Cell Biology 47

Infectious Diseases 59

Joint Research 74

Corporate Division 80

Trust report 90

Members of Trust 91

Postgraduate training 96

Completed students 98

Student awards 99

Awards 100

Grants and funding 103

Publications 106

Lectures 130

Staff 141

Research students 150

Acronyms 152

2 • QIMR - Annual Report 2008-2009 • QIM nual Report 2008-20092 2008-202008-200MR - AnnMR nnM 0

Corporate Services External RelationsScientifi c Services

Administrative

Support

Science CommunicationStores Systems ImplementationAdministrative SupportBuilding Services

Regulatory AffairsSafety

HistotechnologyQ-Gen

Graphic SupportAnimal WelfarePurchasing

DNA & Peptide FacilityRecords & Information

FundraisingFlow CytometryBusiness Development

Culture & Media Services

Information Technology

Business ServicesGlassware ServicesHuman Resources

Animal FacilityFinance

Grants Operational Services

Transgenic Breeding

Experimental Holding

General Manager

ORGANISATIONAL

STRUCTURE

2 • QIMR - Annual Report 2008-2009

QIMR - Annual Report 2008-2009 • 3 QIMR - Annual Report 2008-2009 • 3

Strategic Science

Committee (Advisory)

Clinical & Translational Research Committee

(Advisory)

Assistant

Director

Assistant

Director

Senior Executive

Team (Advisory)

Genetics & Population

Bacterial Vaccines Cellular Immunology Iron Metabolism Cancer Genetics

Molecular Vaccinology Leukaemia Foundation Indigenous HealthMalaria Drug Resistance

Immunology & Infection QCF Transgenics Cancer & Population

StudiesMalaria Biology

Clinical Immunohaematology Signal Transduction OncogenomicsProtein Discovery Centre

Molecular Immunology Molecular Pathology Molecular PsychiatryHIV Molecular Virology

Bone Marrow Transplantation

Radiation Biology & Oncology Genetic EpidemiologyParasite Cell Biology

Tumour ImmunologyRBWH Foundation

Conjoint GastroenterologyScabies

Dendritic Cells & Cancer Drug Discovery Group

Molecular Epidemiology

Neurogenetics

Gynaecological Cancer Group

Molecular Cancer Epidemiology

Familial Cancer

Qld Statistical Genetics

Cancer Control Group

Skin Cancer Carcinogenesis

Helminth Biology

EBV Biology Hepatic FibrosisClinical Tropical Medicine

Cancer Immunotherapy Membrane Transport

Immunovirology

Molecular Parasitology

Mosquito Control

Molecular Genetics

Bacterial Pathogenesis

EBV Molecular Biology


Infl ammatory Bowel Disease

DIRECTORDEPUTY

DIRECTOR

ImmunologyInfectious Diseases Cancer & Cell Biology Mental Health Research

Epigenetics

Mental Health Research


New treatment patents

Vaccine patents

Delivery platform patents

Diagnostic patents

Drug target patents

Research service agreements

Clinical trial agreements

Commercialisation agreements

Intellectual property agreements

License agreements

Others

PATENT PORTFOLIO BY CATEGORY RESEARCH AGREEMENTS

Other granting bodies

The Atlantic Philanthropies

Queensland Cancer Fund

National Institutes of Health

National Health and Medical

Research Council

QIMR COMPETITIVE GRANT REVENUE 2000-2009 – FUNDING RECEIVED/AWARDED

2001

10

20

30

40

50

60

2002 2003 2004 2005 2006 2007 2008 2009

QIMR AT A GLANCE

Supporting scientists who perform world-class medical

research aimed at improving the health and well-being

of all people.

$ Millions


Donations & Gifts Sponsorship

Event Revenue Bequests/Gifts in Kind

2007 2008 2009

Staff Students

STAFF NUMBERS

20062005

100

400

200

500

600

300

2007 2008 2009

SCIENTIFIC PUBLICATIONS

50

200

100

250

300

350

400

450

150

2005 2006 2007 2008 2009

$ Millions

Grants Fellowships and scholarships

NHMRC FUNDING

2

4

14

6

16

8

18

10

20

12

2005 2006

$ Millions

COMMUNITY SUPPORT

2004/05 2005/06 2006/07 2007/08 2008/09

1.0

6.0

3.0

2.0

7.0

8.0

4.0

5.0

RESEARCH HIGHLIGHTS• Clinical trials begin for a vaccine to combat one of

the world’s biggest disease killers – the Group A

Streptococcus (GAS) bacteria.

• Donor antigen presenting cells found to cause

graft versus host disease in bone marrow

transplantation patients.

• The genetic risk of schizophrenia found to be the

result of thousands of common genetic variations

common to schizophrenia and bipolar disorder.

• Identifi ed four new arboviruses from Antarctica.

• Mapped the major chromosomes of Giardia duodenali;

a common parasite that is often contracted from

untreated water sources causing diarrhoea and vomiting.

• Mapped the genome of Schistosoma japonicum;

the fi rst fl atworm to be mapped.

• Mitigated dengue risk in areas in southern Vietnam

through the use of community based, biological

control interventions to control the number of dengue

spreading mosquito larvae.

• Showed that the bacteria Wolbachia effectively

shortens the life cycle of the mosquito Aedes

aegypti, preventing it from spreading dengue fever.

• Identifi ed elevated serum hyaluronic acid levels as a

new diagnostic marker for the detection of cirrhosis in

patients with haemochromatosis, removing the need

for liver biopsy in 60% of patients.


QIMR - Annual Report 2008-2009 • 7 Q IMIMR - Annual Report 2008-2009 • 7

CANCER RELATED

RESEARCH HIGHLIGHTS• Contributed to the development of a topical

treatment for skin cancer by demonstrating the

anti cancer properties of PEP005, found in the

common radium weed.

• Identifi ed the reason women with BRCA1 gene

expression are at a higher genetic risk of developing

breast cancer.

• Identifi ed two gene variants that double the risk

of developing melanoma.

• Discovered women who eat a diet high in fats,

processed and red meats may be at an increased

risk of ovarian cancer.

• Demonstrated that year-round regular sunscreen use

for prevention of skin cancers produces cost savings

for health providers in Australia.

• Showed that a diet characterised by relatively

low intakes of meat, fried foods and full-fat dairy

products halved the risk of developing new cutaneous

squamous cell carcinomas (SCC).

• Found the combined effect of obesity, acid refl ux

and smoking increased the risk of developing

oesophageal cancers.

• Identifi ed additional breast cancer susceptibility

genes through genome wide studies.

AWARDS AND

ACHIEVEMENTS

• Professor Emma Whitelaw, Senior Principal Research

Fellow, received one of only 12 Australia Fellowships

which will provide a $4 million injection of funding to

further her research in the fi eld of epigenetics.

• Professor Dave Kemp, Head of QIMR’s Scabies

Laboratory, was awarded the Order of Australia Medal

in recognition of his service to medical research as a

molecular biologist, particularly in the area of tropical

health and infectious diseases, and for contributions

to Indigenous health.

• Professor Michael Good completed three years as

Chairman of the NHMRC Council.

• Former QIMR Director, Professor Lawrie Powell awarded

the 2008 Distinguished Achievement Award of the

American Association for the Study of Liver Diseases.

He is the only Australian ever to receive the award and

only the third recipient outside the USA in 53 years.

• Dr Stuart Macgregor awarded the 2009 Premier’s

Award for Health and Medical Research.

• Professors Adèle Green, Peter Parsons, Nick Hayward

and Associate Professors Penny Webb and David

Whiteman’s NHMRC Program Grant selected by

the NHMRC for their 2008 list of “10 of the Best”.

• Marina Kvaskoff received the 2008 L’Oreal France-

UNESCO Women in Science Award.

• QIMR’s fi rst Indigenous cadet, Lisa Whop successfully

completed a Bachelor Applied Science (Medical

Science) at the Queensland University of Technology.

• Ms Lorna Lane, Corporate Division, awarded the

Bancroft Medal for an outstanding contribution over

25 years employment at QIMR.

Professor Emma Whitelaw

Division Chair Genetics and Population Health

Laboratory Head Epigenetics Laboratory



CHAIRMAN’S REPORT

In many ways it has been a watershed year for the

Institute. We have seen the passing of our long-serving

and inspirational Chairman, Sir Bruce Watson AC, and

the successful culmination of extensive negotiations

for the development of the QIMR Smart State Medical

Research Centre.

Sir Bruce was Chair of the QIMR Council from

September 1998 and held that position until his

retirement, due to ill health, on 17 October 2008. Prior

to his appointment as Chair of Council he was a

member of the QIMR Trust for nine years. His passing

on 1 November 2008 was a tremendous loss to QIMR.

He was a great man who contributed much to the

Institute and will be greatly missed.

QIMR is moving into an exciting new era with the

confi rmation of the development proposal for a new

$179 million 13 fl oor research facility. The new building

is to be constructed on the site of the old Queensland

Radium Institute which is scheduled for demolition in

July 2009. It will serve as the integrating hub for the

two research facilities already on the Herston site and

provide an inviting street profi le and focal point for

QIMR. The capital expansion will increase the Institute’s

capacity by more than 60% to around 1,200 scientists

and support staff.

We received our largest-ever philanthropic gift,

$27.5 million from The Atlantic Philanthropies. The

donation was triggered by Federal Government

Education Infrastructure funding of $55 million

announced in the 2009 Federal Budget. Together

with $55 million previously received from the Federal

Government in 2007 and $35 million promised by the

Queensland State Government, this funding will allow

construction of the new building to begin in late 2009.

This fi nancial support refl ects the confi dence in QIMR

as a world-class research institute.

2009 saw the appointment of the Hon. Paul Lucas,

Deputy Premier, as the Minister for Health. We look

forward to working with the Deputy Premier and his

team to help further position Queensland and QIMR

as a leader in medical research – both nationally and

internationally.

Since being established by an Act of Parliament in

1945, QIMR has grown to become one of Australia’s

largest and most successful medical research institutes.

The Act is currently being reviewed and it is hoped the

outcome of this review will be in place early 2010.

In June 2009, Professor Peter Brooks announced his

resignation from QIMR Council. Professor Brooks was

initially appointed as a nominee of the National Health

and Medical Research Council in 1994 and then as

nominee of the Senate of The University of Queensland

from May 2000. Professor Brooks chaired the QIMR

Appointments and Promotions Committee from 2000

and was a member of the QIMR Medical Advisory

Board. His valuable support and wisdom over the past

13 years will be greatly missed and we wish him well in

his future endeavours.

For an institute that relies heavily on support from

philanthropic and commercial entities alike, it has been

a trying year due to the effects of the global fi nancial

crisis. Council is grateful for the continued support of

the QIMR Trust and long standing supporters Mr Chuck

Feeney, founder of The Atlantic Philanthropies, Mr Clive

Berghofer, and the many volunteers and supporters in

the community.

The dedication of our researchers has again produced

a number of outstanding research outcomes that

will help to improve the health and well-being of

future generations.

Mr Christopher Coyne

Acting Chair


Sir Bruce Watson AC BE (Elec)BCom

(Chairman to 17 October 2008)

Sir Bruce Watson was born in Queensland in 1928.

In 1956, he joined MIM Holdings Limited and became

General Manager of the Agnew Nickel Mining Joint

Venture in Western Australia in 1975. In 1977, he returned

to Brisbane as a Director and later as CEO and Chairman

of MIM Holdings Limited. Sir Bruce has been a Member

of the Supervisory Board of Metallgesellschaft AG, a

Director of Boral Limited, ASARCO Inc, National Australia

Bank Limited and Chairman of the Gas Corporation of

Queensland Limited. From 1992 to 1995 Sir Bruce served

as National President of the Australian Institute of Company

Directors and in 1992, as President of the Australasian

Institute of Mining and Metallurgy. In June 1985, he was

knighted in recognition of his most distinguished service

to Queensland industry and in 2004 Sir Bruce was made

a Companion of the Order of Australia.

Sir Bruce Watson was appointed Chairman of the QIMR

Council on 3 September 1998 and held that position until

his retirement due to ill health on 17 October 2008. Sadly,

Sir Bruce Watson passed away on 1 November 2008.

Mr Christopher Coyne LLB

(Acting Chair from 21 October 2008)

Christopher Coyne is a solicitor of the Supreme Court of

Queensland having been admitted in 1979. He now

practises on his own account, but was formerly a partner

in the national law fi rm of Clayton Utz from 1984 to 2002.

He was appointed an Adjunct Professor at The University

of Queensland School of Law in 2002. He has been a

Sessional Member of the Queensland Commercial and

Consumer Tribunal since 2004. He has held a number

of appointments relating to medical research including:

Legal Member, Australian Health Ethics Committee from

2003 to 2009; Chair, Mater Health Services Human

Research Committee to 2008; Member of the NHMRC

Gene Related Therapy Research Advisory Panel 2003

to 2006. Chris is currently Chair of the Queensland Law

Society’s captive insurer, Lexon Insurance Pte Limited and

a director of the Incorporated Council for Law Reporting.

Professor Peter Brooks

MD FRACP FRCP Edin FAFRM FAFPHM MD Lund

(Hon Causa) (To 30 June 2009)

Professor Brooks was Foundation Professor of

Rheumatology at the University of Sydney prior to

becoming Professor of Medicine at St Vincent’s Hospital,

Sydney in 1992. He was appointed Executive Dean

of Health Sciences at The University of Queensland in

1998, and has extensive research experience in basic

infl ammation and treatment of rheumatic diseases and

has been a member of the Fellowships Committee and

Partnerships Committee of the NHMRC. Professor

Brooks has been a member of the QIMR Council for over

10 years and has chaired the QIMR Appointments and

Promotions Committee since 2000.

Professor Emeritus Bryan Campbell

AM MD BS FRACP FRACMA

Professor Campbell was formerly Chief Health Offi cer

Queensland and Head of The University of Queensland

Medical School. He has been a Councillor of the Royal

Australasian College of Physicians, the Royal Australian

College of Medical Administrators and a member of the

NHMRC. He was Deputy Chair of the Australian Health

Ethics Committee and a member of the NHMRC

Embryo Research Licensing Committee. Professor

Campbell has been a member of the QIMR Council for

over 20 years. Professor Campbell is also a member of

the QIMR Finance and Audit Committee.

Professor Judith Clements BAppSc MAppSc PhD

Professor Clements has over 20 years experience as

a basic researcher in biomedical research, primarily in

the general fi eld of molecular endocrinology. Her current

research seeks understanding of the molecular basis

of hormone dependent and urogenital cancers such

as prostate, breast, ovarian and endometrial carcinoma.

She is currently Program Leader of the Hormone-

Dependent Cancer Program within the Institute of Health

and Biomedical Innovation at the Queensland University

of Technology and also an NHMRC Principal Research

Fellow. In 2007, Professor Clements was awarded the

prestigious international Frey-Werle Foundation Gold

Medal for her signifi cant contributions to the kallikrein

protease fi eld. Professor Clements is a member of the

QIMR Appointment and Promotions Committee.

Mr Paul Fennelly BA LLB

Paul Fennelly has wide experience in fi nancial

management, business and public administration He is

a Director with Hastings Funds Management which is

a member of the Westpac Group. His focus is on major

equity investments, primarily in social and economic

infrastructure, public private partnerships and major

property transactions. From 2002 to 2006, Mr Fennelly

was Director-General of the then Department of

COUNCIL MEMBERS


State Development; concurrently he served as the

Co-ordinator-General. Prior to joining the Queensland

Government he was Victorian Director of the Australian

Industry Group which is the nation’s largest industry

association. Mr Fennelly is the Chair of the QIMR Finance

and Audit Committee and Chair of the QIMR Personnel

Administration Committee.

Professor Lyn Griffi ths BSc (Hons) PhD

Professor Griffi ths is Director of the Griffi th Institute

for Health and Medical Research and the Genomics

Research Centre at Griffi th University. She has expertise

in human molecular genetics, undertaking research to

map and identify genes involved in common complex

human disorders, including studies on migraine, CVD risk,

MS and certain types of cancer. Her research has been

well funded by national competitive grants and industry

and she has authored approximately 160 peer-reviewed

publications to date in molecular genetics international

journals. She is a past ASMR Director, Current Member

and past Chair of the Scientifi c Program Committee for

the next International Congress of Human Genetics and

has been awarded the Centenary Medal for Distinguished

Service to Education and Medical Research.

Associate Professor Paula Marlton

MB BS (Hons I) FRACP FRCPA

Paula Marlton is the Head of Leukaemia and Lymphoma

Services at the Princess Alexandra Hospital where she

is also Deputy Director of Haematology. Her previous

appointments include three years at the MD Anderson

Cancer Centre in Houston Texas. She has extensive

experience in clinical research including the role of

principal investigator for national trials and supervisor of

molecular translational research associated with trials.

She was the founding Chair of the Australasian

Leukaemia and Lymphoma Group Laboratory Science

Committee and has established and continues to direct

the PwC Leukaemia and Lymphoma Tissue Bank. Her

other professional roles include Medical Advisor and

Board member of the Leukaemia Foundation, member

of several Drug Advisory Boards, Government and

College Advisory Committees as well as a wide range

of academic and clinical service roles.

Dr Jeannette Young

MB BS FRACMA MBA AFACHSE

Dr Young has been the Chief Health Offi cer for

Queensland since August 2005. In her previous position

she was the Executive Director of Medical Services

at the Princess Alexandra Hospital in Brisbane for six

years where she was responsible for the provision of

Medical services across the hospital and a member of

the executive team. She came to the position following

four years as the Director of Medical Services at the

Rockhampton Base Hospital. Prior to that Dr Young

spent nine years at Westmead hospital in Sydney

working, initially, in the area of Emergency Medicine

followed by responsibility for medico- legal issues and

management of junior medical staff.

As the Chief Health Offi cer she is responsible for Mental

Health policy and legislation, Population Health services

policy and regulation, disaster planning and private

facility licensing. She is a member of the Queensland

Medical Board, the Radiation Advisory Council, co-

chairs the Queensland Emergency Medical System

Advisory Committee, chairs the Queensland Blood

Advisory Committee and is Queensland’s representative

on the NHMRC, the Australian Health Protection

Committee and the AHMAC Clinical, Technical and

Ethical Principal Committee.

Left to right: Professor Judith Clements,

Mr Paul Fennelly, Associate Professor Paula Marlton,

Mr Christopher Coyne (Acting Chair), Professor

Emeritus Bryan Campbell, Dr Jeannette Young

(Absent: Professor Lyn Griffi ths

and Professor Peter Brooks)


It is with great sadness

that we saw the passing of

our long-serving Chairman

Sir Bruce Watson AC in

November 2008. I had

the wonderful pleasure of

knowing Bruce over the

last 15 years as he was

Chairman of fi rst, the

Cooperative Research Centre for Vaccine Technology,

and then the Queensland Institute of Medical Research.

During his Chairmanship, I served as his CEO of those

organisations. He was a gifted, caring and wonderful

gentleman and mentor. He was a wise Chairman and

a person of enormous integrity. His leadership and

genuine interest in all people will be greatly missed.

Bruce would have rejoiced in another great year for the

Institute. We continue to produce signifi cant research

fi ndings, obtain competitive grants and external funding,

and our world-class research team continues to expand

and achieve well deserved recognition.

RESEARCH

Our research makes a real difference to the health of all

people. Amongst the many science highlights, QIMR

researchers have:

• Identifi ed genes that double the risk of acquiring

melanoma.

• In association with Peplin, completed Phase III trials

for a natural product that can cure solar keratoses.

• Commenced a clinical trial for a Group A

Streptococcus vaccine to prevent rheumatic

heart disease.

• Discovered the genetic risk of schizophrenia is the

result of thousands of common genetic variations

and these are common for schizophrenia and

bipolar disorder.

We published 367 peer reviewed research papers;

49 of these being in the world’s most highly cited

international journals.

Five new laboratories were established during the year.

The Cancer and Population Studies Group have split

into three, with Associate Professors David Whiteman

and Penny Webb heading their own groups. Dr Dale

Nyholt now leads the Neurogenetics Laboratory with

an emphasis on the study of migraine and other

neurological disorders. Dr Graeme Walker heads

the new Skin Cancer Carcinogenesis Laboratory and

Dr Malcolm Jones leads the Parasite Cell Biology

Laboratory which focuses on exploiting host interactions

of particular parasites in developing control strategies

FUNDING

Our publication productivity was matched by success in

obtaining competitive grants. Funding from the National

Health and Medical Research Council (NHMRC) rose to

a record $24 million, up from $19.6 million in 2007/2008.

We were delighted with the allocation of $55 million

in the Federal Budget. This represents a signifi cant

investment by the Federal Government and further

demonstrates Queensland and QIMR’s position

nationally and internationally as a leader in innovation

and research.

Congratulations to Adèle Green and the Cancer and

Population Studies team who were awarded a program

grant of $5.9 million in conjunction with Associate

Professors David Whiteman and Penny Webb.

It is wonderful to receive such consistent support from

the community, especially in this time of economic

hardship. I would like to thank Suncorp for their ongoing

support for our skin cancer research having donated

$1.2 million since the partnership began in 2004.

A special thank you to Mrs Marno Parsons, a great

supporter and friend of the Institute. Mrs Parsons gave

a very generous donation enabling us to undertake

research in the development of a glioblastoma vaccine.

I would also like to thank long-time supporters Mr Clive

Berghofer and Mr Sean Ryan.

DIRECTOR’S REPORT

Sir Bruce Watson AC and Professor Michael Good AO


PEOPLE

We warmly welcome our new patron the Governor of

Queensland, Ms Penelope Wensley AO. Her personal

interest in health issues, including HIV/AIDS, and in the

promotion of Australian science excellence, is an asset

to our Institute.

We continue to attract high quality researchers and

support staff. I want to take this opportunity to welcome

Associate Professor Michael Breakspear who joins us

as inaugural head of our new Mental Health Research

Division.

Congratulations to Professor Emma Whitelaw who

was awarded one of only 12 prestigious Australia

Fellowships to continue her exciting work into

epigenetics and the interaction between genes and the

environment.

Other achievements include the NHMRC selecting

Adèle Green, Peter Parsons, Nick Hayward, Penny

Webb, and David Whiteman’s application for their 2008

list of “10 of the Best” and Dr Stuart Macgregor being

awarded the 2009 Premier’s Award for Health and

Medical Research.

Our students are our future and this year we admitted

47 new higher degree students and 28 visiting

students. This brings QIMR’s student body to 105.

The education program continues to grow, with a

very successful interactive display in the Brainwaves

Pavilion at the Brisbane Exhibition; 1400 senior science

students taking part in our annual High School Lecture

Series; and over 200 students participating in hands-on

laboratory experiences.

The allocation of $55 million in the Federal

Budget represents a signifi cant investment and

further demonstrates this State’s and QIMR’s

position nationally and internationally as a leader

in innovation and research.


INFRASTRUCTURE

After years of planning, funding commitments from

The Atlantic Philanthropies and State and Federal

governments will allow construction of our new research

facility to begin in late 2009.

This investment will support construction of a new

building, which in the short term, will create 360 full-time

construction jobs. Upon completion the facility will

attract an additional 400 scientists and students, and

will increase our current research capacity in areas

such as tropical diseases, vaccine development,

cancer and genetics.

The new building will enable signifi cant expansion for

QIMR in Aboriginal and Torres Strait Islander health with

room for an additional 20 scientists researching cancer,

asthma, rheumatic heart disease, dementia, maternal

and child health. We will also be expanding QIMR’s

successful Spotlighting Careers in Indigenous Health

and Science Program which brings Aboriginal and

Torres Strait Islander high school students to QIMR

for week long science placements and workshops.

Another exciting feature of the new building will be an

Education Centre to inspire the scientists of tomorrow.

This will build on QIMR’s successful education program

and feature a state-of-the-art research laboratory

dedicated to inspiring school students and their

teachers. The new building will also feature an IT

training centre and a 120 seat auditorium, allowing

extension of our current public lecture program.

HEALTH PRIORITIES

More than three million Australians are estimated to

experience a mental disorder. QIMR is responding to this

health priority with the development of a Mental Health

Research Division. This is an exciting new direction for

QIMR and is aimed at improving our understanding of

serious mental illnesses, including schizophrenia, mood

disorders and neurodegenerative diseases.

We continue to enhance our translational research

capacity. This year saw the development of a

Queensland-US Vaccine Technology Alliance which aims

to combine our expertise and that of the Emory Vaccine

Centre to develop novel vaccines for infectious diseases,

such as malaria and HIV, as well as cancers including

brain cancer, Hodgkin’s lymphoma and melanoma.

I was privileged to chair the Working Group of the Smart

State Council to prepare the report Queenslanders

tackling chronic disease: becoming Australia’s healthiest

State. The report made a number of recommendations

in an attempt to address the fact that one third of all

deaths in Queensland are the result of a chronic disease

that could have been prevented.

CORPORATE

I would like to extend my gratitude for the ongoing

support our researchers receive from the Corporate

Division under the guidance of our General Manager,

Dr Julie-Anne Tarr. Strengthened by the outcomes of the

corporate review, the corporate team is undertaking a

systems change project in order to streamline corporate

service delivery for the Institute. We are also seeing the

results of the newly formed External Relations team with

a range of great fundraising and education initiatives.

In closing, I would like to thank the Acting Chair of

Council, Mr Christopher Coyne, the Council and Trust

members and all others who have served on QIMR

committees. I would also like to acknowledge and thank

all members of staff for their continued dedication and

hard work in performing world-class research.

Invigorated by the upcoming expansion of the Institute

and the success of the past year, I look forward to the

year ahead.

Professor Michael Good AO

Director


PATRON’S MESSAGE

RESEARCHGENETICS AND POPULATION HEALTH

IMMUNOLOGY

CANCER AND CELL BIOLOGY

INFECTIOUS DISEASES


QIMR - Annual Report 2008-2009 • 17 QQQQIMRMRIMRM - AnAAnnuaual Rl epoepoeport rt 200200008-28-2200900900909099 • • • • • • • • • • • • • • • • ••••• • 1171717171717171771717177717177171717717171771717111717171171717777171771717717771177177711717171171

Professor Georgia Chenevix-Trench

with PhD student Julie Johnson


This is a very exciting time in the fi eld of cancer

genetics. We are starting to see the translation

of basic research to targeted treatments for

women with particular forms of breast cancer.

I hope the work Julie is doing now might lead

to new treatments in the future.

Professor Georgia Chenevix-Trench

Laboratory Head Cancer Genetics Laboratory

Genetics and Population Health Division


GENETICS AND POPULATION HEALTH DIVISIONDivision Chair: Professor Emma Whitelaw

The Genetics and Population Health Division has

expanded further this year with the addition of three

new laboratories: the Cancer Control Laboratory,

the Gynaecological Cancer Laboratory and the

Neurogenetics Laboratory. This has greatly increased the

division’s capacity in cancer genetics and the genetics of

neural function.

Genome-wide association studies (GWAS) continue

to identify new genes underlying many important

complex diseases and a number of scientists in the

division have been involved in these studies. A decade

or more of collecting large patient cohorts is reaping

rewards, although identifi cation of the genes involved

is not the end of the story. The challenge now is to

understand the mechanistic role that these genes are

playing in the initiation and progression of the diseases.

The combination of molecular and cellular expertise

within the division, and the Institute at large, will ensure

continued contributions to this emerging fi eld.

The Illumina Genome Analyzer II deep sequencing

platform is now operating and has increased QIMR’s

genome-wide research capabilities. Current projects

using this equipment include the study of genetic

changes in human tumours and the study of the

patterns of DNA-binding proteins across the genome.

The division is anticipating the arrival of a state-of-the-

art in vivo imaging machine which will enable scientists

to follow tumour growth in living animals. It is the fi rst

machine of its kind in Queensland. Funding for this was

made possible by a large equipment grant from the

Australian Cancer Research Foundation. The technology

will help unravel the role of the genes identifi ed by

GWAS studies in various complex diseases.

The Indigenous Health Research Program has expanded

its research areas to include the study of metabolic

syndrome amongst Torres Strait Islander youth, a group

with a particularly high risk of obesity. Another project

focusing on Indigenous people’s understanding of

dementia and their access to mental health services has

also been initiated.


• Demonstrated that year-round regular sunscreen

use for prevention of skin cancers produces

cost-savings for health providers in Australia with

suggestions that the fair-skinned populations of the

US and Europe could also benefi t from cost-savings

if sunscreen was regularly used during summer.

• Showed that a diet with relatively low intakes

of meat, fried foods and full-fat dairy products

was associated with almost half the risk of new

cutaneous squamous cell carcinomas compared

with a diet high in meat and fat intake.

• Produced evidence that relatively high serum

selenium concentrations are associated with

approximately 60 percent decrease in subsequent

incidence of both basal and squamous cell tumours.

• Half the anticipated number of cases have been

recruited for the Queensland Pancreatic Cancer

Study and two new studies have begun – patterns

of care of patients with pancreatic cancer and quality

of life and supportive care needs of patients and

their carers.

The Cancer and Population Studies Group is currently

studying cancers of the pancreas and skin. The primary

aim is to identify the role of environmental factors in

causing these cancers and how genes may modify the

causal effect. The focus continues to be on causes

that can be modifi ed such as smoking, consumption

of certain foods and in certain patterns, body weight

at various ages and excessive sun exposure. Through

collaborations with laboratory colleagues, molecular

markers in biological samples obtained from project

participants are being analysed.

Close collaboration with the Gynaecological Cancer and

Cancer Control Groups is essential for the productivity

of all three laboratories, as indicated by the collective

success in obtaining a NHMRC Program Grant to study

gynaecological, oesophageal and skin cancer in

Australia and develop the evidence base for prevention

and control of these diseases. The Indigenous Health

Research Program is also a close partner in population

research of chronic disease.

The highly active QIMR-RBWH Statistics Unit is situated

within this research group and continues to provide a

valuable statistical consultancy service to QIMR and

RBWH. The biostatistician staff also collaborate with

scientists and clinicians on certain projects including

studies of infl ammatory bowel disease, various cancers

and infectious diseases, nursing and health services

research. Their ongoing statistics training seminars and

workshops have proven extremely popular.

The Cancer and Population Studies Group investigates

the causes and natural histories of cancers and seeks

to generate evidence for their prevention.

GENETICS AND POPULATION HEALTH DIVISION

CANCER AND POPULATION STUDIESLaboratory Head: Professor Adèle Green

HIGHLIGHTS


• Established a tissue and data resource for the

study of oesophageal diseases which includes

a nationwide network of collection centres.

• Demonstrated that patients with Barrett’s

oesophagus have higher levels of the obesity-

related hormone leptin than controls matched by

age, sex and BMI (body mass index).

• Identifi ed the role of smoking in substantially

increasing the risk of oesophageal cancer and

pre-cancer and that the risk of cancer increased

with the duration of smoking, regardless of the

actual amount smoked.

• Quantifi ed the proportion of melanoma attributable

to phenotypic factors such as naevi pigmentation

and family history.

Newly established in late 2008, the Cancer Control

Group conducts research with a view to generating

knowledge necessary to reduce the burden from cancer.

Given that in Australia almost one in three deaths is

due to cancer and this proportion will rise inevitably

as the population ages, the need for such research is

apparent. The challenge is to identify the environmental

and genetic factors that cause various cancers and use

such knowledge for prevention. This group also seeks to

contribute to improvements in the diagnosis, treatment

and survival from cancer.

To date, research has focused primarily on melanoma

and cancers of the oesophagus. Current projects

for melanoma include a re-analysis of 12 datasets in

collaboration with researchers in the USA, Canada and

QIMR and a large epidemiological study which relies on

close collaboration with pathologists at major Brisbane

laboratories.

Another major focus is the epidemic of oesophageal

cancer that is occurring in all western populations.

With QIMR colleagues from the Cancer and Population

Studies and the Gynaecological Cancer Groups, this

group has recently completed recruitment for the

largest epidemiological studies of oesophageal cancers

and pre-cancers yet conducted. An analysis of the

comprehensive data and samples collected is underway.

The work of this group is heavily reliant on the goodwill

of all those people who take part in the studies without

any thought of personal gain, but simply in the hope that

through research will come better health for all.

The Cancer Control Group seeks to identify environmental

and genetic factors that cause cancer and researches

early diagnosis, treatment and survival with a view

to reducing the burden from cancer by successfully

translating research fi ndings into policy and practice.

HIGHLIGHTS


CANCER CONTROL GROUPLaboratory Head: Associate Professor David Whiteman


• Identifi ed additional validated breast cancer

susceptibility genes through genome-wide studies.

• Found that ERBB2 is a novel activator of ras

signalling in serous ovarian tumours of low malignant

potential and that all serous ovarian tumours of low

malignant potential share activation of this pathway.

In the last two years there has been an explosion in the

identifi cation of new genes for complex diseases and,

with several large international consortia, this laboratory

is making great headway in unraveling the genetic

architecture of both breast and ovarian cancer. In both

cases, it is apparent that genetic heterogeneity underlies

histopathological heterogeneity so that different genetic

polymorphisms infl uence the risk for different types of

breast or ovarian cancer.

Researchers in this laboratory have shown that most

of the polymorphisms that affect the risk of sporadic

oestrogen receptor-negative breast cancer also modify

the risk of BRCA1-related breast cancer which is

consistent with the fact that many of these familial breast

cancers are oestrogen receptor-negative.

Although the risks associated with each polymorphism

is small, their identifi cation provides fundamental

insights into the genes and pathways that determine

whether these cancers will develop. By contrast, this

group has also shown that all serous ovarian tumours

of low malignant potential seem to arise by activation

of the ERBB2 pathway, albeit by a variety of different

mechanisms.


CANCER GENETICSLaboratory Head: Professor Georgia Chenevix-Trench

This laboratory investigates why some people get cancer and

how these cancers develop from a normal cell, particularly breast,

ovarian and stomach cancer which are often found together

in the same families and share many similar characteristics.

HIGHLIGHTS


HIGHLIGHTS

• Identifi ed a point mutation in the DNA

methyltransferase 3b that causes craniofacial

defects. The protein product plays a primary role

in setting up the epigenome in early development.

Humans with mutations in the same gene suffer

from immunodefi ciency centromere instability facial

anomaly syndrome.

• Used micro-computed tomography to detect mid-

face and palatal abnormalities in mice exposed to

alcohol while in utero.

This year the laboratory concentrated on developing

mouse models to investigate the role of epigenetics

in disease. In collaboration with two visiting scientists

from Finland, a mouse model of fetal alcohol syndrome

(FAS) has been developed. This group has shown that

maternal consumption of 10 percent ethanol throughout

the fi rst half of gestation results in subtle abnormalities

in the offspring. These include craniofacial defects and

growth retardation, both of which are features of FAS in

humans. They have further shown that these effects are

likely to involve disruption of epigenetic reprogramming

in the foetus.

The ENU mutagenesis screen for modifi ers of epigenetic

reprogramming continues to be fruitful and another

dozen novel mutant lines have been identifi ed. Their

phenotypes are currently being characterised. This year

the underlying mutation has been found in two more

cases – MommeD8 is Peptidylprolyl isomerase (PPie),

the protein product of which is known to associate

with Polycomb group proteins and MommeD14 is DNA

methyltransferase 3b (Dnmt3b). These will be valuable

resources for future studies.


EPIGENETICSLaboratory Head: Professor Emma Whitelaw

The Epigenetics Laboratory aims at understanding

the role of epigenetics in the determination of

phenotype in mammals, both mice and humans.

Craniofacial defects (on the right) following gestational exposure to ethanol.


• Developed a classifi cation scheme for patients with

serrated neoplasia predispositions based on family

history and polyp numbers.

• Identifi ed a phenotypic association for carriers of

variant alleles at 8q24.

• Demonstrated an important cautionary consideration

when using BRAF testing to exclude families as

being at risk for colorectal cancer.

• Established the prevalence of common MYH

mutations in patients with hyperplastic polyposis.

• Identifi ed a genomic region on chromosome 2

overlapping in genome wide linkage and association

studies for susceptibility to serrated neoplasia.

The laboratory continues to study people with hyperplastic

polyposis syndrome (HPS), a severe form of serrated

neoplasia predisposition, as well as families with many

members affected by serrated polyps and colorectal cancer.

A classifi cation system has been developed for

people predisposed to develop serrated polyps using

polyp numbers, family history, histology and special

stains, further suggesting that serrated neoplasia

represents a spectrum of conditions. Latest fi ndings

have shown that people with serrated lesions are

more likely to carry a genetic variant at 8q24, and this

variant may predispose to the methylation of DNA.

The search for the genetic lesion on chromosome

2 which is linked to serrated neoplasia continues.

Research in this laboratory has highlighted an important

aspect of using BRAF testing to exclude familial risk for

colorectal cancer, and has demonstrated that persons

with BRAF mutation and their relatives may also have

increased risk for colorectal cancer. This work has the

potential to identify people at increased risk for colorectal

cancer who currently may be overlooked.


FAMILIAL CANCERLaboratory Head: Associate Professor Joanne Young

The Familial Cancer Laboratory researches the molecular

pathology of tumours and the genetic changes that make

some families more susceptible to colorectal and/or

endometrial cancer. It undertakes studies of patients and

their relatives, and translates fi ndings to cancer patients.

HIGHLIGHTS



GENETIC EPIDEMIOLOGYLaboratory Head: Professor Nick Martin

• Obtained genome-wide association scan (GWAS)

data on 14,000 twins and their relatives.

• Used GWAS to locate a new gene predisposing to

melanoma on chromosome 20.

• Provided replication of GWAS hit for male

pattern-baldness.

• Provided replication of GWAS hit for moliness at

MTAP on chromosome 9p.

• Showed that nine percent of melanoma risk

can be accounted for by polymorphisms at four

pigmentation loci.

• Found a new gene for iron metabolism.

• Showed that blood lead levels are moderately

heritable.

• Mapped a possible gene for depression.

The Genetic Epidemiology group received their fi rst

genome-wide association scans this year in which

half a million or more single nucleotide polymorphisms

(SNPs) are typed on thousands of twins and their family

members who have previously been measured for

hundreds of diverse genotypes.

The group has made major breakthroughs in two of

the principal domains of their research. For melanoma,

the infl uence of a new gene on chromosome 20 in the

vicinity of the agouti signaling protein ASIP has been

shown and a major gene for moliness to the MATP

gene on chromosome 9, which is next to the well

known melanoma gene CDKN2A, has been mapped.

This group was part of a large international consortium that

has found strong, but not quite signifi cant, evidence for a

role for a presynaptic monoamine signaling protein, PCLO.

This group investigates the pattern of disease in families,

particularly identical and non-identical twins, to assess the

relative importance of genes and environment in a variety

of important health problems and to locate the genes

responsible using genetic linkage and association analysis.

HIGHLIGHTS

QIMR - Annual Report 2008-2009 • 25 Q Q Q QQQQ QQQQQQQQQQQQQQQIMRIMRIMRIMRIMRIMRIMRIMRIMRIMRIMRIMRMRIMRIMRIMRIIMRI R ------------ An An An AnAnAnAn An An AnAnAn An An AnAAnAnAnA nuanuanuanuanuanuanuanuanuanuanuanuanuanuanuanuanuaanuaal Rl Rl Rl Rl Rl Rl Rl Rl Rl Rl Rl Rl Rl R Rl RRRRRRRRRepoepoepoepoepoepoepoepoepoepoepopoepoepoepoepoepoepoepoepoepoepopoepooe rt rt rt rt rt rrt rt rtrtt rt rtrt rt rt rtrt rt rrtr 200200200200200200200200200200200200200202002002020020020008-28-28-28-28-28-28-28-28-28-28-28-28-8 2-28-28-28-228-28 0000000000000000000909990090000009000900990 • • • • • • • •• •• • ••• • • • • •• 2525255555555552 QIMR - Annual Report 2008-2009 • 25


GYNAECOLOGICAL CANCERLaboratory Head: Associate Professor Penny Webb

The Gynaecological Cancer Group investigates all aspects

of gynaecological cancer from aetiology to diagnosis,

patterns of care, quality of life and survival, particularly

environmental factors and their interaction with genetic

factors in the causation and prognosis of this cancer.

HIGHLIGHTS• Showed that women who eat a diet high in red and

processed meats and fats may be at increased risk

of ovarian cancer.

• Started the fi rst nationwide study of ovarian

cancer management to investigate levels of care,

identify gaps in care and determine whether

specifi c subgroups in the population are potentially

disadvantaged.

• Commenced follow-up of almost 1500 women

with endometrial cancer to evaluate their ongoing

care, health issues and quality of life.

Investigations continue into the causes of ovarian

cancer through the Australian Ovarian Cancer Study

(AOCS). It is well known that pregnancy reduces a

woman’s risk of ovarian cancer but the group has

investigated this further to show that the risk may

also vary depending on the duration of individual

pregnancies, the sex of the babies and whether or

not a woman breastfeeds and for how long. The

group has also started to investigate the role of diet

in determining ovarian cancer risk using data from

both AOCS and a similar study conducted 10 years

earlier. In addition, several collaborative studies

looking at genes involved in ovarian cancer have

been contributed to through the international Ovarian

Cancer Association Consortium.

Other ongoing investigations into risk factors for

endometriosis have identifi ed that childhood weight

and menstrual characteristics are associated with

risk. A major new study has also begun which aims

to follow up almost 1500 women with endometrial

cancer who previously took part in the Australian

National Endometrial Cancer Study to look at patient

outcomes and quality of life.


HIGHLIGHTS

• Indigenous graduate Lisa Whop completed a Bachelor

of Applied Science in Medical Research at QUT.

• 26 Indigenous, four non-Indigenous high school

students and fi ve teachers participated in the

Spotlighting Careers in Science Program.

• 20 Year 11 and 12 Indigenous students attended

an Indigenous Engineering and Science Camp –

a collaboration between QIMR and UQ Faculty of

Engineering, Physical Sciences and Architecture.

Cancer survivorship issues, including supportive care

needs and survival prospects of Indigenous cancer

patients, has been the main research focus over

the last year with two complimentary studies being

conducted. A supportive care needs assessment tool

is being validated, and the fi rst comprehensive study of

supportive care needs of Indigenous cancer patients

undertaken. An Indigenous Patient Navigator to assist

Indigenous cancer patients address these needs will

then be piloted. A expert in working with Indigenous

cancer survivors has been recruited to co-ordinate

these projects.

Research into the high prevalence of metabolic

syndrome amongst Torres Strait Islander youth

continues. A cross-sectional study of Indigenous

children residing in the Torres Strait has shown a

strikingly high proportion of overweight or obese

youth, some of whom also manifested components

of metabolic syndrome. Prevention and treatment of

obesity ultimately involves healthy diet and increasing

physical activity. To ensure that interventions are relevant

and effective, it is important that data be obtained at

the local level. Nutritional data is now being analysed to

describe the food intake patterns of the young people

included in this study. The adequacy of the number of

servings of fruit and vegetables and dairy based on the

Australian Guide for Healthy Eating will also be assessed.

Chronic suppurative lung disease and bronchiectasis

contribute to the high burden of respiratory disease

in Indigenous children worldwide. In the multicentre

Bronchiectasis Study, 109 children have been enrolled in

the observational study: 37 in Alaska and 72 in Australia,

with new enrolments and follow-ups continuing.

Enrolment of children in the interventional study has

also begun: 20 in New Zealand and 15 in Australia.

This is the fi rst study to prospectively document the

clinical course and therapy of chronic moist cough

and bronchiectasis in Indigenous children.

A project concentrating on Indigenous people’s

understanding of dementia and the provision of

services for Indigenous people with dementia has

also begun with a cross-sectional survey of 211

Indigenous Queenslanders already conducted and

211 aged care facilities surveyed.


INDIGENOUS HEALTH RESEARCH PROGRAMLaboratory Head: Associate Professor Gail Garvey

The program seeks to increase the number of research

projects developed in partnership with Aboriginal and

Torres Strait Islander communities and to increase the

number of Aboriginal and Torres Strait Islander postgraduate

students and researchers working on these projects.

Jessie Murray, a student from the August 2008 Spotlighting

Careers in Science and Indigenous Health Program




MOLECULAR CANCER EPIDEMIOLOGYLaboratory Head: Dr Amanda Spurdle

HIGHLIGHTS

• Initiated multifactorial model development for the

clinical classifi cation of sequence variants in the

colorectal-endometrial cancer mismatch repair genes.

• Provided evidence that some coding sequence variants

may alter both RNA splicing and protein function.

• Showed that splicing aberrations may be caused by

intronic variants that are currently often considered

unimportant in the clinical setting.

Pilot work on unclassifi ed variants in mismatch repair

genes showed that classifi cation of mismatch repair gene

variants is assisted by a comprehensive approach which

includes in vitro, tumour pathology, clinical, and evolutionary

conservation data. By combining data from a number of

different sources, 84 percent of the variants under study

were classifi ed. The laboratory also demonstrated that

bioinformatic tools commonly use for predicting splicing

aberrations need improvement before they can be used

without the support of experimental studies to assess

whether a variant causes cancer or not. This study

has paved the way for development of a multifactorial

classifi cation model.

Work on classifying variants in breast cancer genes

BRCA1 and BRCA2 has continued with the emphasis

on assessing possible splicing aberrations. The

laboratory has shown that two different variants alter

splicing patterns and protein function. This important

fi nding emphasises that:

− apparently benign coding region variants may have

clinically relevant effects via disruption of messenger

RNA splicing, and

− probabilities of pathogenicity based on bioinformatic

analysis of missense alterations need to incorporate

possible splicing defects caused by underlying

nucleotide changes.

This group also found clinically relevant splicing

aberrations associated with non-coding sequence variants

that lie outside the conserved splicing recognition sites,

including those as deep 12bp into the intron. These

results reinforce the utility of splicing assays as a method

for identifying clinically signifi cant variants in high-

risk cancer genes, including variants outside regions

routinely tested for function in clinical laboratories.

This laboratory studies breast, ovarian, endometrial, colon

and prostate cancer with a focus on identifying molecular

signatures of normal and tumour tissue that can point to

the genetic and environmental causes of these cancers.

Sequence from wild-type splice product, and aberrant splice product with

10bp insertion associated with variant BRCA1 IVS 19-12 G>A.

RT-PCR products for BRCA2 IVS 4-12_IVS 4-8 del5. Lanes 11-12

represent BRCA2 IVS 4-12_IVS 4-8 del5. Odd numbered lanes are cyclohexamide

treated and even numbered lanes are untreated samples. Lanes 1-10

are samples not carrying the variant. Lane M is a 100bp DNA marker.

The schematic shows the splice products represented in the gel photograph.


HIGHLIGHTS

• Discovered novel genetic variants contributing to

risk of melanoma.

• Completed the fi rst large genome-wide scan for

risk of endometriosis.

• Discovered novel variants affecting lipid

concentrations, iron metabolism, and male pattern

baldness.

• Prepared samples for genome-wide association

analysis on 17,000 individuals for gene discovery

in several major projects.

Genetic variation contributes substantially to risk for

many common diseases. All chromosomes can now be

rapidly screened in several thousand disease cases and

controls. These genome-wide scanning methods have

been applied by this laboratory to fi nd genes associated

with common diseases affecting many Australians

including endometriosis, melanoma, infl ammatory bowel

disease, and nicotine dependence.

Endometriosis is a common gynaecological disease that

affects up to 10 percent of women in their reproductive

years causing pelvic pain, severe dysmenorrhea and

sub-fertility. A region on chromosome 10q26 likely

to contain genes contributing to endometriosis risk

has been previously identifi ed by this group and this

year, a comprehensive search across the region found

possible association with variants just upstream of

a strong candidate gene. This group is a member of

the International Endogene Consortium which has

recently completed the fi rst genome-wide screen for

endometriosis and results are currently being analysed.

Studies of melanoma are more advanced and novel

genetic variants contributing to risk of melanoma have

been identifi ed. These variants are associated with

genes in pigmentation pathways and also the fi rst genes

found to increase melanoma risk by increasing the risk

of developing moles.


MOLECULAR EPIDEMIOLOGYLaboratory Head: Professor Grant Montgomery

The Molecular Epidemiology Laboratory investigates

complex diseases using high throughput genomics

platforms to identify genes and pathways contributing

to disease risk.

Illumina BeadScan data analysis used in genome-wide association studies


• Completed a pilot genetic study for early onset

recurrent depression.

• Expanded a collection of Indian SZ cases.

• Genome-wide association study (GWAS)

collaboration with US yielded association

on chromosomes 6p22.1 and 3q.26.33.

• Developed an accurate and sensitive assay for

quantitative allelic discrimination in heterozygotes

and completed measurement in 100 elderly persons

heterozygous for genetic risk to dementia.

• Completed DNA collection and fi rst phase

genotyping from Longitudinal Ageing Womens

(LAW) cohort.

• Completed a transcriptomic study which identifi ed

IL-33 gene in dementia.

The Schizophrenia Genetics Group within this laboratory

is headed by Professor Bryan Mowry with researchers

and collaborators at QIMR including Cheryl Filippich,

Heather Smith, Suzanne Manning and Dr Dale Nyholt.

A pilot genetic study of early onset recurrent

depression to assess the feasibility of recruiting a

large case-control sample has commenced using

a comprehensive clinical interviewing protocol and

taking blood samples from each participant.

A collaboration with Indian colleagues continues to

recruit cases and controls from the south-eastern

Indian state of Tamil Nadu and a (GWAS) of the fi rst

phase Indian cohort consisting of affected sibling pair

and trio families has commenced.

Blood samples from cases and controls recruited

as part of the Australian Schizophrenia Research

Bank continue to be processed in this laboratory. In

collaboration with colleagues in the US an association

on chromosomes 6p22.1 and 3q.26.33 with

schizophrenia is being reported in Nature.


MOLECULAR PSYCHIATRYLaboratory Head: Dr Corinne Lendon

HIGHLIGHTS

This laboratory seeks to identify and understand the

actions of the genes and environmental factors involved in

mental health disorders including dementia and cognitive

ability, schizophrenia and depression. The laboratory

currently consists of two research groups: Dementia

Research Group and the Schizophrenia Research Group.


• Led and published the largest to date molecular

genetic study of migraine.

• Confi rmed the previously reported comorbidity

between migraine and endometriosis and showed

common genetic infl uences completely explain their

co-occurrence within individuals.

• Found strong evidence for a novel schizophrenia risk

gene on 1p31.1 and 1q23-25.

• Provided replication of a GWAS for male

pattern-baldness.

Although only recently established, the Neurogenetics

Laboratory has already published a study of common

variation in 155 ion transport genes using 5,257 single

nucleotide polymorphisms (SNPs) utilising a total of

3676 unrelated migraine cases and 3624 unrelated

controls from Finland, the Netherlands, Germany and

Australia. This important study, the largest of such to

date, concluded that common variants of moderate

effect size in ion transport genes do not play a major

role in susceptibility to common migraine, a fi nding that

runs contrary to the previously leading hypothesis.

The group also made important fi ndings concerning

the localisation of novel schizophrenia risk genes on

chromosomes 1p31.1 and 1q23-25 and is currently

performing more detailed gene mapping studies on

both of these core traits.

The laboratory also recently confi rmed the previously

reported comorbidity between migraine and

endometriosis and showed common genetic infl uences

completely explain their co-occurrence within

individuals. Therefore, taking into account the status of

both migraine and endometriosis may provide a novel

opportunity to identify the genes underlying them.

Finally, collation of GWAS data from approximately

15,500 unrelated individuals has been completed

which will now be utilised in numerous, ongoing gene

mapping projects.


NEUROGENETICSLaboratory Head: Dr Dale Nyholt

HIGHLIGHTS

The Neurogenetics Laboratory studies the role of genetics

in the development and mechanism of the nervous system to

identify genes that cause neurological disorders. A particular

focus is on migraine, a frequent, debilitating and painful

headache disorder that normally affects people during their

most productive years.


HIGHLIGHTS

• Identifi ed new tumour suppressor genes mutated in

melanoma.

• Identifi ed new tumour suppressor genes inactivated

by methylation in melanoma.

• Identifi ed a new gene associated with melanoma

predisposition.

• Identifi ed genes associated with tumour

development in testes and ovaries.

Work has continued in understanding the molecular role

of the tumour suppressor menin, and the mechanisms

of tumour development in the syndrome multiple

endocrine neoplasia type 1 (MEN1), using gene

expression profi ling and other approaches. New tumour

suppressor genes and oncogenes involved in gonadal

tumours have been identifi ed.

Oesophageal adenocarcinoma expression data from

several research groups has been worked with to

develop a classifi er consisting of genes that distinguish

cancer, pre-cancer and normal tissue types.

In collaboration with researchers from Flinders

University, it has been demonstrated that the pattern

of aberrant DNA methylation at selected cancer genes

in Barrett’s tissue is very similar to that of oesophageal

adenocarcinoma, suggesting that Barrett’s oesophagus

may be more than a pre-curser to cancer.

Eight well known cancer related factors are currently

being screened in a large cohort, block from 350 patients,

of archival tumour sections. The latest digital slide

technologies and highly detailed patient data are being

applied to identify relationships between these proteins

and oesophageal adenocarcinoma patient survival.


ONCOGENOMICSLaboratory Head: Professor Nicholas Hayward

This laboratory identifi es novel cancer genes and studies

the way in which defects in these genes are associated

with cancer predisposition or development.

Single nucleotide polymorphism arrays used to accurately defi ne regions of DNA copy number alteration in cancer.



QUEENSLAND STATISTICAL GENETICSLaboratory Head: Professor Peter Visscher

Queensland Statistical Genetics (QSTAG) specialises in

quantitative and statistical genetics, population genetics,

human genetics and bioinformatics to investigate the

genetic basis of differences in risk to disease and other

phenotypes between individuals.

HIGHLIGHTS

• Further elucidation of the genetic basis of

susceptibility to schizophrenia and bipolar disorder.

• Quantifi cation of the genetic structure of North-West

European populations.

• Understanding and explaining genetic variation for

iron metabolism phenotypes in the population.

In collaboration with the International Schizophrenia

Consortium, this laboratory has shown that common

polygenic variation contributes to risk of schizophrenia

and that there is a substantial overlap between the risk

to schizophrenia and bipolar disorder.

In collaboration with the Genetic Epidemiology

Laboratory and the GenomEUtwin Consortium, the

fi ne-scale genetic structure of North-Western European

populations has been quantifi ed, and a part of the

genome that has been under recent selection has

been identifi ed.

A GWAS on iron metabolism phenotypes measured

in blood has been performed in collaboration with the

Molecular Epidemiology and Genetic Epidemiology

Laboratories. A number of genetic variants were

identifi ed that, in total, explain nearly half of all genetic

variation for serum transferrin levels.


IMMUNOLOGY DIVISIONDivision Chair: Professor Geoff Hill

This is the fi rst year of the Immunology Division as

a stand-alone group of over 100 scientists. The

laboratories have a signifi cant focus on tumour and

infectious disease based immunology. In particular,

a central theme of the division is that of preclinical

modelling as a prelude to prospective clinical trials

of vaccine and cellular therapies. By expanding this

knowledge base, the ultimate aim is to provide improved

diagnostics and treatments for infectious diseases and

malignancies. The last 12 months has seen a number of

successes at a personal and laboratory level, refl ected

by ongoing national funding support and landmark

studies published in high impact journals including

Nature Medicine, Immunity, The Journal of Experimental

Medicine and Blood.

The progressive developmental testing of novel

vaccines for infectious agents such as Human

Cytomegalovirus (HCMV), Epstein-Barr virus (EBV),

malaria and streptococcus continues. A protein

microarray core facility has been established within the

division as a discovery tool for identifying new antigenic

malaria proteins. New mouse lines that allow the

dissection of pathways of antigen presentation during

infection, cancer and graft-versus-host disease have

also been established.

Manipulation of cellular responses during infection,

cancer and allograft rejection allows researchers

to identify desirable therapeutic and deleterious

immunological responses. Early stage preclinical

and clinical studies of cellular therapy are underway

for a number of malignancies including leukaemia,

lymphoma, nasopharyngeal carcinoma, breast cancer

and melanoma. New studies linking the pathophysiology

of EBV infection to autoimmunity (multiple sclerosis) and

cancer (lymphoma) have begun.


Our research takes time, and the advances we

make are for the most part incremental. However,

ultimately, we will contribute to the development

of vaccines and treatments for infectious diseases

that affect some of the poorest countries.

Dr Christian Engwerda

Laboratory Head Immunology and Infection Laboratory

Immunology Division



IMMUNOLOGY DIVISION

BONE MARROW TRANSPLANTATIONLaboratory Head: Professor Geoff Hill

HIGHLIGHTS

• Demonstrated the mechanism of effect by which

growth factors impair transplant outcome and

developed a logical paradigm for their administration.

• Demonstrated that donor conventional dendritic cells

are the major cell type presenting alloantigen after

bone marrow transplantation.

• Delineated the effect of plasmacytoid dendritic cells

on transplant outcome.

• Demonstrated the effects of a novel highly potent

form of granulocyte colony-stimulating factor (G-CSF)

on stem cell mobilisation and graft-versus-leukaemia

(GVL) effects.

• Demonstrated the effects of various forms of natural

killer T-cell activation on transplant outcome.

This laboratory continues to investigate the mechanisms

of graft-versus-host disease (GVHD) and (GVL) effects

after haematopoietic stem cell transplantation. In the last

year, a large body of work on

cytokine dependent activation of the adaptive immune

system and the mechanistic effects therein has been

fi nalised. Subsequent work on the effect of natural killer

T-cell activation by G-CSF or glycolipid administration

after bone marrow transplantation has been published

in major international journals and received widespread

media attention.

New studies on donor antigen presenting cells and

their role in antigen presentation have also progressed.

These studies have allowed, for the fi rst time,

determination of alloantigen specifi c donor T-cell

responses in the presence or absence of specifi c

antigen presenting cell subsets. This recently published

work confi rms that conventional dendritic cells are the

important donor cell population presenting alloantigen.

This opens the way for logical therapeutic strategies to

modulate this population. Newly generated transgenic

lines are now being used that allow the researchers to

image effector T-cell responses in vivo and in real time

to quantify the important sites of antigen presentation

after bone marrow transplantation.

The Bone Marrow Transplantation Laboratory

works towards understanding the mechanisms by

which transplant recipients eradicate leukaemia but

also develop life-threatening complications, particularly

graft-versus-host disease.


HIGHLIGHTS

• Characterised the dendritic cells used to vaccinate

patients in two clinical studies.

• Demonstrated that a high proportion of T-cells

specifi c for cancer antigens are functional in patients

with a complete clinical response to immunotherapy.

• Showed that objective clinical responses in

immunotherapy trials correlate very signifi cantly with

the kind of antigens used.

Growing cancers can both stimulate and suppress

immune responses against tumour antigens. This

laboratory previously found that dendritic cell-

based immunotherapy led to the complete or partial

regression of advanced metastatic melanoma in about

20 percent of patients.

It is generally assumed that the dominant determinant

of clinical outcome in such trials is the nature of the

dendritic cells, and in particular, that immature dendritic

cells will not be effective at inducing immune response.

The dendritic cell vaccines from 42 patients were

therefore examined for characteristics associated with

the ability to stimulate immunity. Nine patients with

an objective clinical response were compared to 33

who had progressive disease following treatment. No

signifi cant differences were found in surface markers,

nor in the dendritic cells’ ability to secrete immunogenic

factors or generate functional immune responses in a

mixed lymphocyte reaction. This led to the conclusion

that other factors play a dominant role in determining

the clinical outcome of patients.

Publications of immunotherapy for advanced cancer

were analysed to fi nd that trials employing cancer cell-

derived antigens rather than synthetic antigens were

much more clinically effective. Therefore, the breadth of

the antigens presented by cancer vaccines may be an

important determinant of patient outcome.

A patient with a complete clinical response harbours CD8+ T cells directed

at a cancer antigen (NY-ESO-1; labelled by tetramer and indicated by red

dots), which have a highly differentiated CD27-CD127- effector phenotype

(compared to all other cells, in grey). Flow cytometry by Ronald Schilderink

and Michelle Neller, tetramer supplied by Dr Didier Colau and Prof Pierre van

der Bruggen, epitope discovery by Drs Volker Lennerz and Thomas Wölfel.

IMMUNOLOGY DIVISION

CANCER IMMUNOTHERAPYLaboratory Head: Dr Chris Schmidt

The focus of research in this laboratory is on

understanding how the immune system succeeds in

its fi ght against malignancies, which is central to the

future development of cancer immunotherapies.


IMMUNOLOGY DIVISION

CELLULAR IMMUNOLOGYLaboratory Head: Associate Professor Scott Burrows

HIGHLIGHTS

• Demonstrated decreased T-cell reactivity to Epstein-

Barr virus-infected cells in multiple sclerosis patients.

• Demonstrated that peptides of up to 25 amino acids

in length can bind to class I molecules.

Epstein-Barr virus (EBV) is responsible for glandular fever

and in the Western world, approximately 95 percent of

adults are infected with the virus. EBV has the unique

ability to infect, activate and persist without detection in

important cells of the immune system.

Evidence indicates that Multiple Sclerosis (MS) is due

to an attack on the brain by antibodies and white blood

cells, cells of the immune system which defend the body

against infectious diseases. It is not known why this

immune attack on a person’s own tissue is not switched

off in people with MS but EBV is now being seen as a

likely cause. This year, in collaboration with Professor

Michael Pender from The University of Queensland and

the RBWH, this group has shown a signifi cant defect

affecting the immune system of patients with MS, with

recognition of EBV-infected cells shown to be signifi cantly

weaker in MS patients than in healthy people. This study

suggests that in future it might be possible to treat MS

by boosting the EBV-specifi c immune response, or

prevent MS by vaccinating against EBV infection.

The main focus of the Cellular Immunology Laboratory is

the cytotoxic T lymphocyte (CTL) and factors controlling its

primary function in recognising and killing virus-infected cells.

Associate Prof Scott Burrows (right) with Prof Michael Pender,

collaborators investigating the role of Epstein-Barr virus in

Multiple Sclerosis.


HIGHLIGHTS

• Commenced a Phase Clinical Trial of adoptive

immunotherapy in EBV-positive lymphomas.

• Profi led in-depth a newly developed model of virally

driven B-cell differentiation.

• Commenced a multi-centre Phase 2 lymphoma trial,

in which this laboratory is to perform a correlative

laboratory study in collaboration with Professor Lyn

Griffi ths from Griffi th University.

• Identifi ed a previously uncharacterised immune

defect that leads to fulminant infectious

mononucleosis.

• Established that herpes-virus specifi c effector

T-cells selectively accumulate within the peripheral

blood stem cell compartment.

The laboratory supports a range of translational studies

that will heighten understanding of the biology of

lymphoma. The laboratory performs highly detailed

functional immunoassays and genetic biomarkers on

healthy individuals as well as clinical samples obtained

from lymphoma sufferers. This work has led to disease

insights and therapeutic advances.

The transforming abilities of the EBV have been used to

establish a model system for investigating key events in

the pathogenesis of lymphoma.

Lymphomagenesis is a complex process, which in part

refl ects the nature of the transforming event, as well as the

stage of differentiation of the B-cell. B-cell differentiation

represents a continuum that is initiated when naïve

B-cells encounter antigen, undergo a germinal centre

(GC) reaction and ends with terminal differentiation

into a memory B-cell. Interruption of this process by a

transforming event may result in a clonal proliferation

which blocks differentiation of the cell at this stage.

Physiologically relevant human models that imitate the

various stages of B-cell differentiation are lacking. Using

high effi ciency EBV infection of isolated naïve B-cells, this

group has recently demonstrated that the use of EBV

infection of isolated human naïve B-cells provides a highly

relevant in-vitro model that mimics the GC reaction.

From a therapeutic perspective, a novel Phase

Clinical Trial of autologous EBV-specifi c T-cell therapy

in patients with relapsed and refractory EBV-positive

lymphomas has begun in collaboration with the Tumour

Immunology Laboratory and investigators at the Peter

MacCallum Cancer Centre. To date, three patients have

been enrolled.

IMMUNOLOGY DIVISION

CLINICAL IMMUNOHAEMATOLOGYLaboratory Head: Associate Professor Maher Gandhi

The major research area in this laboratory is the

immunobiology of lymphoma including biomarkers,

immuno-evasion, microRNA expression and cellular

immunotherapies for virus associated lymphomas.


IMMUNOLOGY DIVISION

DENDRITIC CELLS AND CANCERLaboratory Head: Associate Professor Alejandro López

HIGHLIGHTS

• Described critical characteristics of breast cancer

stem cells that were identifi ed in established breast

cancer cell lines.

• Identifi ed antigens expressed in breast cancer

stem cells.

The importance of cancer stem cells in the development

of cancer has been further highlighted in the scientifi c

literature, however the identifi cation of their defi ning

qualities is still incomplete. In order to be able to harness

the potential of those cells for immunotherapy, a clear

understanding of the origin and functionality of cancer

stem cells is vital.

This laboratory has progressed the defi nition of the

qualities that make breast cancer cells – research

which yielded the characterisation of a large number

of established cell lines which contain stem cell-

like populations. With those cells, properties that

could be targeted for immunotherapy are now being

characterised.

The main outcome of this work is a new understanding

of the surface tags (phenotype) identifying stem cell-like

cells where it has now been established that the origin

of breast cancer cells (basal or luminal) is very likely to

determine the phenotype of potential stem cells.

This laboratory explores the function of dendritic cells (DC)

in patients with breast cancer and investigates the role of

breast cancer stem cells in the generation of tumours.

Resulting fi ndings will yield novel DC-based immunotherapies.


HIGHLIGHTS

• Began a clinical trial in nasopharyngeal carcinoma

(NPC) patients in collaboration with Princess

Alexandra Hospital.

• Defi ned the immune response in healthy individuals

and NPC patients using the SAVINE vaccine

encoded within adenovirus.

A new formulation has been designed that includes

all of the possible immunogenic determinants of

proteins expressed within NPC biopsies. Referred to

as SAVINE, this formulation is undergoing preclinical

testing. Results indicate that this formulation, when

delivered in a replication-defi cient adenovirus, is capable

of activating immune responses from both healthy

individuals and NPC patients. These results provide

a platform for future clinical trials.

A clinical trial has begun using NPC patients recruited

from the Head and Neck Clinic at Princess Alexandra

Hospital in collaboration with Professor Bill Coman and

colleagues. This trial involves adoptive transfer of in vitro

activated T-cells from NPC patients. Activation of T-cells

involves the use of a peptide encoded within a protein

associated with NPC. This procedure is conducted

within the Q-Gen facility of QIMR, and to date, two

patients have been treated.

A library of bioactive compounds derived from natural

sources is currently being screened for immunological

activity. This project is a collaborative project with QIMR’s

Drug Discovery Group. The overall aim is to identify

compounds that might have clinical applications,

particularly those with immunosuppressive or anti-

herpes virus activity.

IMMUNOLOGY DIVISION

EBV BIOLOGYLaboratory Head: Professor Denis Moss

This laboratory is committed to understanding the biology

and immunology of two clinically important human pathogens,

Epstein-Barr virus (EBV) and vaccinia virus, and capturing

laboratory fi ndings and using them in human clinical trials.


IMMUNOLOGY DIVISION

IMMUNOLOGY AND INFECTIONLaboratory Head: Dr Christian Engwerda

HIGHLIGHTS

• Identifi ed host molecules that mediate parasite

accumulation in tissue sites during experimental

cerebral malaria.

• Discovered a method to alter malaria-specifi c T-cell

responses generated in response to vaccination so

they do not cause disease.

• Developed a way to enhance T-cell activation during

visceral leishmaniasis to improve disease outcome

by activating a molecule called GITR.

• Discovered a way to modulate T-cell responses

to prevent experimental cerebral malaria using

interleukin-2 (IL-2).

• Discovered a novel way to treat autoimmune disease

in a pre-clinical model of lupus.

The Immunology and Infection Group has taken

advantage of state-of-the-art imaging technology

at QIMR to investigate the accumulation of malaria

parasites in various tissue sites throughout the course

of infection. The group’s research has identifi ed

components of the host immune response that

promote accumulation of parasites in tissues to

cause severe malaria disease. Collaborations with

the Molecular Immunology Laboratory have resulted

in the development of a strategy to generate potent

anti-malaria T-cell responses following vaccination

without causing disease. Other research on malaria

has identifi ed key roles for granzymes in both disease

induction and the development of anti-parasitic

immunity. The groups will continue to defi ne the exact

functions of this family of molecules during malaria.

Work on visceral leishmaniasis has identifi ed a way to

enhance T-cell responses during infection by activating

a molecule called GITR. It has been shown that this

strategy can be used as an adjunct therapy with

conventional drug treatment to greatly enhance disease

control. Other research has led to the discovery of a

novel way to enhance anti-parasitic immune responses

by altering signals via the lymphotoxin beta receptor.

Currently, this laboratory is determining how T-cells are

activated during visceral leishmaniasis, and in particular,

identifying the specifi c antigen presenting cells involved

and the tissue sites where this occurs.

This laboratory studies the host immune response during

malaria and leishmaniasis, and aims to distinguish host

immune responses that control parasite growth from those

that contribute to disease.

Dr Ashraful Haque getting ready to sort cells for an experiment in the QIMR

Flow Cytometry and Imaging Laboratory


HIGHLIGHTS

• Identifi ed four new arboviruses from Antarctica.

• Found that a drug that inhibits the infl ammatory

chemokine MCP-1 was able to ameliorate the

symptoms of Ross River virus disease in mice.

• Showed that intratumoral treatment with Kunjin

replicon virus-like particles encoding granulocyte-

macrophage colony-stimulating factor (GM-CSF), were

able to cure established aggressive tumours in mice.

• Found that curing tumours with the new locally

applied anti-cancer compound PEP005 induces

anti-cancer immunity, which can regress distant

metastases.

To assess the potential risk to Antarctic tourists of

Antarctic arboviruses, ticks were collected from penguin

colonies on Macquarie Island. Four new viruses were

identifi ed and found to be distantly related to viruses that

cause illness in humans. The nearest relatives of these

viruses reside in the northern hemisphere, suggesting

ticks and their viruses are regularly transported around

the world on migrating seabirds.

In collaboration with Professor Mahalingham from the

University of Canberrra, the laboratory has been working

to fi nd better treatments for the arthritis caused by Ross

River virus. Bindarit, a drug that inhibits synthesis of MCP-1,

was found to be able to signifi cantly reduce symptoms

of the disease in mice. This opens new avenues for

treatment of this, and perhaps other, viral arthritides.

Kunjin replicon, a new arbovirus vector system

developed by Dr Khromykh from The University of

Queensland was genetically engineered to express GM-

CSF. Intratumoural injection of GM-CSF Kunjin replicon

was able to cure a number of established aggressive

tumours and to regress distant metastases in mice.

The new anti-cancer compound PEP005 being

developed by Peplin showed that it not only cures the

treated tumour but also adjuvants the dead tumour

resulting in CD8 T-cell anti-cancer immunity, which can

regress distant metastases in mice.

IMMUNOLOGY DIVISION

IMMUNOVIROLOGYLaboratory Head: Associate Professor Andreas Suhrbier

The Immunovirology Laboratory is exploiting new knowledge

about interactions between viruses and the immune system

to develop novel anti-viral and anti-cancer strategies.


IMMUNOLOGY DIVISION

MOLECULAR IMMUNOLOGYLaboratory Head: Professor Michael Good

HIGHLIGHTS

• Plans to initiate a Phase I Clinical Trial on

human volunteers using low doses of whole

malaria parasites.

• Produced GMP grade Group A Streptococcus

(GAS) vaccine for a Phase I Clinical Trial.

• Found that in vivo administration or in vitro

stimulation of dendritic cells (DC) with lipopeptide

GAS vaccines did not induce phenotypic

maturation of DC.

Malaria is a major cause of morbidity and mortality

worldwide. A new strategy has been developed combining

low-doses of whole parasite extract adjuvanted in CpG-

oligodeoxynucleotide (CpG-ODN) to elicit robust T-cell

responses directed against multiple parasite antigens.

This vaccine engenders long-term protection as well

as vigorous long-lived immune responses against

homologous and heterologous parasites, including

different strains and species of lethal malaria.

The nature of long-term protection is rather novel.

Historically, successful vaccines have worked by eliciting

long-lived antibody responses. In these studies however,

broad and prolonged protection against malaria is

achieved through the generation of vigorous T-cell

responses. Such an approach would facilitate poly-

specifi c immunity and assure antigen procurement

for economical manufacture. In collaboration with the

Clinical Tropical Medicine Laboratory, a Phase Clinical

Trial for the vaccine is being initiated.

Group A Streptococcus research is focused on a

novel, dual antigen, synthetic peptide subunit vaccine

approach to prevent streptococcal- associated

cardiovascular disease, and on strategies designed

to enhance peptide vaccine effi cacy.

The use of Toll-like receptor (TLR) ligands as vaccine

adjuvants and the cell signalling mechanisms involved

in TLR signalling in dendritic cells are being investigated.

In collaboration with the Bacterial Vaccines and Clinical

Tropical Medicine Laboratories, the GMP manufacture

of the vaccine candidate J8-diphtheria toxoid to be

used in a Phase I Clinical Trial for the vaccine is almost

complete.

The Molecular Immunology Laboratory studies the

immune response to pathogens, principally Plasmodium

and Group A Streptococcus (GAS), with the goals of

understanding pathogenesis and developing vaccines.


HIGHLIGHTS

• Established a protein microarray core at QIMR.

• Identifi ed the profi le of Plasmodium falciparum

proteome-wide antibody reactivity in Papua

New Guinea.

• Identifi ed regional differences in P. falciparum

proteome-wide antibody reactivity between

populations in Papua New Guinea and Africa.

• Established in vitro and in vivo models to investigate

cell mediated responses to pre-erythrocytic stage

malaria.

• Developed a mouse model to investigate the effects

of adjuvants on vaccine-induced T-cell responses.

To facilitate development of a vaccine against malaria,

this group is undertaking a process of rational vaccine

design on a proteome-wide scale. A protein microarray

core has been established to identify, via antibody

responses, novel Plasmodium parasite proteins that

are associated with naturally acquired or experimentally

induced protective immunity. Comparative studies of

geographically distinct human populations and of cross-

species immunity are being undertaken.

A complementary approach to identifying novel

Plasmodium antigens recognised by cell mediated

immunity has been established. A subset of novel

P. falciparum antigens identifi ed from protein microarray

data as promising vaccine candidates are being

assessed in vitro and in vivo for immunogenicity,

protective effi cacy and biological function. Laboratory

models to evaluate candidate vaccines and to identify

and prioritise potential human use compatible adjuvants,

capable of augmenting cell mediated immunity, have

also been established. To understand how an effective

cell-mediated response can be generated by vaccination,

the factors that may modulate the function and phenotype

of effector T-cells and in particular the acquisition of

effector function by CD8 T-cells is being investigated.

IMMUNOLOGY DIVISION

MOLECULAR VACCINOLOGYLaboratory Head: Dr Denise Doolan

Research in this laboratory investigates the molecular basis of

immunity to disease, with a focus on malaria and model systems

that can inform the basic immunology, mechanisms and antigenic

targets of immunity, and evaluation of candidate vaccines.


IMMUNOLOGY DIVISION

TUMOUR IMMUNOLOGYLaboratory Head: Associate Professor Rajiv Khanna

HIGHLIGHTS

• Initiated a Phase 1 Clinical Trial on nasopharyngeal

carcinoma in collaboration with University of

Hong Kong.

• Developed novel T-cell-based therapy for the

treatment of cytomegalovirus treatment in stem

cell recipients.

• Completed preclinical studies on a prophylactic

vaccine for human cytomegalovirus.

• Determined the infl uence of mRNA structure on

the antigen presentation to cytotoxic T-cells.

This laboratory is involved in developing immune-based

therapies and novel diagnostic tools for human herpes

virus associated diseases. These studies are primarily

focused on two viruses, namely Epstein-Barr virus (EBV),

which causes glandular fever and Hodgkin’s lymphoma

(HL), and the cytomegalovirus. EBV is also associated

with a number of cancers including nasopharyngeal

carcinoma (NPC).

A large clinical study has been initiated in collaboration

with colleagues at the University of Hong Kong to test a

killer T-cell-based therapy for advanced NPC patients.

This therapy is based on a propriety technology (referred

to as E1-LMPpolyTM) developed by this laboratory. The

possibility of expanding this therapy for other EBV-

associated cancers such as HL and non-Hodgkin’s

lymphomas is also being explored. In addition, this

group has signed a collaborative agreement with a UK-

based biotech company to jointly develop a therapeutic

vaccine for both NPC and HL.

Another aspect of research is focused on developing

novel immune-based diagnostic tools for human

cytomegalovirus which are a major cause of morbidity

and mortality in transplant patients. In collaboration with

an Australian biotechnology company, a new whole

blood diagnostic kit has been developed which will allow

identifi cation and prediction of which transplant patients

are at the highest risk of developing cytomegalovirus

disease after organ transplantation. This diagnostic kit

has recently been registered in the European Union as

a clinical immune monitoring kit. It is anticipated this kit

will also be available at most pathology centres in US

and Australia within the next 12-18 months.

This laboratory seeks a deeper understanding of the

mechanisms by which an immune response to tumours

may be generated, augmented and applied to the

inhibition of tumour growth.

QIMR - Annual Report 2008-2009 • 47 QIMR - Annual Report 220020000222 8-28-28-220090090090 • • • •• • 47474

The Cancer and Cell Biology Division consists of

10 laboratories located in the Bancroft Centre, the

Clive Berghofer Cancer Research Centre and The

University of Queensland Centre for Clinical Research.

Research carried out in the division covers a variety

of topics from specifi c investigations of the molecular

and genetic aberrations of tumour cells, to clinical

and pathological studies of cancers and metabolic

disorders. Scientists in the division are particularly

devoted to translating research fi ndings into

clinical outcomes.

Tumours studied include melanoma, leukaemia,

breast, prostate, liver and colorectal cancer. Research

themes cover the normal mechanisms that control

cell growth, cell division and inheritance; the DNA

damage response and DNA repair; mechanisms of

iron homeostasis; development of mouse models to

study in vitro functions of cancer genes; developing

screening tools for early detection of cancers; devising

strategies for cancer treatment; and investigation

of liver disease in both the adult and paediatric

populations. The division has strong collaborative links

with other QIMR divisions, the Royal Brisbane and

Women’s Hospital and The University of Queensland.

CANCER AND CELL

BIOLOGY DIVISIONDivision Chair: Professor Greg Anderson


On discovery of a key repair protein in humans (hSSB1),

I decided to relocate my work. I found that QIMR offered

the best environment in the world, the core cancer experts,

resources, clinical links and an enthusiastic research

environment. Since then, this research has shown that

hSSB1 is the central protein required to protect humans

from cancer causing DNA damage.

Dr Derek Richard

Signal Transduction Laboratory

Cancer and Cell Biology Division



CANCER AND CELL BIOLOGY DIVISION

DRUG DISCOVERY GROUPLaboratory Head: Professor Peter Parsons

HIGHLIGHTS

• Achieved expression of the MIC-1 cytokine in cell

lines by lentivirus constructs.

• Identifi ed a signaling partner for MIC-1.

• Discovered a small molecule that has signifi cant

anticancer activity in animal models.

The Drug Discovery Group identifi es and studies the

function of genes that are important in the development

and treatment of certain cancers. The longer term aim

is to discover agents that may be effective against

specifi c targets. Several such genes have been identifi ed

in melanoma and squamous cell carcinoma of the

head and neck and these are being followed up at the

functional level.

Elucidation of the role of a novel cytokine MIC-1, found

by this group to be closely associated with melanoma

progression, has been stepped up following successful

expression of the molecule via lentivirus technology. This

has allowed probing of the function of MIC-1 in a wider

range of cell types, and provided an important clue

about how MIC-1 is regulated within the cell.

In collaboration with Dr Ben Panizza of the Princess

Alexandra Hospital, MIC-1 was also found to be

expressed in some squamous cell carcinomas (SSC)

of the skin, including invasive SCC of the face and

associated with nerves (perineural). These results are

being followed up in SCC of the head and neck, by ear

nose and throat trainee fellows.

The drug discovery program has expanded from anti-

cancer screening to a range of other assays including

a search for small molecule regulators of pigmentation.

The chemical library was sourced from a variety of

natural products including a collaborative arrangement

with an Australian biotech company. A novel compound

with a complex structure has been found to have anti-

tumour activity in mice, and this is being followed up

with studies of mechanism.

In collaboration with Griffi th University, a library of

organometallic compounds was screened against cultured

tumour cells. A high degree of selectivity was found for

some structures and this property, together with overall

potency, has provided a structural paradigm for the

design and synthesis of a new series of compounds.

This laboratory combines expertise in cancer biology

with genomics and drug discovery. Research into cell

communication networks in sun-induced cancers,

cancers of the head and neck, and ovarian cancer,

reveal responses that may lead to potential prevention

and treatment options.



HEPATIC FIBROSISLaboratory Head: Associate Professor Grant Ramm

HIGHLIGHTS

• Demonstrated, for the fi rst time, physical

interaction between the fi brogenic and regenerative

compartments of the liver through lymphotoxin-β and

its receptor. In addition, identifi ed the lymphotoxin-β

receptor as playing a key role in mediating the wound

healing response of the liver.

• Showed that the iron storage protein ferritin, displays

cytokine-like activity on the hepatic stellate cell that is

independent of iron, activating a signalling cascade that

activates NFkB and enhances the expression of key

proinfl ammatory genes involved with hepatic fi brosis.

• Identifi ed elevated serum hyaluronic acid levels as a

new diagnostic marker for the detection of cirrhosis

in patients with haemochromatosis, obviating the

need for liver biopsy in 60 percent of patients with

this disease suspected of having cirrhosis.

• Demonstrated a role for the chemokine monocyte

chemotaxis protein-1 (MCP-1), derived from peri-scar

hepatocytes in the recruitment of scar-forming hepatic

stellate cells in cholestatic liver diseases of children

including cystic fi brosis and biliary atresia, and a

mechanism for its induction via the hydrophobic bile

acid, taurocholic acid.

• Identifi ed a panel of serum makers that can be

used in conjunction with either liver biopsy or

ultrasound scans to predict development of serious

liver complications, including portal hypertension,

in children with cystic fi brosis.

The hepatic stellate cell produces scar tissue in

liver disease, thus understanding the processes that

regulate this cell is crucial to developing future therapies.

This laboratory has now identifi ed three such regulatory

mechanisms: the signalling mechanisms/genes regulated

by Lymphotoxin-β in hepatic regeneration, tissue ferritin

in infl ammation and a hepatic stellate cell chemokine,

MCP-1, in cholestatic liver disease. Knowledge from

studying these mechanisms will greatly assist in targeting

research towards therapeutics to support liver function,

aid regeneration and treat liver disease.

Signifi cant advances have been made in developing

diagnostic tests to assess liver fi brosis in

haemochromatosis and cystic fi brosis (CF) patients.

This group has demonstrated that elevated serum

hyaluronic acid levels accurately identify haemochromatosis

patients with cirrhosis, and when serum ferritin is used

as an initial screen of risk, 60 percent of patients no

longer require an invasive liver biopsy. More recently

a panel of serum markers have been identifi ed that

are better than current clinical tests predicting whether

a child with CF will develop serious complications

associated with their liver disease.

Indirect immunofl uorescence and confocal microscopy showing close spatial

association between αSMA positive (fi brogenic) hepatic stellate cells (red) and

LT-β positive oval cells and small hepatocytes (green) in a mouse model of

chronic liver injury and fi brosis.

The Hepatic Fibrosis Group investigates the cellular and

molecular mechanisms of scar tissue formation in the liver,

such as the iron overload disease haemochromatosis, that

leads to fi brosis and cirrhosis in adults, and cystic fi brosis

and biliary atresia in children.

The Iron Metabolism Laboratory focuses on understanding

the homeostasis of the essential trace element iron in the

body and the natural history of disorders of iron metabolism

such as the iron loading disease haemochromatosis.


IRON METABOLISMLaboratory Head: Professor Greg Anderson

HIGHLIGHTS

• Defi ned disease progression and penetrance in

hereditary haemochromatosis.

• Examined iron homeostasis in chronic haemolytic

anaemia.

• Identifi ed key factors involved in the modulating

expression of the iron regulatory hormone hepcidin.

• Demonstrated a role for iron in duodenal

ulcerogenesis.

Iron is essential for a large number of critical cellular

processes but its concentration in the body must be

kept within defi ned limits. Too little iron can result in

anaemia while too much can cause damage to vital

organs such as the liver and heart. A central goal of

the Iron Metabolism Laboratory is to understand the

mechanisms of cellular iron transport and the way in

which these processes are regulated. A particular theme

is to describe the pathways of intestinal iron absorption

and to understand how absorption is altered in disorders

of iron metabolism such as haemochromatosis and

thalassaemia.

Recent efforts have been directed towards

understanding physiological variations in iron absorption

at the molecular level and this work has helped defi ne

the mechanism by which the liver-derived regulatory

peptide hepcidin acts to regulate iron absorption. Key

recent studies have examined how hepcidin is regulated

in chronic haemolytic anaemia, defi ned interactions

between different stimuli that alter hepcidin expression,

and examined iron homeostasis during pregnancy and

in neonates.

This group also maintains a strong interest in the

pathogenesis, penetrance and genetics of the iron

loading disorder haemochromatosis and has recently

contributed to a series of important studies to defi ne the

penetrance of haemochromatosis and the natural history

of the disease in caucasians.



The Leukaemia Foundation of Queensland Laboratory

is seeking to understand the role of critical cellular

proteins in the causation and evolution of leukaemia

and other cancers.


LEUKAEMIA FOUNDATION

(WITH THE UNIVERSITY OF QUEENSLAND)

Laboratory Head: Professor Andrew Boyd

HIGHLIGHTS

• Developed and undertook pre-clinical studies of

antibodies for treatment of leukaemia and other

cancers.

• Analysed the effects of epigenetic silencing of Eph

genes in human cancer.

• Developed a Glioblastoma Research Unit at QIMR

following a charitable donation by Mrs Marno

Parsons.

• Continued pre-clinical development of novel

Eph-based therapeutics for nerve injury.

This laboratory has continued pre-clinical studies on

antibodies to Eph proteins. In particular an antibody to

EphA3, raised initially against a childhood leukaemia,

has been tested in leukaemia and other cancer models.

Antibodies to other EphA proteins have been investigated

in a variety of human tumours, complementing studies

of expression in clinical samples. A clear dichotomy

between oncogenic roles in some cancers, including

glioma, with tumour suppressor roles in other cancers,

especially those of epithelial origin, is being investigated.

In the latter, downregulation of Eph expression, mediated

by epigenetic mechanisms, predicts poor survival in

colorectal cancers.

Investigation of EphA4 function has led to the intriguing

observation that inhibitors of this gene can treat spinal

cord injury in mice. This is being pursued in collaboration

with the Queensland Brain Institute as a potential

human therapy.

Differentiating Glioblastoma cells following EphA3 knockdown.


This laboratory studies how iron metabolism is regulated

by the liver. Identifi cation of the molecules involved in iron

metabolism, and defi ning the way they work has major

implications for the treatment of iron-related disorders

such as hereditary haemochromatosis and anaemia.


MEMBRANE TRANSPORTLaboratory Head: Associate Professor Nathan Subramaniam

HIGHLIGHTS

• Established that serum ferritin and hyaluronic

acid levels can be used to accurately predict liver

cirrhosis.

• Demonstrated that Kupffer cells modulate iron

homeostasis by regulation of the liver specifi c iron

regulatory peptide hepcidin.

• Demonstrated that juvenile haemochromatosis may

be due to other causes than iron regulation.

Research in this laboratory is aimed at defi ning how

iron metabolism is regulated and how genes which

are mutated in iron disorders regulate this process.

The group has been instrumental in defi ning a number

of new mutations in genes which are associated with

atypical or non-HFE haemochromatosis in Australia and

internationally.

In a collaborative study with Professor Crawford of

the Greenslopes Hospital and the Hepatic Fibrosis

Laboratory, it was shown that liver cirrhosis, which

can be caused by increased iron in the liver, can be

accurately predicted through the analysis of serum levels

of ferritin and hyaluronic acid. These studies are an

advance in the generation of non-invasive markers for

the diagnosis of liver disease. It was also shown that the

macrophage cells of the liver, the Kupffer cells, have a

negative effect on the expression of the iron regulatory

hormone hepcidin.

A recent study is aimed at identifying how matriptase-2

works to regulate hepcidin. Preliminary studies show

that hemojuvelin, a positive regulator of hepcidin, is

a substrate for matriptase-2. These studies will be

important in defi ning the molecules and mechanisms

involved in the regulation of iron disorders such as

anaemia and haemochromatosis.

The role of iron in liver disease



CANCER COUNCIL QUEENSLAND (CCQ) TRANSGENICSLaboratory Head: Dr Graham Kay

HIGHLIGHTS

• Used microarray gene expression analysis to identify

autosomal genes where expression is controlled by

the action of SmcHD1.

• Used gene targeting to generate a mouse which

has the endogenous SmcHD1 gene engineered

to produce a fusion protein with green fl uorescent

protein (GFP) attached to SmcHD1 protein opening

up a myriad of potential studies which can examine

the function of SmcHD1.

• Found that compound deletion of Rb1 and p53

in the adrenal medulla results in spontaneous

pheochromocytoma with 100 percent penetrance.

Epigenetic control of gene expression is mediated by

mechanisms that modulate access of the transcription

machinery to the genome. This is ultimately how

patterns of gene expression are established and is one

of the most important areas of research in molecular

biology at the moment – unravelling the mechanism by

which the information encoded in the genome translates

into phenotypic outcomes.

Recently this group has shown that SmcHD1 is an

important new player in the epigenetic mechanism that

silences one of the two X chromosomes in females

during early development. Subsequent studies using

microarray gene expression analysis have shown that

SmcHD1 is not uniquely involved in X inactivation but

is also involved in silencing the expression of numerous

autosomal genes during development in both males and

females. The mechanism by which SmcHD1 modulates

gene expression at these numerous genomic locations is

now being investigated.

Other studies are concentrating on the role of the

pocket protein family of tumour suppressors Rb1, Rbl1

and Rbl2, in the cascade of events leading to cancer.

Development and cellular homeostasis necessitates

the orchestrated interplay of oncogene and tumour

suppressor gene function. Disruption of this delicate

interaction can lead to transformation or apoptosis

depending on the cell type. An integral event in cellular

transformation is the escape of the cell cycle from

normal regulatory constraints. The pocket proteins

constitute an important family of tumour suppressors

that regulate cell cycle progression. The group has

shown that the compound knockout of Rb1 and

Trp53 in adrenal chromaffi n cells is suffi cient to induce

adrenal medulla tumours at 100 percent penetrance.

The tumours are commonly bilateral and bear all the

hallmarks of typical pheochromocytoma.

The CCQ Transgenics (previously QCF) Laboratory

studies the epigenetic mechanisms that act

during embryonic development to modulate gene

expression and the role of tumour suppressor genes

in preventing cancer.



RADIATION BIOLOGY AND ONCOLOGY(WITH THE UNIVERSITY OF QUEENSLAND)

Laboratory Head: Professor Martin Lavin

HIGHLIGHTS

• Produced fi rst description of a patient with defi ciency

in Rad50 – a member of the complex that senses

DNA double strand breaks.

• Described a role for senataxin, defi cient in AOA2

(Ataxia-oculomotor apraxia, Type 2), in RNA

processing for the fi rst time.

• Discovered a role for aprataxin, defective in AOA1

(Ataxia-oculomotor apraxia, Type1), in single strand

break repair.

• Determined the importance of the Pseudonaja textilis

protease inhibitor as an anti-bleeding agent.

• Described the Pseudonaja textilis Factor V-like

protein as a constitutively active procoagulant.

• Demonstrated that the prostate cancer specifi c

gene (PCA3) is embedded in a second gene

(BMCC1) and revealed its potential role as a

biomarker for prostate cancer.

Previously, this laboratory has focused on the human

genetic disorder ataxia-telangiectasia (A-T) as a

model system to investigate cancer development and

neurogeneration. More recently, the work has extended

to include several other disorders that overlap with A-T

in their clinical phenotype including AOA1 and AOA2.

Progress has been made in describing additional

autophosphorylation sites important in the activation of

the ATM gene. In collaboration with Thilo Dork from

Hannover, the fi rst Rad50 defi cient patient has been

identifi ed. Rad50 represents a member of the Mre11

complex (Mre11/Rad50/Nbs1) that acts as a sensor of

DNA double strand breaks, and is a new substrate for

ATM. Studies are underway to investigate the functional

signifi cance of Rad50 phosphorylation in response to

DNA damage.

This laboratory has reported the fi rst comprehensive

description of the characteristics of senataxin, the protein

defective in AOA2. This protein has a role in protecting

cells against this form of stress and is also involved in

transcriptional control and mRNA splicing. Progress

was also made on the function of aprataxin, defective in

AOA1, with data demonstrating that it binds to proteins

involved in DNA single strand and DNA double strand

break repair. A role in the process is being investigated.

In collaboration with Professor Gardiner of The University

of Queensland, important progress in developing

biomarkers for prostate cancer has been made. Greater

complexity in the prostate cancer gene (PCA3) has been

demonstrated and also that it is embedded in a second

gene BMCC1. Work is underway to identify additional

biomarkers for diagnosis and prognosis of the disease.

As part of a collaborative program with QrxPharm,

the venomics group in this laboratory has successfully

described the proteome of 20 Australian snake

venoms and further progressed two anti-bleeding

agents, Textilinin and Haempatch that have potential

as therapeutics with application in haemostasis.

DNA damage response and its role in maintaining

the integrity of DNA to minimise the risk of cancer

and neurodegeneration is the major focus of

research activities in this laboratory.



RBWH GASTROENTEROLOGYLaboratory Head: Professor Barbara Leggett

HIGHLIGHTS

• Found that distinct methylation signatures in

histologically normal colorectal tissue can predict the

subtype of colorectal polyp that may develop.

• Identifi ed a subset of colorectal polyps more likely to

exhibit aggressive clinical behavior.

• Found that cancers with the combination of both

BRAF mutation and p53 mutation are more likely to

present at an advanced stage.

• Demonstrated that methylation of the ID4 gene

correlates with BRAF mutation, microsatellite

instability and can modify in vivo tumour growth.

• Found a signifi cant association between PIK3CA

mutation and mutation of the K-ras oncogene.

• Completed a multicentre study to evaluate different

methodologies for clinical mutation testing of the

K-ras oncogene.

Molecular changes underlie the initiation of bowel polyps,

and progression of these polyps to cancer. Bowel polyps

and cancers can be divided into clinically relevant

subgroups based on molecular changes. A better

understanding of these lesions will improve management

of patients with polyps and will ultimately lead to

improved therapy for patients with advanced disease.

By conducting a large, prospective study of patients

undergoing colonoscopic screening, this group has

identifi ed methylation signatures in normal colorectal

tissue that associate with either conventional or serrated

type polyps. These fi ndings may impact future surveillance

strategies. Another recent fi nding – that a proportion of

conventional polyps showing mild villous morphology share

molecular features characteristic of advanced polyps -

suggests that patients presenting with these lesions may

require more frequent colonoscopic surveillance.

This laboratory has also demonstrated that the p53 tumour

suppressor gene is frequently mutated in the subset of

BRAF mutant cancers that are more likely to present at an

advanced stage, and are further characterising this group

of cancers with the aim of improving understanding of

why they exhibit this aggressive behavior.

This laboratory identifi es genetic changes which defi ne

distinct subtypes of colon cancers and premalignant

polyps with the aim of predicting the clinical behaviour

of these tumours.



SIGNAL TRANSDUCTIONLaboratory Head: Dr Kum Kum Khanna

HIGHLIGHTS

• Characterised the function of hSSB1 and hSSB2

as a critical regulator of genome integrity.

• Characterised the role of repair nuclease EXO-1

in regulation of DNA damage-induced apoptosis.

• Identifi ed a novel role of PTEN tumour suppressor

in the regulation of mitotic spindle checkpoint.

• Characterised a new centrosomal protein, centrobin,

as a crucial regulator of mitotic spindles.

Progress on the functional analysis of two single

stranded DNA binding proteins, reported last year,

showed that hSSB2 plays a similar role as hSSB1 in

DNA damage response pathways. Both hSSBs are

recruited immediately to sites of DNA damage induced

by laser microirradiation or soft x-ray. This raises

interesting questions concerning potential roles of these

proteins in DNA damage detection as well as in repair.

A role for the mammalian DNA repair enzyme

Exonuclease 1 (Exo1) in DNA damage-induced

apoptosis, where EXO-1 was shown to act upstream

of caspase-3, has been described. In addition, induction

of apoptosis with DNA-damaging agents led to cleavage

of Exo1. These fi nding led to the conclusion that Exo1

has a role in the timely induction of apoptosis and that it

is subsequently cleaved and degraded during apoptosis.

A novel role for PTEN tumour suppressor, a key

regulator of PI-3 kinase pathway, frequently affected in

breast cancer, in the regulation of mitotic checkpoint has

been identifi ed. Evidence has also been provided that

the chromosome segregation defects, due to defect in

mitotic checkpoint, are the primary cause of the observed

chromosomal aberrations in PTEN-defi cient tumours.

Centrobin is a recently identifi ed centrosomal protein

that plays a role in stabilising the microtubule structure.

Evidence that Centrobin-depleted cells display a range

of spindle abnormalities including unfocused poles

that are not associated with centrosomes has been

provided. These results indicate that Centrobin promotes

anchoring of mitotic spindle to the centrosomes, which

is required for the stability of microtubule-kinetochore

attachments and biogenesis of properly functioning

mitotic spindle.

GFP-tagged hSSB2 accumulates at laser-induced DNA damage sites.

Time-lapse imaging

This laboratory researches signal transduction pathways

involved in the detection, signalling or repair of DNA

damage and seeks other genes in these pathways which

might have similar involvement in cancer susceptibility by

preventing the generation of mutations in DNA.

58 • QIMR - Annual Report 2008-200958 • QIMR - Annual Report 2008-2009


SKIN CARCINOGENESISLaboratory Head: Dr Graeme Walker

HIGHLIGHTS

• Found that melanocyte stem cells are only activated

by signals from surrounding Kit-responsive transit

amplifying melanoblasts.

Lentigo melanomas that are associated with chronic

sun exposure seem to emanate from the follicle. It is not

known whether the most undifferentiated melanocytes,

melanocyte stem cells, are activated to UVR. The only

confi rmed location of such cells is the bulge region of

the hair follicle in both humans and mice.

Recently established at QIMR, this laboratory has used

normal mice as a model to assess whether these cells

are activated by UVR exposure. In isolation they do not.

However the results suggest that it is the surrounding

transit amplifying cells that proliferate in response to

UVR, after which the stem cells respond. Thus the stem

cells are very sensitive to the presence of surrounding

melanocytes.

These studies will improve understanding of how activation

of follicular melanocytes may play a role in the initiation

of some melanomas.

This laboratory is interested in the interaction of

genetic and environmental factors in melanoma

development and in particular how ultraviolet

radiation (UVR) initiates melanoma.

Arrows denote melanocytes (red) stained an anti-Trp1 antibody. UVR-activated melanocytes

(arrowed) can be seen at the base of the epidermis and in the upper portion of a hair follicle.

B - Atypical melanocytes in a melanoma.

QIMR - Annual Report 2008-2009 • 59 • t 22 8-28-2009009MRMR -- An Annuanual l MM 2002008-28-2

INFECTIOUS DISEASES DIVISIONDivision Chair: Professor James McCarthy

The 13 laboratories that comprise the Infectious

Diseases Division study how a range of important

pathogenic organisms cause illness, and search for

better ways to diagnose and treat, as well as developing

vaccines to prevent disease. A major emphasis of

work undertaken in the division is on pathogens that

disproportionately affect people living in the developing

world and tropics.

Pathogens studied include parasites such as malaria,

worms, scabies, and intestinal protozoa, bacteria

such as streptococci, and viruses including HIV and

mosquito-borne viruses. One laboratory in the group

focuses on the application of proteomic technology to

biomedical science.

In the last 12 months, members of the division have

successfully secured funding for their work from

prestigious bodies including the National Institute of

Health (NIH), National Health and Medical Research

Council (NHMRC) program and project grant system,

as well as the Gates Foundation. A new laboratory

headed by Dr Malcolm Jones has been established in

the division focusing on the cell biology of parasites.

• • 595999 AnAnAnAnnnQQIMIMQQIMIM RRepoeportrtl Rl R rtrtt 2002008-28-2MM rt rt QIMR - Annual Report 2008-2009 • 59


INFECTIOUS DISEASES DIVISION

BACTERIAL PATHOGENESISLaboratory Head: Professor Kadaba Sriprakash

HIGHLIGHTS

• Found that Group G Streptococci (GGS) and not

Group A Streptococci (GAS) are the major beta-

haemolytic bacterial species found in the throats

of Indian children.

• Demonstrated that Streptococcus gordonii is a

viable model for the live delivery of peptide antigen

for GAS vaccines.

• Demonstrated that recombinant expression of a

GAS peptide vaccine candidate induces functional

antibody response.

• Established the evolutionary relationships of clinically

relevant GGS through multi-locus sequence profi ling

of 250 isolates.

• Demonstrated that DNA can be exchanged between

GGS and other bacterial species when grown in

biofi lms.

• Identifi ed SpeB, a major GAS virulence factor,

in some GGS isolates.

• Showed that catheters diagnosed as sterile by

traditional microbiology methods, are colonised

by numerous bacterial species.

This laboratory investigates the causes and

consequences of genetic diversity that occurs in

streptococcal populations around the world.

Last year, MLST (multi locus sequencing typing)

genetic profi ling of 250 skin and throat streptococcal

isolates from India were completed and this data

is currently being assessed to determine whether

streptococci from the skin are genetically different to

streptococci from the throat. MLST profi les generated

in this laboratory from Australian GGS isolates, and by

collaborators from the USA and Portugal, are being used

to construct a map of evolutionary relationships between

different GGS isolates. Such a map may help identify

related bacteria that are more likely to cause specifi c

streptococcal disease.

Work on a recombinant Group A Streptococcal vaccine

is also showing great promise with the demonstration

that this vaccine (JJo) induces signifi cant antibody

production in mice and that these antibodies can also

kill GAS and GGS in in vitro assays. This is a part of a

collaborative study with researchers in India.

In collaboration with colleagues at Griffi th University,

bacterial populations on the surface of catheters are

being investigated with experiments showing that

many different species can be found on the surface of

catheters taken from hospital patients. The implications

of these fi ndings to clinical practice are currently being

evaluated.

This laboratory undertakes research into Streptococci,

Staphylococci, and other medically important bacteria.


The focus of this laboratory is the identifi cation,

characterisation and evaluation of potential vaccine

candidates for Group A Streptococcus (GAS) specifi cally

Streptococcus pyogenes, and other bacterial pathogens.


BACTERIAL VACCINESLaboratory Head: Dr Michael Batzloff

HIGHLIGHTS

• Demonstrated that J8-DT mediated protection

against Group A Streptococcus is antibody mediated

(in collaboration with the Molecular Immunology

Laboratory).

• Commenced pre-GMP (good manufacturing)

pilot runs of the J8-DT/alum vaccine formulation

(in collaboration with the Molecular Immunology

Laboratory).

• Demonstrated a novel pathway for Burkholderia

pseudomallei infection of the nasal cavity leading to

direct infection of the brain.

Signifi cant progress has been made towards a vaccine

for Group A Streptococcus and associated diseases.

Using a variety of techniques including passive transfer

and T-cell depletion this group has demonstrated that

J8-DT/alum induced protection is antibody mediated.

This observation has a large impact on vaccine design

and adjuvant selection. Coinciding with this, two pilot

production runs of the J8-DT/alum vaccine have been

commenced in preparation for the GMP production run.

Burkholderia pseudomallei is another bacterial

pathogen that is a serious problem in tropical areas

including northern Australia. In collaboration with Griffi th

University through the Griffi th Medical Research College,

this laboratory was able to demonstrate a possible

new route of infection - intranasal exposure in mice

resulting in direct infection of the brain. Traditionally, this

bacterium was thought to colonise the lung, progress

into the blood and then cross the blood brain barrier.

This observation could impact on currently proposed

vaccine strategies.



CLINICAL TROPICAL MEDICINELaboratory Head: Professor James McCarthy

HIGHLIGHTS

• Documented evidence of increasing in vitro tolerance

of scabies mites to ivermectin in scabies endemic

communities.

• Validated the role of metabolic degradation as a

mechanism that the scabies mite uses to resist

permethrin treatment.

• Established a pig model of human scabies infection

that will serve as an invaluable source of material for

studying scabies.

• Completed a Phase 1 trial of a new formulation of

the blood stage malaria vaccine candidate MSP2.

• Discovered that hookworms develop resistance

to the anthelmintic pyrantel by changing their

expression of acetylcholine receptors.

This laboratory continues to explore the molecular

mechanisms of acaricide resistance in the scabies

mite which has led to developing of tests for improved

resistance management and treatment strategies.

This year, in vitro molecular and biochemical techniques

have been employed, promoting substantial progress,

particularly concerning the contribution of metabolic

pathways to acaricide resistance.

In August 2008, the group participated in the fi rst

ever national scabies meeting in Darwin. The meeting

brought together scabies experts from fi ve different

institutions across Australia and highlighted the need

for a multidisciplinary approach to battle scabies.

Topics addressed included public health, clinical,

molecular, genetic, immunological and veterinary

aspects of the disease.

The group is also participating in several international

collaborative research projects including work on

anthelmintic resistance, the effect of various antiretroviral

regimens on the incidence of malaria, and on malaria

control in the Solomon Islands and Vanuatu.

Collaborations with QIMR’s Molecular Immunology and

Bacterial Vaccines Laboratories are bringing a Group

A Streptococcus vaccine to Phase 1 clinical trial and

developing a live malaria parasite stock for human

challenge studies and vaccine development.

This laboratory investigates how parasites such as the

malaria parasite, hookworm, threadworm and scabies

cause disease and how they become resistant to drugs

used to treat them. The group also identifi es new drugs

and drug targets, and develops novel diagnostic techniques.


The Helminth Biology Laboratory explores the

molecular basis of host-parasite interactions, with

a particular emphasis on the proteins secreted by

parasitic helminths and their effi cacy as vaccines

and novel therapeutics for autoimmune disorders.


HELMINTH BIOLOGYLaboratory Head: Dr Alex Loukas

HIGHLIGHTS

• Showed that human hookworm infection can

suppress pathology of celiac disease in a clinical trial.

• Identifi ed granulin as a growth factor secreted by

parasitic liver fl ukes that causes host cells to multiply

and establish a carcinogenic environment.

• Generated neutralising antibodies against the Na-

APR-1 human hookworm vaccine antigen and used

these antigens to make soluble chimeras for clinical

development.

• Characterised the secretomes of hookworms and

liver fl ukes using proteomics.

This group has identifi ed effi cacious recombinant

vaccines for the two major blood-feeding helminth

parasites of humans (schistosomes and hookworms)

and both are under clinical development. Funding

has been secured from the Sabin Vaccine Institute

to develop the Sm-TSP-2 schistosomiasis vaccine

and take it into clinical trials. Proteomics are being

used to characterise the secretomes of hookworms,

schistosomes and liver fl ukes for antigen discovery and

the search for novel therapeutics.

A clinical trial with gastroenterologist colleagues to

assess the ability of hookworms to suppress infl ammation

in celiac disease was recently completed. Mouse models

of celiac disease and infl ammatory bowel diseases are

also being developed to assess the therapeutic

potential of hookworm secreted proteins. The group

is actively searching for proteins secreted by liver

fl ukes that cause biliary cells to proliferate and establish

a pro-tumourigenic environment.

This year, Dr Alex Loukas became Editor-in-Chief of

the International Journal for Parasitology, the highest

ranked journal devoted to publishing research articles

exclusively dealing with parasitology.

Histological section showing the human liver fl uke, Opisthorchis viverrini,

in the bile duct of an experimentally infected hamster. Orange staining

highlights Ov-GRN-1, a growth factor secreted by the parasite into the host

bile ducts where it causes proliferation of cholangiocytes.



HIV MOLECULAR VIROLOGYLaboratory Head: Associate Professor David Harrich

• Found that phosphorylated reverse transcriptase

isoforms are prominent during the infection process.

• Showed that cell factors stimulate HIV-1 Late DNA

synthesis in vitro.

• Showed that the repressor of reverse transcription,

a novel RNA element, is critical for optimal HIV-1

replication.

• Determined that the protein arginine

methyltransferase 6 (PRMT6) regulates the steady

state level of Tat in cells.

• Showed that a mutant form of Tat (an important HIV

protein) is a potent inhibitor of HIV-1 replication.

HIV is the cause of acquired immunodefi ciency

syndrome (AIDS) for which there is no cure or effective

protective vaccine. There are currently 25 million

infected people worldwide and approximately two million

new infections yearly. People living with HIV/AIDS have

access to antiretroviral drugs that can stop HIV growth

and which have decreased the fatal consequence of

infection. Many infected people have lived with HIV for

more than 20 years. Unfortunately, HIV is able to rapidly

mutate so that antiretroviral drugs are no longer effective.

This laboratory studies the HIV life cycle at the molecular

level and seeks to fi nd new means to stop virus growth

through a detailed analysis of virus interaction with

the host cell and is particularly interested in how cellular

proteins facilitate synthesis of viral DNA. To this end,

the group has devised a novel test that can be used

to identify cellular factors required for HIV growth.

Their experiments show that an important HIV protein

called Tat is stabilised in cells by a cellular protein

called PRMT6.

The group also investigated how viral factors facilitate

the infection process and made two new discoveries.

Firstly, they devised a way to dramatically slow HIV

growth using a mutated viral protein, and secondly,

disrupted virus replication by targeting a novel repressor

of HIV DNA synthesis. These projects will potentially

result in novel means to stop virus growth in people

living with HIV/AIDS.

HIGHLIGHTS

The principal focus in this laboratory is detailed

analysis of HIV replication. This includes the processes

by which HIV is able to convert its genetic material,

composed of RNA, into a form compatible with human

DNA. Elucidating the role of viral and cellular factors in

regulating HIV replication is a primary goal.



MALARIA BIOLOGYLaboratory Head: Dr Donald Gardiner

HIGHLIGHTS

• Determined the crystal structure of the M1

aminopeptidase from Plasmodium falciparum.

• Identifi ed REX1 as a vital component of

P. falciparum maurers clefts.

• Developed a FACS-based assay system to

measure the effect of antimalarial drugs on

P. falciparum gametocytes.

Malaria remains a leading cause of morbidity and

mortality worldwide with between one and two million

deaths per annum directly attributable to this disease.

The Malaria Biology Laboratory has several ongoing

projects which focus on rational drug targeting and novel

intervention strategies.

Production of sexual stages or gametocytes is essential

for transmission of the malaria parasite through the mosquito

vector but little is known about this life cycle stage.

This group is examining the effect of antimalarial drugs

on gametocytes and looking at basic gametocyte

biology with a particular focus on potential intervention

strategies.

In collaboration with colleagues at University of

Technology Sydney, aminopeptidases have been shown

as promising drug targets. Currently these enzymes

are being characterised and the activity of specifi cally

designed inhibitors investigated in vitro and in vivo.

The antimalarial activity of the APIs continue to be

investigated, both alone and in combination with

other drugs. Recent evidence suggests that these

drugs target an uncharacterised P. falciparum aspartic

protease. The group plans to determine the function and

structure of this enzyme so that new inhibitors, that are

both potent and specifi c, can be developed.

This laboratory uses transgenic approaches to

investigate antimalarial drug targets, mechanisms

of antimalarial drug action and antimalarial drug

resistance. These studies are essential in the current

era of multi-drug resistant (MDR) malaria parasites.


HIGHLIGHTS

• Characterised parasites used to test the performance

of malaria rapid diagnostic tests (RDTs) and analysed

the results of product testing for the WHO-FIND Malaria

Rapid Diagnostic Tests (RDT) Evaluation Program.

• Identifi ed and characterised Plasmodium falciparum

parasites that lack genes that encode antigens

targeted by malaria RDTs, a fi nding which has

profound implications in the selection of malaria

RDTs for malaria control and elimination.

• Simulated multiple P. falciparum control and

elimination strategies using a mathematical model to

help identify the likely impact of these strategies in

different regions.

• Investigated the phenomenon of parasite dormancy

following exposure to artemisinin drugs and defi ned

the duration and recovery rates in parasites with

different genetic backgrounds.

• Demonstrated that chromosomal rearrangements

occur frequently around the pfmdr1 locus following

the development of parasite resistance to artelinic

acid in vitro.

• Worked with the Pacifi c Malaria Initiative Support

Centre (PACMISC) at The University of Queensland

(UQ) to conduct molecular epidemiological surveys in

Tanna Island, Vanuatu and Santa Cruz Islands in the

Solomon Islands.

As part of the WHO-FIND Malaria RDT Evaluation

Program, parasites used for product testing have been

characterised and data obtained from round one of the

product testing analysed. Test results provided a direct

comparison of the performance of malaria RDTs under

laboratory conditions - a valuable tool for countries

and agencies to make informed choices. Filed parasites

from South America lacking genes encoding antigens

that are often targeted by malaria RDTs have also been

identifi ed. This also has important implications in the

selection of effective malaria RDTs.

This laboratory is investigating the possible causes of

treatment failure when artemisinin derivatives are used

alone for the treatment of malaria. One hypothesis is that

the parasite arrests its growth following exposure to the

artemisinin drugs and the group has demonstrated that

this is plausible. Frequent chromosomal rearrangements

have also been observed around the pfmdr1 locus

in parasites resistant to artelinic acid. This may be an

important mechanism used by the parasite to develop

resistance to this class of drugs.

A stochastic simulation model of malaria transmission

has been used to investigate the long-term outcomes

of different intervention strategies. The fi ndings will have

signifi cant impact on the global malaria control and

elimination.


MALARIA DRUG RESISTANCE

AND CHEMOTHERAPYLaboratory Head: Dr Qin Cheng

This laboratory studies the mechanisms and factors

infl uencing the development and spread of drug

resistance in malaria parasites, and investigates ways to

improve the diagnosis and treatment of malaria.



MOLECULAR GENETICSLaboratory Head: Associate Professor Peter Upcroft

This laboratory works on the three most medically

important anaerobic protozoan parasites, the sexually

transmitted Trichomonas vaginalis, the intestinal parasite

Giardia duodenalis and invasive Entamoeba histolytica.

HIGHLIGHTS

• Developed new lead compounds from previous

research on novel nitroimidazoles to bypass drug

resistance in anaerobic protozoa.

• Used click chemistry to generate fourth and fi fth

generation novel nitroimidazoles that are over 300

times more potent than previous nitroimidazoles and

are nontoxic and nonmutagenic. Over 1000 new

compounds have been generated and are at various

stages of evaluation.

• Mapped major chromosomes of Giardia duodenalis

chromosomes using DNA probes specifi c for

individual NotI –cleaved chromosome segments,

and corrected assembly errors generated by solely

computer-utilised whole genome sequencing

approaches, thereby resolving anomalies between

published putative chromosome sizes.

The protozoan parasites Giardia and Trichomonas are

susceptible to the 5-nitroimidazole drug, metronidazole.

This laboratory has developed resistance against a

highly effective new 5-nitroimidazole, C17, in several

Giardia isolates. The C17-resistant parasites proved

to be far more resistant to metronidazole than any line

previously developed. This mechanism of super cross-

resistance is being rigorously pursued.

The key proteins involved in activation of the prodrug

metronidazole to its toxic state are pyruvate ferredoxin

oxidoreductase (PFOR) and ferredoxin (Fd). There are

2 PFOR genes in the Giardia genome database. This

group has determined that only pure PFOR (PFOR1)

is responsible for metronidazole activation. The group

therefore concluded that PFOR1 is a member of a

membrane complex and that the characteristics of the

PFOR1 enzyme varies according to the state of the

complex, such that different substrates can be used

by the enzyme in the complex. The signifi cance of this

fi nding to mechanisms of drug resistance and enzyme

substrate specifi city in Giardia is being pursued.

There are fi ve major chromosomes in the Giardia duodenalis

genome, ranging in size from 1.5-3.8 Mb, and until now no

sequence map has been compiled. Prior to the release

of the Giardia genome sequence, this laboratory compiled

maps of chromosome-specifi c NotI segments. They are

now able to confi rm these maps by correlating sequences

of chromosome specifi c probes identifying the NotI

segments with scaffold sequences in GiardiaDB, the Giardia

genome sequence database. Scaffolds have been

assigned to all chromosomes, errors in scaffold construction

identifi ed and solutions proposed to some of the issues,

exemplifying the value of multiple approaches to

understanding genome organisation.



MOLECULAR PARASITOLOGYLaboratory Head: Professor Don McManus

• Completed a draft genomic sequence for

Schistosoma japonicum, which is the fi rst reported

for any fl atworm, indeed for any member of the

superphylum Lophotrochozoa which includes the

platyhelmith worms, annelids and molluscs.

• Showed that buffaloes are the major reservoir

hosts of human schistosomiasis in southern China,

reinforcing the rationale for the development and

deployment of a transmission blocking anti-S.

japonicum vaccine targeting bovines.

• Continued the development of a transmission

blocking vaccine in dogs against hydatid disease.

Schistosomiasis

This laboratory monitored the preventive effects of the

anti-malarial drug artemether against S. japonicum

infection in humans, including the effectiveness

of combined artemether and praziquantel treatment.

The group developed and tested several schistosome

vaccine candidate molecules for blocking transmission

in buffaloes. A mathematical model of S. japonicum

transmission was validated and used to predict the

impact of interventions, particularly vaccination. The group

continued to work on the environmental and genetic

factors involved in predisposed schistosome infection,

and also analysis of the molecular and cellular mechanisms

leading to chronic disease in schistosomiasis.

The laboratory completed a draft genomic DNA

sequence for S. japonicum. This landmark research will

have major implications for understanding the biology

and evolution of schistosomes and for identifying new

targets for vaccination and diagnosis.

Echinococcosis

Work on echinococcosis included the continuation of

major fi eld and epidemiological studies in China, and as

well as further successful vaccination trials in China against

echinococcosis in dog defi nitive hosts. This is important,

because it provides further proof that vaccination of the

dog host against Echinococcus granulosus is feasible

using recombinantly-derived proteins and that this

approach can be developed as an important intervention

for the control of hydatid disease.

This laboratory researches the biology, pathogenesis and

epidemiology of parasitic worms that infect humans with

the aim of developing new public health interventions,

including vaccines, and diagnostic procedures that will

lead to their elimination through integrated control.

HIGHLIGHTS

A mated pair of

Schistosoma

mansoni blood fl ukes

at approximately

x265 magnifi cation

(photomicrograph

by David Scharf).

Reprinted by

permission from

Macmillan Publishers

Ltd: Nature 460,

7253 (16 July 2009)

Cover.


• Determined the impact of householder behaviours

in use of rainwater tanks and other water storage

containers in south east Queensland and the

potential for increased habitat for mosquito larvae.

• Mitigated dengue risk in areas in southern

Vietnam through the use of community-based

biological control interventions to control immature

Aedes aegypti.

• Showed that a Wolbachia endosymbiont blocks

susceptibility of Ae. aegypti to the dengue virus.

• Characterised important age-related changes in

protein abundance in Ae. aegypti.

Research has focused on defi ning and improving

current and future arboviral disease threats in Australia

and Asia. Aedes aegypti, the global mosquito vector

of dengue viruses, is widespread in Queensland but

not in Brisbane. Recently, drought and subsequent

water restrictions have led to signifi cant changes in

householder behaviours regarding water conservation.

In south-east Queensland this group found that 45 to 57

percent of households had one or more rainwater tanks,

and 25 to 32 percent of households stored water

in other containers, which in some areas accounted

for 30 percent of the larval mosquito population. This

increase in household water storages is a potential

public health threat as it provides a habitat for Ae.

aegypti in urban areas.

In rural areas in Vietnam, signifi cant progress has been

made in mitigating dengue risk through the use of

community-based biological control interventions to

control immature Ae. aegypti. Important age-related

changes in protein abundance in Ae. Aegypti have

also been defi ned. This work will form the basis of

future fi eld-deployable assays to measure insect age

and thereby provide better estimates of pathogen

transmission risk and also to evaluate interventions that

aim to reduce adult mosquito longevity.

HIGHLIGHTS

Dr Tim Hurst from the Mosquito Control Laboratory samples for mosquito

larvae in a suburban Brisbane backyard as part of a large scale survey to

evaluate the impact of changes in water storage patterns on local mosquito

populations and future receptivity to exotic dengue mosquitoes.


MOSQUITO CONTROLLaboratory Head: Dr Peter Ryan

Research in the Mosquito Control Laboratory focuses on

the biology and control of mosquito-borne viruses such

as dengue, Ross River virus and Barmah Forest virus.



PARASITE CELL BIOLOGYLaboratory Head: Dr Malcolm Jones

• Completed the fi rst comprehensive description of

mechanisms controlling the hatching biology of

schistosome eggs.

• Characterised the functions of a novel ferric

reductase of schistosomes demonstrating its location

in the parasite tegument.

• Provided the basis of a tissue-specifi c gene atlas for

Schistosoma japonicum.

Disease in schistosomiasis arises from host responses

to parasite eggs that have been entrapped in tissues.

Research in this newly formed laboratory has focused on

the biology of the egg, investigating how it provokes the

immune response that leads to chronic disease and how

it is equipped for survival both within and outside of the

human host.

A comprehensive structural and dynamic imaging

analysis of the eggs was completed, resulting in a model

of the molecular interactions that lead to emergence

of the parasite from the egg. A major focus of this

laboratory and others in recent years has been to

provide a transcriptional profi le of specifi c tissues of

schistosomes so the roles of many uncharacterised

proteins in parasite biology and host interactions can

be understood.

By use of the methods of laser microdissection

microscopy and microarray analysis, this group has

completed a major investigation of the tissue-specifi c

expression patterns of female schistosomes, uncovering

novel parasite molecules that are currently being

investigated as vaccine targets.

The Parasite Cell Biology Laboratory researches three

specifi c parasites: schistosomes, the hydatid tapeworm

Echinococcus granulosus and the malaria parasite

Plasmodium, particularly their host interactions which can

be exploited in control strategies.

HIGHLIGHTS



PROTEIN DISCOVERY CENTRELaboratory Head: Professor Jeff Gorman

• Demonstrated that the latent Dioxin receptor is

highly post-translationally modifi ed and that these

modifi cations are substantially shed upon activation

of this transcription factor by xenobiotics and

developmental stimuli.

• Characterised the interaction between the ankyrin

subdomain of the transcription factor Notch and

the enzyme (FIH) that also hydroxylates the hypoxia

regulating transcription factor, hypoxia inducible

factor (HIF).

• Identifi ed cellular antiviral response proteins, including

interferon induced proteins, that are suppressed by

the respiratory syncytial virus (RSV) non-structural

protein NS1 and the viral attachment protein (G) in

order for the virus to evade cellular defense mechanisms.

• Identifi ed dramatic differences in breast cancer cell

phenotypes.

• Detected suppression of the host cell TNF-alpha

pathway by RSV using a proteomic profi ling/

arraying protocol.

The QIMR Protein Discovery Centre (PDC) is a specialty

node of the national proteomics consortium, Proteomics

Australia. Its role is to provide Australian researchers

collaborative access to specialist proteomics capabilities

in the fi elds of analysis of post-translational modifi cation

and infectious disease agents.

This year, the Centre became involved in major activities

involving the serious paediatric respiratory pathogen,

respiratory syncytial virus (RSV) in collaboration with

Dr Kirsten Spann of the Sir Albert Sakzewski Virus

Research Centre and Dr Peter Collins from the National

Institute of Allergy and Infectious Diseases of the US

National Institutes of Health. Another major focus has

been on regulation of signal activated transcription

factors by post-translational modifi cation pathways in

collaboration with Drs Murray Whitelaw and Daniel Peet

from The University of Adelaide. Strong collaborations

have been forged with Professor John Bateman of The

Murdoch Children’s Research Institute involving the

proteomic analysis of cartilage development and disease.

At QIMR, a series of in-house collaborations have

commenced involving identifi cation of biomarkers

of mosquito age, identifi cation of serum biomarkers

for the classifi cation of chronic bowel diseases and

characterisation of the phenotype of breast cancer cells.

The Centre has invested in the latest mass spectrometry

hardware and recently commissioned the fi rst Thermo

MALDI-Orbitrap mass spectrometer in Australia and

the fi rst Bruker ultra high-performance ESI-Qq-TOF

instrument in the Asia-Pacifi c region. The latest advance

in gas-phase fragmentation technologies has also been

installed on the existing ESI-Orbitrap instrument. These

innovations have already contributed to achievements

refl ected in this year’s research highlights.

The Protein Discovery Centre aims to discover

the identities of proteins involved in or affected

by physiological and disease processes and the

infl uence of post-translational modifi cations on

the ways proteins function and interact.

HIGHLIGHTS



SCABIESLaboratory Head: Professor Dave Kemp

• Found that scabies mite inactivated serine protease

paralogs (SMIPP-Ss) inhibit all three complement

pathways independently and that they inhibit at the

start of each cascade by binding to C1q, MBL and

properdin.

• Determined that scabies mite serpins and cysteine

proteases also inhibit human complement.

• Showed that these scabies mite molecules enhance

GAS growth in bactericidal assays and thus directly

demonstrating a major causal link between the

biology of scabies and associated streptococcal

infections.

In collaboration with researchers from Monash University,

this laboratory determined high resolution structures for

two SMIPPs and studied their binding properties. All

SMIPPs that were tested have been shown to inhibit

complement, and because the gut of the mite contains

plasma, complement may be the central target of

SMIPPs. With the group’s Swedish collaborators, it was

confi rmed that SMIPP-Ss inhibit all three complement

pathways independently. It was shown that they inhibit

at the start of each cascade and that they bind to C1q

and MBL and possibly to C3b and properdin. This work

will be followed up in a PhD thesis.

This year, the importance of complement inhibition has

been signifi cantly reinforced by the discovery that the

products of two other scabies mite multigene families

that are found in the mite gut and faeces also inhibit

complement. This group has found that scabies mite

cysteine proteases and scabies mite serpins also inhibit

the complement cascade, both acting on different steps

to that of the SMIPPs.

In collaboration with the Bacterial Pathogenesis

Laboratory, it was demonstrated that all of these inhibitors

of complement result in enhanced growth of Group A

Streptococci in the presence of antibody and complement.

Hence, a molecular basis for the long-observed link

between scabies infestation and streptococcal infection

appears to have fi nally been found.

Work in this laboratory concentrates on the control of

diseases caused by the scabies mite, Sarcoptes scabiei.

HIGHLIGHTS

QIMR - Annual Report 2008-2009 • 73nunuanuuauauauaaaual l RRl Rl RRRRRl eeee rtrt 222QQQQQIMIMMRIMRMRIMM - AAAAAAAnAnnnAnAnA AAAAAAAAAAAnAAAAAAAAA nnnnnnn 200200200000 8-2-2222228 2222000000000 •••••••••••••••••• •••••••••••• 33333333333333333333333333

Scabies remains a truly neglected

infectious disease despite its

prevalence in Australian Indigenous

populations. I love that our research

may possibly provide the way forward

to new approaches to control scabies

and associated infections. Research

is driven by curiosity and creativity;

hence it is very rarely boring.

Dr Katja Fischer

Scabies Laboratory

Infectious Diseases Division

AAAAAAAAAAAAAAAAAAAAAAAA nnnn • •••• • 0009009090009 ••••••••• 7777777373777377737333737373737737377737737373737737377373737333RRReeepoepoe ort rt 2RRRRReeepoepee rtrt 2222 QIMR - Annual Report 2008-2009 • 73

JOINT RESEARCH



JOINT RESEARCH

AUSTRALIAN CENTRE FOR INTERNATIONAL

TROPICAL HEALTH (ACITH)

The Australian Centre for International and Tropical

Health (ACITH) is an Australian Government funded

teaching and research collaboration. Established in

1995 as joint venture with The University of

Queensland’s Faculty of Health Sciences and QIMR,

the ACITH aims to improve the health of populations

in Australia and internationally through excellence in

education, research and service.

Public health education and research capacity has

improved nationally with the instigation of the Public

Health Education and Research Program (PHERP) in

1987. However, amidst the current economic times,

it was not surprising that this program will not be

renewed for a fi fth fi ve year phase from 1 January 2011.

Nevertheless, the new Director of ACITH, Professor

Maxine Whittaker, has indicated that the strong

collaborative relationship between The University of

Queensland’s Faculty of Health Sciences and QIMR

should continue, albeit under a new model.

The intent of PHERP was to build the national capacity

to address public health emergencies; provide evidence

based research to inform policy; promote networking

and collaboration in priority areas of chronic, emerging

infectious diseases and Aboriginal and Torres Strait

Islander health; and ensure a strong output of graduates

in public health.

In 2008, ACITH produced 65 graduates through The

University of Queensland’s School of Population Health

(SPH), and 15 PhD graduates. It provided professional

development courses to government and industry

through SPH short courses on biostatistics, and

partnerships involving mosquito control and arbovirus

surveillance in Queensland and China.

One highlight was the growth of the Pacifi c Malaria

Initiative Support Centre, a collaborative arrangement

between SPH, QIMR and the Army Medical Institute,

funded by AusAID. The program focuses on three

priority areas of program management: teaching and

training; technical assistance and operational research

in Vanuatu and the Solomon Islands.

Using $1.8 million from PHERP as leverage, ACITH

reported $5.1 million of government audited and

$90 million of additional grant holdings in 2008. These

funds fuel research and facilitate the development of

Australian networks such as the Queensland Tropical

Health Alliance and the Griffi th Medical Research

College, both of which continue to be important to

both Australia and its regional partners.

In 2009, QIMR’s Professor Brian Kay chaired an

Expert Working Group under the banner of the Prime

Minister’s Science, Engineering and Innovation Council.

The report Epidemics in a Changing World listed

capacity building, interpretative skills, forward regional

engagement and cross-portfolio networking as

essential elements.

In August, Professor Kay was invested with the “Memorabilia of Peoples’ Health” medal by the

Ministry of Health, Vietnam for his outstanding and sustained contribution to dengue control.


JOINT RESEARCH

AUSTRALIAN CENTRE FOR VACCINE

DEVELOPMENT (ACVD)

The Australian Centre for Vaccine Development (ACVD)

is dedicated to providing advanced training; developing

novel technology platforms to enhance the effi cacy of

existing vaccines; and to formulating the next generation

of vaccines aimed primarily towards infectious diseases

and human malignancies. This is achieved through

collaborative links between research and manufacturing

laboratories at QIMR and international institutions.

During 2008-2009, a new Queensland-US Vaccine

Technology Alliance Program was established.

This will combine expertise from ACVD and the Emory

Vaccine Centre (EVC) at Emory University in Atlanta. The

alliance was recently awarded a three-year grant of $1.8

million from the Smart Futures Fund of the Queensland

National and International Research Alliances Program.

Additional funding has been provided by QIMR and

the Emory University, with total project funding from all

sources equalling $8.5 million over three years.

By expanding existing academic and research links,

the ACVD and EVC plan to establish an internationally

recognised vaccine research program and develop

intellectual capital in the area of vaccine technologies.

The aim is to develop novel vaccines for infectious

diseases such as glandular fever, malaria, HIV and

cytomegalovirus as well as cancers such as brain

cancer, Hodgkin’s lymphoma and melanoma. It will also

focus on developing immune-based cellular therapies

for human cancers and infectious complications in

transplant patients.

Scientists working at the ACVD made a number

of seminal contributions towards vaccine and

immunotherapy development including:

• Development of a peptide-based vaccine to prevent

EBV-associated glandular fever.

• Major progress on the development of a Group A

Streptococcus (GAS) vaccine.

• Development of Phase I clinical studies aimed at

testing novel immune-based therapies for human

cancers (e.g. nasopharyngeal carcinoma, Hodgkin’s

lymphoma, post-transplant lymphomas, glioblastoma,

and prostate cancer).

• Completion of Phase III testing of novel anti-cancer

drug PEP005.

• Development of novel diagnostic tools to

predict viral diseases in transplant patients and

immunocompromised individuals (e.g. HIV patients).

• Signing of collaborative agreements with international

biotechnology companies to co-develop vaccines for

infectious diseases and virus-associated cancers.

• Description of critical characteristics of breast cancer

stem cells identifi ed in established breast cancer

cell lines.

• Identifi cation of antigens expressed in breast

cancer stem cells.

• Demonstrated decreased T-cell reactivity to Epstein-

Barr virus-infected cells in multiple sclerosis patients.

• Demonstrated that peptides of up to 25 amino acids

in length can bind to class I molecules.

• Established a protein microarray core at QIMR.

• Identifi ed regional differences in P. falciparum

proteome-wide antibody reactivity between

populations in Papua New Guinea and Africa.

• Identifi ed host molecules that mediate parasite

accumulation in tissue sites during experimental

cerebral malaria.

• Discovered a method to alter malaria-specifi c T-cell

responses generated in response to vaccination so

that they do not cause disease.

• Developed a way to enhance T-cell activation during

visceral leishmaniasis to improve disease outcome by

activating a molecule called GITR.

• Discovered a way to modulate T-cell responses

to prevent experimental cerebral malaria using

interleukin-2.

• Complete genome sequencing of Schistosoma

japonicum as part of an international consortium.



JOINT RESEARCH

COOPERATIVE RESEARCH CENTRE

FOR ABORIGINAL HEALTH (CRCAH)

The Cooperative Research Centre for Aboriginal Health

(CRCAH) is Australia’s only national Aboriginal-led health

research organisation and brings together the Aboriginal

health sector, government health agencies and research

institutions. Established in 2003, it is governed by an

Aboriginal-majority board with representation from 12

core partners of which QIMR is one. Its vision is one of

sustained improvements in Aboriginal health through

strategic research and development.

QIMR is an active partner through in-kind contributions

to research, research transfer activities, student

research, education and training activities, capacity

development activities, administration and meetings.

Projects which involve QIMR include:

• Research towards vaccines in scabies and Group

A Streptococcus and its associated diseases –

rheumatic fever and rheumatic heart disease.

• Investigations into chronic suppurative lung disease

(CSLD) and bronchiectasis.

• Cancer research.

The CRCAH continues to support Aboriginal students

studying at QIMR through scholarships and the

Institute is an important part of the Centre’s educational

and training program. The Board and Executive of the

CRCAH are currently seeking a fi ve year extension

of funding under the Australian Government’s CRC

Program to continue the valuable work when current

funding ends in 2010. Concurrent with this application,

the CRCAH is seeking government and private sector

support to establish a more permanent independent

National Institute for Aboriginal and Torres Strait

Islander Health Research to ensure a legacy post

CRC Program funding.

The Griffi th Medical Research College (GMRC) is a

joint initiative of Griffi th University (GU) and QIMR. It

aims to promote collaboration between researchers of

both organisations. The GMRC is headed by Professor

Michael Good with committee members Professor

Gillian Bushell and Professor Lyn Griffi ths from GU and

Dr Greg Anderson and Dr Alex Loukas from QIMR.

GMRC Committee member Professor Lesley Johnson

retired in 2009 and will be sadly missed. Her vision and

commitment have been integral to the success of the

college since its establishment in 2004. In April, the

GMRC welcomed the new Griffi th University Deputy

Vice Chancellor (Research), Professor Ned Pankhurst,

as her replacement.

HIGHLIGHTS

• The award of over $100,000 in collaborative seed

funding grants to QIMR and GU researchers to study

cancer and other human diseases.

• Dr Scott Burrows from QIMR was awarded an ARC

Discovery Project entitled Noncanonical epitope

recognition by CD8+ T lymphocytes?

• Dr Charlene Willis was awarded a three year NHMRC

Biomedical Australian Fellowship to research haemolysins

and haemoglobinases as anti-hookworm vaccines.

• GMRC members participated in the GU Gold Coast

Health and Medical Research Congress in December,

2008 which included a GMRC Colloquium session.

• 65 faculty and students from the QIMR and various GU

Schools and Centres attended a GMRC Retreat in April

2009 at The Ship Inn on the GU South Bank campus.

GRIFFITH MEDICAL RESEARCH

COLLEGE (GMRC)


JOINT RESEARCH

Q-PHARM

Q-Pharm conducts early phase clinical trials of

pharmaceutical and biotechnology products across

the areas of therapeutic, diagnostic and disease

prevention agents. It offers the best appointed early

phase clinical trials facilities in Australasia which include

recruitment and outpatient clinics, a specialised 18-bed

clinic for the conduct of the most medically demanding

trials and an open plan 24 bed facility for larger healthy

volunteer trials.

Q-Pharm concluded its seventh year of trading as a

private company on 30 June 2009. The 2008/2009

fi nancial year saw the company consolidate its

fi nancial position during a period of turbulence for the

pharmaceutical industry. Gross revenue from operations

grew from the previous year in line with the budget

forecast and the company traded profi tably following

a modest trading loss in the previous year. The domestic

and international bioequivalence markets provided better

than forecast revenues and a strategic alliance with

TetraQ continued to position the alliance partners at

the forefront of these markets.

Steady growth and service diversifi cation have continued

in early phase trials which now account for 75% of

revenue. The continued growth in clients from the United

States, particularly the bay area of California, is the

result of concerted business development activities in

this region.

Q-Pharm continues to play a leading role as a member

of the Queensland Clinical Trials Network and has been

actively involved in promoting both the company’s

and Queensland’s capabilities at various national and

international conferences.

The refurbishment of Level 6 of Block 8 at the RBWH

was completed in February 2009. Q-Pharm has secured

tenancy in Block 8 until 2013 and this will provide the

company with excellent clinical facilities through the

period of the SSMRC building project. Q-Pharm is

extremely appreciative of the signifi cant support of QIMR

for occupancy of this facility.


CORPORATE

Left to right: Sarah-Jane

Matthews, Doug Evans,

Margaret Stromberg,

Andrew van der Beek,

Margie O’Hara, Lynn Lin,

Glen Cunningham, Joan

Whybird and Keith Dry


It has been another busy and productive year for the

Corporate Division. The focus has been on improving

the level of service provided to our research staff

through examining current systems and processes.

Funding has been secured for the new Smart State

Medical Research Centre. Members of the Corporate

Division have been heavily involved in the design and

development of the new facility. This new suite of

laboratory spaces will meet the needs of researchers

particularly in the areas of cellular analysis and imaging,

genetic and protein analysis and preparation of

histological specimens.

The capital expansion marks a new era for QIMR and

all staff look forward to completion late 2011.

HEALTH AND SAFETY

This year the Safety Committee held 11 meetings and

reviewed 607 applications.

An online induction and training system was introduced,

including four units of competency in laboratory safety,

non-laboratory safety, radiation safety awareness and

fi re and emergency evacuation.

Changes to waste management procedures were

implemented to reduce hazards associated with the

handling of biological and chemical waste and to ensure

a safe transition of services during onsite building works.

BUILDING SERVICES

The building management system continues to be

upgraded using additional funds secured from the

Health Department’s Asset Management Unit. Relocation

of restructured departments and modifi cations within

the Bancroft Centre, including the insectary, have been

completed.

REGULATORY AFFAIRS

Approximately 17% of the QIMR Human Research

Ethics Committee (HREC) workload has been associated

with commercially sponsored clinical trials.

The QIMR Animal Ethics Committee (AEC) and QIMR

staff were commended by the Queensland Department

of Primary Industries and Fisheries audit team for

compliance with the Australian Code of Practice for

the Care and Use of Animals for Scientifi c Purposes.

QIMR procedures and practices in animal welfare were

considered to be at the forefront of systems available

in Queensland.

SCIENTIFIC SERVICES

The Scientifi c Services group is responsible for the

provision of research support in key operational areas

and specialist facilities, including high-quality reagents

and consumable, sterile glassware, the care of animals

used as research models and core research facilities.

The QIMR Equipment Committee facilitated the purchase

of a range of equipment with funding from both QIMR

core funds and the NHMRC Standard Equipment Grant.

These included a FujiFilm STARION Imager and

Molecular Devices Axon GenPix Scanner, both of which

will be used in protein analysis; an upgrade to the

Aperio ScanScope Pathology Slide Imager and a Roche

xCELLigence Cell Analysis System for use in analysing

cell morphologies; and a MassArray Liquid Handling

Robot and an upgrade to the Agilent Microarray

Scanner to cope with demand for high throughput

genetic analysis.

A dedicated group of corporate staff provide the

support services required by QIMR scientists, enabling

them to perform world class research. General Manager Dr Julie-Anne Tarr


CORPORATE SERVICES The Corporate Services team continues to support

researchers in their scientifi c endeavours by delivering

the necessary corporate requirements to meet

statutory obligations and providing stewardship and

management of major services to the Institute. These

include Finance, Grants Administration, Information

Technology, Purchasing, Human Resources, Records

and Information Services including library services and

Business Development including the commercialisation

of intellectual property.

It has been a busy year for Corporate Services, with a

major focus on improving core business systems.

• A new web-based Web Reporting Suite has been

developed in-house. It is rich in functionality and

provides scientists and managers with more timely

and detailed fi nancial information to help manage

their research projects.

• A major project to evaluate, select and implement

a new human resources system and replacement

of the Institute’s payroll and fundraising software

systems is underway. This will continue into the

2009-10 year.

• Signifi cant upgrades to computer software and

hardware have taken place across the Institute,

including the latest version of Microsoft Offi ce,

upgrade of the PABX system, implementation of a

new ITIL compliant I.T. help desk system, data and

printer migrations to new platforms and deployment

of a new I.T. antivirus solution.

• A new online library system to improve access by

staff to research materials has been developed and

implemented.

• Restructuring of the purchasing and logistics

functions will provide a more effi cient service

to researchers and staff. This has provided a

commercially enhanced procurement function in

preparation for the expansion of the Institute.

• The Finance and Grants departments have been

separated. This has facilitated the subsequent

building of the Grants Administration team into a

specialised function with capacity to proactively

support individual scientists across their portfolio of

grants. In addition, the Payroll department has been

merged with the Human Resources department.

• A new Human Resources Manager and Human

Resources Adviser have been recruited in order

to build professional human resource skills in

the Institute and to prepare for expansion and

recruitment of an additional 400 scientists and

support staff over the next few years.


QIMR PATENTS

PATENT INVENTOR NUMBER

Patent Families Managed By QIMR

Novel molecules Toni Antalis PCT/AU1995/00085

Immunogenic agent and pharmaceutical composition for use against

homologous and heterologous pathogens

Michael Good PCT/AU2004/00080

G-CSF derivative for inducing immunological tolerance Geoff Hill PCT/AU2004/00116

Polytope vaccines Andreas Suhrbier PCT/AU1995/00461

Synthetic peptides and vaccines comprising the same Michael Good PCT/AU1995/00681

Cytotoxic T-cell epitopes Denis Moss PCT/AU1995/00140

EBV CTL epitopes Rajiv Khanna PCT/AU1997/00328

CTL epitopes from EBV Scott Burrows PCT/AU1998/00531

EBV peptide epitopes, polyepitopes and delivery system therefore Rajiv Khanna PCT/AU2003/01451

Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising

same and diagnostic and prophylactic and therapeutics uses therefore

Rajiv Khanna PCT/AU/2002/0089

Human cytomegalovirus immunotherapy Rajiv Khanna PCT/AU2005/00178

Anchored MAP Istvan Toth PCT/AU199347154

Novel human ssDNA binding proteins and methods of cancer diagnosis Kum Kum Khanna PCT/AU2008/000181

Therapeutic antibodies, antibody fragments and antibody conjugates Michael Good US 11/950217

Synthetic chimeric peptides Michael Good US12/333222

Cancer drug targets and methods of diagnosis Andrew Boyd PCT/AU2009/000672

Methods of diagnosis of Infl ammatory bowel disease Graham Radford-Smith PCT/AU2009/000562

QIMR Patent Families Managed outside QIMR

Detection of genes Catherine Hyland PCT/AU1994/00506

Receptor ligand system and assay Andrew Boyd USA 7,037,662

Modulation of cell adhesion and tumour cell metastasis Andrew Boyd PCT/AU2004/000142

Flavivirus vaccine delivery system Andreas Suhrbier PCT/AU02/01598

Flavivirus replicon packaging system Andreas Suhrbier PCT/AU2004/000752

Flavivirus replicon delivery system Alex Khromykh PCT/AU98/00993

Flaviviral replicon constructs for tumour therapy Andreas Suhrbier PCT/AU2006/000198

A method for Treatment Andrew Boyd PCT/AU1999/00931

Differentiation modulating agents and uses therefore Johannes Prins PCT/AU2005/000008

A method of treatment and agents useful for same Geoff Hill PCT/AU02/01512

Treatment for EBV associated disease Denis Moss PCT/AU2006/001854


PATENT INVENTOR NUMBER

QIMR Patent Families Managed outside QIMR (continued)

Vaccine Michael Batzloff US 10/706,275

Melanoma-associated MHC Class 1 associated oligopeptide and its use Chris Schmidt PCT/EP2006/008533

Method for screening for anticancer agents Kum Kum Khanna PCT/GB2008/00330

A novel receptor-type tyrosine kinase and use therefore Andrew Boyd PCT/AU2006/55299B2

Patent Families Resulting from Contract Research Performed at QIMR

Use of angeloyl-substituted ingenones in combination with other agents to treat

cancer

Andreas Suhrbier PCT/AU2006/001700

Treatment of solid tumours Andreas Suhrbier PCT/AU2005/001827

Chaperonin 10 modulators of toll-like receptors inducible cytokine and cytokine

secretion

Andreas Suhrbier PCT/AU2005/000041

Therapeutic agents I Peter Parsons PCT/AU2001/00679

Therapeutic agents II Peter Parsons PCT/AU2001/00680

Therapeutic agents III Peter Parsons PCT/AU2001/00678

Patents Families Administered by QIMR as Trustee for the CRC-Vaccine Technology

T helper epitopes David Jackson PCT/AU00/00070

Expression of hydrophobic proteins Elizabeth Webb PCT/AU03/00910

Novel immunogenic lipopeptides comprising T-helper and cytotoxic T

lymphocyte (CTL) epitope

David Jackson PCT/AU03/01019

Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes David Jackson PCT/AU03/0101

Truncated LHRH formulations David Jackson PCT/AU05/001383

Immunogenic molecules David Jackson PCT/AU06/000162

QIMR PATENTS (CONTINUED)


Q-GEN

It has been a year of critical changes at Q-Gen. After

extensive examination of the company’s operational

record, QIMR Council moved to return Q-Gen to its

original state as a research facility, rather than continue

into the more commercially orientated production

schedule embraced several years ago. The decision

also marked the conclusion of bioprocessing projects at

Q-Gen to focus only on cellular therapies, an area where

QIMR is building a solid track record.

Michael Gerometta joined Q-Gen as Chief Operating

Offi cer in April 2008 to preside over the transition period,

and Joanna Youngson took over a year later as Acting

Operations Manager to coordinate Q-Gen’s activities

as a fully integrated QIMR facility. Both staffi ng and

activity levels have decreased signifi cantly, however,

a new operating model will be implemented that will

accommodate an increasing number of research

projects from around Queensland and Australia under

the more focused banner of cell therapies. It is expected

that new projects will originate from QIMR research

laboratories as well as external institutions.

Currently, manufacturing of cellular vaccines for

two Phase I clinical trials is taking place. The trials

are based on research on adoptive immunotherapies

led by Drs Rajiv Khanna and Maher Gandhi.

A fi nancial commitment for both the research activities

and facility maintenance at Q-Gen has been received

from the National Collaborative Research Infrastructure

Strategy (NCRIS) program via Research Infrastructure

Support Service (RISS Ltd). The Australian Red Cross

Blood Service has also provided advisory services under

the RISS subsidy scheme.

Q-Gen staff are working with various stakeholders to

develop a new strategy for the expansion of QIMR’s

cellular therapy activities and are working closely with

Regulatory Affairs, Safety and Building Services to

seamlessly integrate Q-Gen once again into the Institute.


EXTERNAL RELATIONS

The past year saw the creation of a new department

called External Relations which comprises the former

Development and Marketing Department, Science

Communication and Graphic Support Units.

The purpose of External Relations is to contribute to the

realisation of QIMR’s strategic goals by developing and

implementing communication, fundraising and marketing

strategies with the aim of protecting and strengthening

QIMR’s reputation and profi le; building relationships with

external stakeholders; and generating fundraising revenue.

Staff enthusiastically rose to the many challenges re-

structuring presents. This puts the department in good

stead for realising its 2009-2010 revenue targets and

communication objectives.

HIGHLIGHTS

• A comprehensive market research project

undertaken to better understand community

perceptions of QIMR and inform the communication

and fundraising effort.

• The initiation of a major project to re-develop the

QIMR website.

• A review and introduction of a new visual identity.

• An interactive display at Queensland’s annual show (Ekka).

SCIENCE COMMUNICATION

The Science Communication Unit raised the awareness

of QIMR and its research through a range of community

and education programs. The ever-popular annual High

School Lecture Series attracted over 1400 senior

science students and their teachers from across South-

east Queensland. Speakers included the Queensland

Chief Scientist Professor Peter Andrew AO, QIMR

researchers, the Young Scientists of Australia (YSA

Brisbane) and the Griffi th Honours College.

Students from remote areas were able to participate

via a videoconference hook-up - 21 students, three

teachers from Mareeba, Atherton and Ravenshoe

schools in Far North Queensland, and later 20 students

from The Southport School.

Over 200 students from metropolitan and regional

schools toured our facilities and participated in hands

on research experiences. The QIMR High School Work

Experience Program saw over 60 Year 11-12 students

spend a week immersed in a lab working alongside our

world-class researchers.

Professor Emma Whitelaw participated in the Science-

in-Schools program, partnering with Clontarf Beach

State High School. Professor Whitelaw visited the school

twice through the year as well as hosting a class of

Year 11 students in her lab to participate in hands on

research activities.

Hoping to inspire the scientists of tomorrow, QIMR went

on display at the 2008 Ekka (Queensland’s annual show)

engaging with over 46,000 children and their parents

with an array of interactive science activities. Thank you

to the many researchers who volunteered their time to

participate in the display.

QIMR was given another signifi cant opportunity to

engage with the public when our patron the Queensland

Governor, Penelope Wensley, invited us to participate in

the annual Open Day at Government House in Brisbane.

QIMR - Annual Report 2008-2009 • 87 Q Q Q QQQQQQQQQQQQQQQQQ Q QQQQQQQQQQQQQIIMIMIMIMIMIMIMMMMMMMMRMRMRMRMRRRMMMRMRMMRIMIMMMMRMRRIMIMIMIMIMIMIMMMRMRIMIMIMMMIIMMRIMMRRIIIMIMIIMMMMRIMRMIMIMMMRRMMM ------------ A A A AAAAAAAAAnAAAAAnAnAnAnAnAnAnAnnn AAAnAAAnAnAn AAAAAAAAAnAnnnnAn AAAnnnnAnnnAnnnAAAnnAAAnAAnnnAAnnAAAAAAAAnAAAAAAAAAA nnununnunnnuanuanuanuauanuauanuauaanuanuannnnnuuannnnuuanuannnnnnunnuannnnnunuaaannnnnn aannnnnnnuuaannnnnnnunuaaaannnnnnuunununnunuaannnnunnnnnununuuannnnuaannnnnnnuaaannuuunuuuan l Rl Rll Rl RRl Rl RRRRRRl RRl RRRl RRl RRl RRRRl RRRRRRRRRReeeeeepoepoepoepoepepoepoeeppoepopooepoeeepoepoepooeeeepooee oepoeepoeeepoeepooooe oeeee ooooortrttrtrtrtrtrtrtrtrtrt trtrt rrt rt rrtrrtrt rtrtt rtt rtrt t 2222202020000200200200202000020222220002 08-28-28-28-28-228 228 228 222000000000000009090000009009090000900000000000000000000 9000 900 • ••• • • •• • 878878878787887888887777 QIMR - Annual Report 2008-2009 • 87

Our research facilities at Herston in Brisbane continue

to be a drawcard for community groups and service

organisations with more than 700 people touring our

laboratories over the past 12 months. A further 1,700

people learnt about QIMR from an address by our

Community Relations Offi cer to their group or club.

A free public lecture was held with a panel of QIMR

scientists speaking on research into mosquito borne

diseases. This was the fi rst of what we hope will be

regular series with plans for a skin cancer forum in

late 2009.

2008-2009 also saw the introduction of a quarterly

e-newsletter QIMR Link, showcasing QIMR’s many

research achievements and profi ling our outstanding

scientists.

Our efforts to inform the community about what we

do were boosted with national media coverage of a

number of research papers published in prestigious

scientifi c journals. Dr Louisa Gordon’s work on the

dangers of sunbeds, Dr Michael Batzloff’s trial vaccine

for Group A Streptococcus and Dr Naomi Wray’s study

on the genetics of schizophrenia were among the

papers that generated both Australian and international

media interest.

In April, the Corporate Division welcomed Ms Sarah

Tennant as its Science Communication Manager. Sarah

has an honours degree in Biotechnology, a Masters of

Environmental Science and Law as well as an extensive

background in science communication and education.

FUNDRAISING

A sincere thank you to everyone who has made a donation

to QIMR and helped support the important work of the

Institute. As a not-for-profi t organisation, QIMR relies on

community fundraising to maintain its position as a leading

medical research institute and to pioneer new research.

Like many charities, QIMR’s fundraising effort in the

2008-2009 fi nancial year was impacted by the global

fi nancial crisis. Thankfully supporting research remained

a priority for many loyal supporters including regular

donors; corporate partners such as Suncorp and

Xstrata; philanthropists Mr Clive Berghofer AM, and

Mrs Marno Parsons AM; and the planned givers who

kindly made provision for QIMR in their wills.

Medical research is an investment with long term

potential. The new treatments being developed can save

lives and potentially improve the health of all. Each year

QIMR acknowledges some extraordinary people whose

support of medical research has been outstanding and

who share QIMR’s vision and values. The recipients of

2008-2009 Ambassador Awards were: Muriel Comino,

Jean Conroy, Sunny Drescher, Betty Harrison, Pat King,

Beth McLary and Anne Stanton. Mrs Marno Parsons AM

was announced the winner of the QIMR Humanitarian

Award at the 2008 Derrick-Mackerras Memorial Lecture.

Mr Clive Berghofer AM continues to be a

major supporter of cancer research at QIMR

Medical research is an investment with long term

potential. The new treatments being developed can

save lives and potentially improve the health of all.


Another important source of funding is generated by

individuals and businesses who organise events for

which QIMR is the benefi ciary. QIMR is very appreciative

of their support and acknowledges their dedicated

efforts. They include: Sean Ryan (Knights of the Round

Table), Anne Stanton (Walking on Sunshine), Sunny

Drescher (Happy Face Cent Auctions), the staff of

Cellnet (Corporate Golf Day), the tenants of the Riverside

Centre (Corporate Golf Day), the Institutes friends at

Tattersall’s Club, the comedians from The Sit Down

Comedy Club who donate their services for the annual

Depression is not a laughing matter gala comedy night;

the staff at MBF who organise and attend the annual

Champer’s Ball; employees of Witchery Fashions

who sell pink ribbons throughout their Queensland

stores in support of the Institute; the organisers of the

RACQ Batteries All British Day and Del and Ron Fitton,

organisers of the Fitton Charity Race Day and Darling

Downs Equine Extravaganza in Toowoomba.

While many supporters live in Queensland, QIMR’s

donor community includes a number of people in Hong

Kong supporting the QIMR Nasopharyngeal Carcinoma

clinical trial. In November 2008 Director Professor

Michael Good travelled to Hong Kong to update them

on progress of the research project.

Special thanks are extended to Suncorp who continue to be a major

corporate partner through their support of skin cancer research at QIMR

Professor Michael Good AO (left) with Mr Graeme Ewin Grand Master of the

United Grand Lodge of Queensland who presented a substantial cheque from

the Freemasons in 2007 to purchase a Delta Vision microscope for our cancer

research program. This state of the art microscope, only the second of its

kind in Australia, arrived to great excitement in early 2008.

Professor Michael Good AO with Mrs Marno Parsons AM, recipient of the

QIMR Humanitarian of the Year Award.


QIMR thanks and acknowledges the support of the

following valued friends and platinum donors:

Mr Clive Berghofer AM

Mrs Marno Parsons AM

Freemasons Queensland

Estate of Violet Maud Lingard

Suncorp Metway

Estate of Jonathan Bown

Miss Grace Dunn in memory of J Morrison

Estate of Nancy Agnes Pinner

Xstrata

Estate of Alice Dorothy Norma Wright

Cellnet Corporate Golf Day

Estate of Geoffrey John Shepherd

BT Investments Pty Ltd

Champers Ball Committee (Karen Low and MBF team)

Witchery Fashions Pty Ltd

Estate of June Marie Breuer

Riverside Golf Day (organised by Jones Lang LaSalle)

Merrett Foundation

Mr Barry and Mrs Maureen Stevenson

Walking on Sunshine (Anne Stanton - Ambassador)

Estate of Thelma Margaret Fletcher

Darling Downs Equine Extravaganza (Del and Ron Fitton)

Elsie Squires Perpetual Trust

Queensland Community Foundation

Henry and Stella Robjohns Trust

Barbara Dalton Perpetual Charitable Trust

Tattersall’s Club

The Selwyn Thomas Fassifern Ozanne and Doreen

Elaine Ozanne Trust

Happy Face Cent Auction (Sunny Drescher - Ambassador)

Mr Don Mason

Dr Glenn and Mrs Itngrid Francis

Ms Helen Gow

Mr Ivan Mitchell

QIMR relies on community fundraising to maintain its

position as a leading medical research institute and to

pioneer new research.


TRUST REPORT

Every time I visit QIMR, I am awestruck by the

knowledge, expertise and dedication of the 600

scientists who produce the life-changing work that

is outlined throughout this report. A number of those

scientists received public recognition through grants,

fellowships and awards, and represent a growing body

of world class researchers who strive every day to

improve public health, in Australia and elsewhere.

The past 12 months has been a period of change,

challenges and triumphs for the Institute.

The announcements of funding for QIMR’s Smart State

Medical Research Centre by the Federal Government,

State Government and, most recently, by Atlantic

Philanthropies, will ensure that QIMR continues

to play a vital role in Australia and throughout the

medical research world. This funding will support the

construction of a new 13 storey building, which will

house an additional 400 scientists, ensuring that QIMR

continues to attract world-class scientists both within

Australia and internationally.

The global fi nancial crisis has affected QIMR, as it has

all charities and not-for-profi t organisations, through

a decrease in the value of Trust capital reserves and

investment earnings, and increased competition for

corporate sponsorship and fundraising dollars. In

this very diffi cult environment our External Relations

team, which undertakes the marketing and fundraising

functions of QIMR, has performed very well. I would

like to thank them for their hard work, expertise and

dedication. They are supported by a wonderful band of

volunteer fundraisers, holding a great many balls, golf

days, boardroom lunches and other functions, of which

QIMR is a benefi ciary. I would also like to thank our

individual and corporate partners and donors for their

support of QIMR over the last year. In particular, I would

like to pay tribute to the continuing generosity of Mr Clive

Berghofer. Clive’s support over many years has enabled

vital clinical trials to treat many forms of cancer, and to

develop new treatment methodologies which will benefi t

all of us and future generations.

The work of Trust is done by an increasingly small

number of dedicated members, supported by

an experienced and able staff. During the year, a

longstanding member of Trust, Mr Ian Manly, stood

down due to work commitments. Ian has been a

valuable and hardworking member of Trust for fi ve years,

and his business experience and contribution will be

greatly missed.

The remaining members of Trust, Rod Wylie, Patricia

McCormack and David Stirling, have continued to play

a vital role, and their expertise and guidance is highly

valued. However, a smaller number means that the work

of all Trust members is exponentially increased. We

are hopeful that a forthcoming review and changes to

the Queensland Medical Research Act will result in new

Ministerial appointments to Trust and Council, to enable

us to further support and guide the excellent work of

all of QIMR’s staff, volunteers, partners and donors to

continue QIMR’s vital research in the future.

Jane Seawright

Acting Chair


TRUST

Jane Seawright BA LLB (Hons) MBus (Marketing)

Acting Chair

Jane Seawright is a lawyer with extensive experience

in marketing and strategy. She established a freelance

marketing consultancy, Seawright Consulting, in 2000,

and held the position of Independent Chair of the

Queensland Furnishing Industry Superannuation

Trust for 13 years. She practices in corporate and

commercial law, and is also a Law Society-accredited

mediator and registered adjudicator, pursuant to the

Building and Construction Industry Payments Act 2004.

She has been the Convenor and Acting Chair of The

Queensland Institute of Medical Research Trust since

February 2008, and is a member of the QIMR

Marketing Committee.

Rodney Wylie OBE B Comm BA FCA FAICD

Rod Wylie is a Brisbane-based Chartered Accountant

with substantial experience in investment, company

management and corporate governance issues

across a wide range of organisations, in many cases

with nationwide and international activities. He has

been involved through Board/Council membership

in the administration of a number of professional and

community non-profi t groups. Mr Wylie chairs the

QIMR Investment Committee and is a member of

the QIMR Finance and Audit Committee and QIMR

Personnel Administration Committee.

Ian Manly MBA FAIM (TO 23 DECEMBER 2008)

Ian Manly has extensive experience in business

management and corporate development. He is the

Managing Director of First 5 Minutes Group Pty Ltd,

a company providing fi re safety, consulting services,

compliance management and emergency procedures

and training to the property industry throughout Australia.

Mr Manly chaired the QIMR Marketing Committee.

Patricia McCormack BA (Psych and IR) FAHRI, MAICD

Patricia McCormack is a highly regarded people

management professional with extensive experience in all

facets of human resource management. She established

People Focus in 2002 with the aim of providing HR

services specialising in organisation development

and human resources management. Ms McCormack

is a member of the QIMR Personnel Administration

Committee and the QIMR Marketing Committee.

David Stirling

David Stirling has had extensive commercial experience

over the past 40 years in the areas of Banking, Merchant

Banking and Investments. Before joining the QIMR Trust,

David was Managing Director of a fi nancial services fi rm

and partner of an international Chartered Accounting

fi rm. He has been a member of a considerable number

of professional organisations including the Institute of

Engineers, Commercial Law Association, Institute of

Chartered Accounts affi liate, FPA, Securities Institute

of Australia and a Fellow of the Australian Institute of

Company Directors. David is a member of the QIMR

Investment Committee.

Left to right: Patricia McCormack, Rodney Wylie, Jane Seawright

(Acting Chair), David Stirling.


OFFICIAL COMMITTEES 2008-2009

QIMR COUNCIL

Sir Bruce Watson (Chair) (To 17/10/08)

Mr Christopher Coyne (Acting Chair) (From 21/10/08)

Prof Emeritus Bryan Campbell

Prof Peter Brooks (To 30/06/09)

Prof Judith Clements

Mr Paul Fennelly

Prof Lyn Griffi ths

Assoc Prof Paula Marlton

Dr Jeannette Young

COMMITTEES REPORTING TO COUNCIL

Finance and Audit Committee


Mr Paul Fennelly (Chair) (From 21/10/08)

Prof Emeritus Bryan Campbell

Mr Rod Wylie

Appointments and Promotions Committee

Prof Peter Brooks (Chair) (To 30/06/09)

Prof Graham Brown

Prof Julie Campbell

Prof Judith Clements

Prof Lyn Griffi ths

Prof James McCluskey

Dr Jurgen Michaelis

Prof Joe Trapani

Prof Michael Good (ex offi cio)

Human Research Ethics Committee (HREC)

Dr Ian Wilkey (Chair)

Dr Roger Allison

Ms Madeline Brennan

Sr Regis Dunne (To 05/12/08)

Mrs Gwen Eardley (From 15/07/08)

Mr Angus Edmonds

Ms Clare Endicott

Mrs Mary Mackenzie (From 21/10/08)

Mr David Russell

Dr Christopher Schmidt

Dr Katharine Trenholme

Dr Tom Sculley

Dr Julie-Anne Tarr (ex offi cio)

Dr Agnieszka Mitchell (ex offi cio)

Ms Rebecca Lacey – Secretary

Scientifi c Sub-Committee (SSC)

Dr Katharine Trenholme (Chair) (From 10/07/08)

Dr Ian Wilkey (Deputy Chair)

Dr James Doecke (To 09/08)

Mr Paul Fahey (From 10/08)

Assoc Prof Gail Garvey (From 01/09)

Dr Helen Leonard

Dr Alex Loukas (To 10/08)

Dr Agnieszka Mitchell

Dr Andrew Redmond (From 07/08)


Dr Tom Sculley

Dr Kadaba Sriprakash

Ms Dixie Statham (To 01/09)

Dr Brett Stringer

Dr Marion Woods

Mrs Rebecca Lacey – Secretary

Clinical Trial Protocol Committee (CTPC)

Dr Peter Roeser (Chair)

Dr Graham Radford-Smith (Deputy Chair)

Dr Geoff Beadle

Prof Andrew Boyd

Dr Wendy Chung (To 04/09)

Dr James Doecke (To 09/08)

Dr Suzanne Elliott

Mr Paul Fahey (From 10/08)

Assoc Prof James McCarthy


Dr Michael Moore


Prof Denis Moss

Ms Brenda Rosser (From 10/08 to 04/09)

Dr Lesley Ross-Lee


Dr Joanna Youngson (From 04/09)

Mrs Rebecca Lacey – Secretary

Council Personnel Administration Committee


Mr Paul Fennelly (Chair) (From 21/10/08)

Mr Christopher Coyne (From 21/10/08)

Ms Patricia McCormack

Mr Rod Wylie

COMMITTEES REPORTING TO THE DIRECTOR

Senior Executive Team (SET)

Prof Michael Good (Chair)

Prof Adèle Green

Prof Andrew Boyd

Ms Donna Hancock (From 12/08/08)

Ms Natalie Karger (To 16/12/08)

Prof Brian Kay (From 19/08/08)

Prof Martin Lavin

Prof Emma Whitelaw (From 19/08/08)

Dr Julie-Anne Tarr

Ms Nerida Fox – Secretary

Safety Committee

Dr Helen Leonard (Chair)

Dr Glen Boyle (Deputy Chair)

Dr Michael Batzloff

Mr Brendan Butcher (To 01/09)

Mr Ron Buttenshaw

Mr Paul Collins

Dr Juan Cooper

Ms Gwen Cuthbert

Dr Geoff Gobert

Mr Andrew King


Prof Denis Moss

Ms Michelle Richards

Dr Christine Rzepczyk

Mr Alan Stockman

Dr Joanna Youngson from April 2009

Dr Julie-Anne Tarr

Assoc Prof Peter Upcroft

Ms Jo Chow – Secretary

Equipment Committee

Dr Juan Cooper (Chair)

Dr Greg Anderson

Prof Andrew Boyd

Dr Geoff Hill


Ms Allison McLean (To 04/08/08)

Mr Christopher Ward

Dr Emma Whitelaw

Mrs Joanna Youngson (From 16/03/09)

Higher Degrees Committee (HDC)

Assoc Prof Nathan Subramaniam (Chair)

Ms Simone Cross

Prof Joy Cumming

Prof Michael Good

Dr Judith Greer

Dr Sergei Kozlov

Assoc Prof Alan Lawson

Dr Kelli MacDonald

Dr Grant Montgomery

Ms Michelle Neller

Mr Chris Peatey

Dr Peter Ryan

Dr Kevin Spring

Dr Katherine Trenholme


Dr Malcolm Jones (To 12/08)

Dr Patricia Valery

Dr Margie Wright

Ms Nicci Wayte

Dr Terry Walsh

Prof Gail Williams

Joint Consultative Committee (JCC)

Ms Nicole Green (Chair) (To 08/08)

Mr Trevor Greenaway (Chair) (From 10/08)

Ms Pauline Buratowski

Mr Paul Collins

Prof Michael Good

Dr David McMillan

Dr Penny Webb

Prof Emma Whitelaw

Dr Julie-Anne Tarr

QPSU Representative

QNU Representative

Medical Advisory Board

Prof Peter Brooks (Chair) (To 30/06/09)

Prof Andrew Boyd (Deputy Chair)

Dr Paul Bartley

Dr Geoff Beadle

Dr Ian Bunce

Dr Don Cameron

Prof Adèle Green

Prof Michael Good

Dr Barbara Leggett

Dr Joseph McCormack

Dr Paul Sandstrom

Dr Mark Smithers

Dr John Varghese

Dr Michael O’Rourke

Mentoring Committee

Dr Grant Ramm (Chair) (To 12/08)

Dr David Whiteman (Chair) (From 12/08)

Dr Georgia Chenevix-Trench

Dr Nick Hayward

Dr Rajiv Khanna

Professor Emma Whitelaw

Scientifi c Advisory Board

Prof Graham Brown (Chair)

Prof Dallas English

Prof Douglas Hilton

Prof Joe Trapani

Seminars Committee

Prof Martin Lavin (Chair)

Prof Michael Good

Dr Geoff Hill

Dr Grant Montgomery

Ms Jann O’Keefe

Prof Emma Whitelaw

Consumer and Community Participation Committee

Prof Adèle Green (Chair)

Dr Geoff Beadle

Mr Felipe Beltran (To 07/08)

Ms Simone Cross

Mr Ken Dutton-Regester (From 04/09)

Assoc Prof Gail Garvey

Ms Melina Georgousakis

Mr Jeremy Gill (From 07/08)

Ms Imogen Gillions (From 04/09)

Ms Vivienne Johnson (From 07/08)

Prof Denis Moss

Dr Arne Mould

Ms Jann O’Keefe

Mr Andrew van der Beek (To 07/08)

Mr Sri Shekar (To 12/08)

Dr Amanda Spurdle

Dr Vicki Whitehall

OFFICIAL COMMITTEES 2008-2009 (CONTINUED)


COMMITTEES REPORTING TO SET

Strategic Science Committee


Dr Greg Anderson


Prof Michael Good

Prof Adèle Green

Dr Geoff Hill


Prof Emma Whitelaw

Ms Mandie Quince – Secretary

Clinical and Translational Committee

Prof Andrew Boyd (Chair)


Prof Michael Good

Prof Adele Green

Dr Geoff Hill

Dr Corinne Lendon

Dr Alex Loukas

Ms Allison McLean (To 04/08/08)


Prof Denis Moss

Dr Grant Ramm

Dr Chris Schmidt

Dr Nathan Subramaniam

Dr Joanna Youngson (From 04/09)

Ms Mandie Quince – Secretary

IT Committee

Dr Dale Nyholt (Chair)

Dr Glen Boyle

Assoc Prof Scott Burrows

Dr Juan Cooper

Mr Mark Feodoroff

Ms Michelle Gatton

Ms Heather Matthews


Mr Mark Spanevello

Dr Nathan Subramaniam

Assoc Prof Peter Upcroft

Mr Christopher Ward

Ms Jann O’Keefe

Records and Information Committee (From 16/12/08)


Dr Suyinn Chong

Dr Deepak Darshan

Dr Katja Fischer

Mr Owen Griffi ths

Mr Simon Jaremczuk

Dr Jason Jeffery

Ms Nelly Kremko

Dr Rachel Neale

Dr Wayne Schoder

Dr Daniel Wallace

Dr Michelle Wykes

QIMR TRUST

Ms Jane Seawright (Acting Chair)

Mr Ian Manly (To 23/12/08)


Mr David Stirling

Mr Rod Wylie

COMMITTEES REPORTING TO TRUST/COUNCIL

Investment Committee

Mr Rod Wylie (Chair)

Mr Bruce Phillips

Mr David Stirling

Marketing Committee

Mr Ian Manly (Convenor) (To 23/12/08)


Ms Jane Seawright


Postgraduate students are an important part of

the health and medical research effort at QIMR.

The excellent research facilities, support services,

extensive network of international and national research

collaborations and the internationally-ranked quality of

QIMR scientists provides an outstanding environment for

advanced training in health and biomedical research.

The Institute admitted 47 new higher degree students

and 28 visiting students. The student body at QIMR

currently comprises 70 PhD students, 3 Research

Masters, 8 Coursework Masters and 24 Honours

students. The QIMR Summer Vacation Scholarship

program which was run between December 2008

and February 2009 attracted a signifi cant number of

applications and 14 were awarded. These scholarships

give undergraduate students an opportunity to work

with QIMR scientists on a focused and well supervised

research project. While the majority of students at QIMR

are enrolled through The University of Queensland, a

signifi cant number are also enrolled at the Queensland

University of Technology and Griffi th University.

QIMR’s postgraduate students have continued to make

an impressive impact on the wider scientifi c community

this year and have received numerous notable awards.

Magda Ellis was a standout, winning the JFA Sprent

prize for the best PhD in Parasitology (2006-2008), a UQ

Deans’ Commendation for an outstanding thesis and a

NHMRC CJ Martin Fellowship.

Our students also did very well in receiving travel awards

to attend international conferences including Gabriella

Blokland, Melissa Burke, Nico Martin, Karin Verweij and

Brendan Zietsch.

The Higher Degrees Committee (HDC) evaluates

students prior to their acceptance as candidates at

the Institute, monitors student progress, provides

education programs for students, establishes policy

on student-related issues, and assesses applicants for

travel awards, Honours and PhD top-up scholarships.

The monitoring of student progress is one of our most

important activities and members of the HDC devote

considerable time to the rigorous review of students

during their study program. This year the HDC has

undertaken over 33 reviews of students.

QIMR’s postgraduate students have continued to make an

impressive impact on the wider scientifi c community this year

POSTGRADUATE TRAINING

QIMR - Annual Report 2008-2009 • 97QQQQQIIMIMIMRMRMRMRMRMRIMMRMRI RMRM ------- A AAAnAnAAnnAnAnnAn A A AA A l Rl Rl RepepepoepoepepopoopeppQQQQQQ 977979797997 AnAnnnnnnAnnnAnnnunununununuuauauaaaaanuannuuaaaanuun all R R rttrt rt rt rrt rt 202022220020000002 0008888-8-2-2-2-200090009 • orAnnAnAAnnnAAnnn all Rl Rl Rl RQQQQIMIIMM QIMR - Annual Report 2008-2009 • 97

My research required me to go to rural

China to collect samples and data on human

schistosomiasis infections. I saw fi rsthand the

people and communities we were trying to

assist, helping me truly appreciate the impact

of the disease. This was incredibly inspiring

and really motivated me with my research.

Magda Ellis

Molecular Parasitology Laboratory

Infectious Diseases Division


STUDENT UNIVERSITYQIMR SUPERVISOR

THESIS

PHD

Julie BalenSPH, UQ D McManus

Determinants of Schistosoma japonicum and soil-transmitted helminth infections, and associated morbidity in Hunan province, China: an epidemiological assessment

Will CoventrySBCSS, University of New England N Martin

Perceived social support: its genetic and environmental etiology an association with depression

Bryan DaySchool of Medicine, UQ A Boyd

Potential novel targets for treatment of malignant glioma

Matthew DixonSPH, UQ K Trenholme and D Gardiner

Gametocytogenesis in Plasmodium falciparum

Melina GeorgousakisSPH, UQ K Sriprakash, D McMillan, M Batzloff

Towards a mucosal vaccine against group A streptococcus based on a live bacterial delivery system

Fabriba Kolahdooz UQ, P Webb Ovarian cancer and diet: from nutrients to lifestyle

Steven KoppSchool of Veterinary Sciences, UQ J McCarthy

Pyrantel resistance in the canine hookworm, Ancylostoma caninum

Kim LohSchool of Medicine, UQ B Leggett

The role of BMP3 in colorectal carcinogenesis

Rita MiddlebergSchool of Medicine, UQN Martin

Genetics of lipid cadiovascular risk factors in Australian families

Louise RandallSPH, UQ C Engwerda

Characterisation of the immunopathology associated with cerebral malaria

Najju Ranjit QUT, A Loukas Haemoglobin digestion cascade in the human hookworm Necator americanus

Paweena Rattanasena UQ, A Suhrbier Characterisation of Kunjin replicon vaccines

Simone ReynoldsSchool of Veterinary Science, UQK Fischer

Analysis of the binding properties and functions of scabies mite serine proteases

Sri ShekarSchool of Medicine, UQ N Marti, D Duffy

Genetics of melanoma susceptibility and development

Haran Sivakumaran SPH, UQ, D Harrich The regulation of HIV-1 transactivator of transcription

Katherine WynnSchool of Medicine, UQ R Khanna

T-cell responses to cytomegalovirus

STUDENT UNIVERSITYQIMR SUPERVISOR

THESIS

BSC HONOURS

Nick Barker Life Science, QUTCharacterisation of mammalian Mon1a: a putative traffi cking protein and modifi er of the Haemochromatosis phenotype.

Jessica CornockLife Science, QUT G Anderson

Effects of alcohol on the expression of the iron regulatory protein hepcidin

Ken Dutton-Regester (Hons)

QUT, V Whitehall Investigation of ID4 in colorectal cancer development

Winnie FernandoSMMB, UQ K Spring

Characterisation of SLC5A8 methylation in serrated polyps of the colon

Peter Giacomantonio UQ, A Loukas Tetraspanins as vaccines against Schistosoma mansoni

Joanne LimSMMB, UQD Gardiner

Investigation of M18 aspartyl aminopeptidase and S33 prolyl aminopeptidase of Plasmodium falciparum as potential antimalarial drug targets.

Alex Mulherin (Hons)SBMS, UQ C Engwerda

The role of conventional dendritic cells in the activation of T-cells in response to Leishmania donovani infection

Sam Nayler (Hons)Life Science, QUTM Lavin

Characterisation of the DNA damage response in Amyotrophic Lateral Sclerosis 4

Klara Unosson MSc University of Linköping, SwedenA regulatory role for parasite-specifi c CD8+ T cells during the pathogenesis of experimental cerebral malaria

Elizabeth Watt (MBBS Hons)

School of Medicine, UQ G Anderson, L Powell

Clinical expression of HFE-associated haemochromatosis in subjects under 40 years of age

Philip WhileyUQ, A Spurdle

Functional analysis of BRCA1 and BRCA2 sequence variants of unknown clinical signifi cance

QUT = Queensland University of Technology, SBCSS = School of Behavioural and Cognitive Social Sciences,

SMMB = School of Molecular and Microbial Biosciences, SBMS = School of Biomedical Sciences, SPH = School of Population Health,

UQ = The University of Queensland

COMPLETED STUDENTS 2008-2009


RECIPIENT BESTOWER AWARD, REASON, CITATION

Gabriella Blokland

Australian Twin RegistryTravel Award – 15th Annual Meeting Organisation for Human Brain

Mapping, Dec 2008

Organisation for Human Brain

Mapping

Trainee Abstract Award – 15th Annual Meeting Organisation for

Human Brain Mapping, Apr 2009

CMR UQTravel Award – 15th Annual Meeting Organisation for Human Brain

Mapping, Apr 2009

Melissa Burke Keystone Symposia Travel Award – Keystone Meeting on Immunopathogenesis, 2009

Enda Byrne QIMR Dr Diana Cavaye Scholarship

Ken Dutton-Regester Qld Gastroenterology SocietyYoung Investigator Award Finalist - oral presentation at annual

meeting, June 2009

Magda K Ellis

Australian Society of ParasitologyJFA Sprent Prize for best PhD in Australia in parasitology for 2006-

2008, Jul 2008

UQDean’s commendation, Top 10% of PhD theses awarded annually by

UQ, Jul 2008

NHMRC CJ Martin Fellowship, Dec 2008

Kimberley Jones Leukaemia Foundation PhD Scholarship, Dec 2009

Susan Jordan UQ Selection to Dean’s Commendation list for PhD, Jul 2008

Fariba Kolahdooz

SPH, UQAward for Research Achievement: outstanding record of research

performance and publication within SPH, Jun 2009

QIMR PhD Student Top-up Award, Jul 2008

Elizabeth LeddyGastroenterological Society of

Queensland

Young Investigator Award – best abstract and presentation at annual

meeting, Jun 2009

Kate Markey

Transplantation Society of Australia

and NZ

Young Investigator – highly ranked abstract from young investigator,

Jun 2009 and best presentation in laboratory research, Aug 2008

Australian Society for Medical

Research

Runner up – Premier’s Postgraduate Student Award for Medical

Research and Runner up best presentation in category, May 2009

Nico Martin

ANZ Banking Corporation ANZ PhD Scholarship, Jun 2009

ENGAGE - Institute of Molecular

Medicine, Finland

Travel Award – Basic introduction course on GWA analysis,

Rotterdam, Netherlands, Aug 2008

Brian Morrison Eskitis InstituteSecond Year Student Oral Presentation Prize,

Mar 2009

Miriam Mosing ANZ Banking Corporation ANZ PhD Scholarship, Jan 2009

Michelle Neller UQ3 Minute Thesis Competition – Winner, School of Medicine UQ and

Runner-up Faculty of Health Sciences UQ, Sep 2008

Najju Ranjit QUTDean’s award for outstanding PhD thesis,

Jan 2009

Renee RobbTransplantation Society of Australia

and NZ

Young Investigator – highly ranked abstract from young investigator,

Jun 2009

Sri Shekar NHMRC NHMRC Overseas Based Public Health Training Fellowship, Jan 2009

Karin Verweij Australian Twin RegistryTravel Award – 22nd International Workshop on Methodology of Twin

and Family Studies, Boulder USA, Dec 2008

Philip WhileySchool of Chemistry and Molecular

Biosciences, UQ

Biochemistry Award for outstanding achievement in undergraduate

studies 2008, Dec 2008

Nadia WhitelawLorne Genome Promega Student Award, Feb 2009

Keystone Symposia Keystone Symposia Scholarship, Jan 2009

Brendan Zietsch UQ School of Psychology

Travel Award – 20th Annual Meeting of Human Behavior and Evolution

Society, Kyoto, Japan,

Jun 2008

STUDENT AWARDS 2008-2009

QIMR AWARDS 2008-2009

The Derrick-Mackerras Memorial Lecture

Each year, an eminent person is invited to deliver the

Derrick-Mackerras Memorial Lecture, named after the

founding Director and Deputy Director of QIMR. This year

Professor Chris Goodnow, Chief Scientifi c Offi cer of the

Australian Phenomics Facility at The Australian Catholic

National University gave the lecture entitled Connecting

genome with phenome through multiplex libraries of

nucleotide variants in the mouse genome sequence:

examples from the immune system plus cancer.

Bancroft Medal

The Bancroft Medal is awarded annually to those who

have made an outstanding contribution to the Institute.

This year’s recipient was Lorna Lane who joined QIMR in

1983 and since 1989 has been a vital and highly valued

member of the Human Resources team.

Fellows of the Institute

Outstanding individuals are named as Fellows of the

Institute each year, and this year three such individuals

became QIMR Fellows: Professor Graham Brown,

the Chair of QIMR’s Advisory Board who attends the

Institute’s retreats and provides strategic advice on

grant submissions; Professor Bob MacLennan, a former

QIMR scientist who founded the Epidemiology unit at

the Institute during the 1980s, making QIMR the fi rst

medical research institute in Australia to recognise the

value of epidemiological studies; and John Garnsey,

long-serving member of the QIMR Trust, in recognition

of his infl uence in changing the Trust’s focus from

community campaigns to corporate acquisitions.

Ralph Doherty QIMR Science Prize

The prestigious Ralph Doherty Science Prize for

outstanding achievement and leadership in medical

research was given to Professor Emma Whitelaw who

was lead author in a successful $3 million grant for

Cancer Epigenetics and has been recipient of a number

of special external awards and accolades during the year.

Postdoctoral Prize

The Postdoctoral Prize went to Dr Stuart MacGregor

of the Queensland Statistical Genetics Laboratory who

was a fi nalist in both the 2006 and 2007 Queensland

Premier’s Awards and has recently published in both

Nature and Nature Genetics.

Humanitarian Award

The QIMR Humanitarian Award recognises people

within the community who tangibly and actively raise

awareness or revenue for the Institute. Mrs Marno

Parsons AM received this Award for her signifi cant

contribution towards QIMR’s vision to improve cancer

outcomes. Mrs Parsons’ generous donations for the

past two years have enabled the establishment of the

Glioblastoma Research Centre at QIMR.

Left to right: Dr Stuart MacGregor, Professor Emma Whitelaw and Ms Lorna Lane.


HIGH ACHIEVEMENTS 2008-2009

Professor Emma Whitelaw – Australia Fellow

Professor Emma Whitelaw, head of the QIMR

Epigenetics Laboratory, was awarded one of only 12

Australia Fellowships in January 2009. Her most notable

research achievements are in the area of epigenetics, in

particular, her studies on the transgenerational inheritance

of epigenetic marks have stimulated a great deal of

interest from the wider scientifi c community. The

Fellowship injected a further AUD$4 million into this work.

Professor Dave Kemp – Order of Australia

Professor Dave Kemp leads the Scabies Laboratory at

QIMR and was awarded the Order of Australia Medal by

the Australian Government in January 2009. The Order

was awarded in recognition of his service to medical

research as a molecular biologist, particularly in the

areas of tropical health and infectious diseases, and for

his contributions to Indigenous health.

Professor Geoff Hill – Ian McKenzie Prize

Professor Geoff Hill leads the Bone Marrow Transplantation

Laboratory at QIMR and this year received the Ian

McKenzie Prize from the Transplantation Society of

Australia and New Zealand in June 2009. The prize was

awarded for his outstanding contribution to the fi eld of

bone marrow transplantation over the past decade.

Professor Lawrie Powell – Distinguished

Achievement Award

Professor Lawrie Powell, previously a Director of QIMR

and now working within the Iron Metabolism Laboratory

was awarded the Distinguished Achievement Award by

the American Society for the Study of Liver Diseases.

The award is bestowed upon an eminent hepatologist

who has made a major contribution to the discipline and

has very rarely been awarded outside of the USA.


OTHER AWARDS 2008-2009

RECIPIENT BESTOWER OF AWARD AWARD

Dr Kathy Andrews Australian Society for Medical Research Appointed as a National Director, Nov 2008

Dr Alyson Ashe University of Cambridge Herchel Smith Postdoctoral Fellowship, Feb 2009

Dr Beben Benyamin NHMRC Postdoctoral Fellowship, Jan 2009

Dr Glen Boyle Australian Academy of Science Invited Participant – Theo Murphy High Flyers Think

Tank on Preventative health: Nov 2008

Australian Society for Medical Research Queensland Premier’s Awards for Medical Research –

Runner-up Senior Researcher, May 2009

Mr Darren Gray School of Population Health, University of

Queensland

Certifi cate of Research Achievement – excellence in

population health research studies in China, 2008

Dr Motoko Koyama Transplantation Society of Australia and NZ Young Investigator – highly ranked abstract from

young investigator, Jun 2009

Dr Penelope Lind XVIth World Congress on Psychiatric

Genetics in Osaka, Japan

Best Oral Presentation Award, Oct 2008

XVIth World Congress on Psychiatric

Genetics in Osaka, Japan

Congress Award for Best Oral Presentation, Best Oral

Presentation, Oct 2008


Assoc Prof

Alejandro López

Australian Academy of Science High Flyers Think Tank on Preventative Health,

Nov 2008

Dr Stuart Macgregor Australian Society for Medical Research Queensland Premier’s Awards for Medical Research –

Senior Researcher, May 2009

Prof Don McManus World Health Organisation Member of WHO Expert Advisory Panel on Parasitic

Diseases (Schistosomiasis), 2009

Liver Disease Review Letters (LDRL) Elected to membership of Editorial Board, 2009

Ms Sarah Medland Virginia Institute for Psychiatric and

Behavioural Genetics (VIPBG)

The Lindon J. Eaves Award for excellence in Postdoctoral

research USA academic year 2008, Aug 2008

Ms Celestine Rickman Queensland Gastroenterology Society Young Investigator Award – fi nalist selected for oral

presentation at annual meeting, Jun 2009

Dr Danielle Smyth Churchill Fellowship 3 months at University of Pennsylvania, US, Jul 2008

Dr Patricia Valery Australian Society for Medical Research Queensland Premier’s Awards for Medical Research –

Finalist Senior Researcher, May 2009

Dr Daniel Worthley Royal Brisbane and Women’s Hospital

Foundation

Basic Sciences Prize and QIMR Laboratory

Attachment Prize, Oct 2008

Gastroenterological Society of Australia Young Investigator – fi nalist selected for oral

presentation at annual meeting, Oct 2008

Royal Australasian College of Physicians Cottrell Fellowship, Feb 2009

TRAVEL AWARDS


Dr Kathy Andrews ARC/NHMRC Research Network for

Parasitology

Travel Award, 2 week research visit to lab of A/Prof.

Zbyneck Bozdech, Nanyang Technological University,

Singapore, Jan 2009

Dr Richard Ruddell 14th International Symposium on Cells of the

Hepatic Sinusoid

Young Investigator Travel Award – 14th International

Symposium on Cells of the Hepatic Sinusoid,

Sep 2008

Dr Logan Walker Australasian Microarray and Associated

Technologies Association (AMATA)

AMATA Early Career Researcher Travel Bursary, based

on submitted abstract

Dr Naomi Wray QIMR QIMR Travel Award – World Congress of Psychiatric

Genetics, Tokyo Japan, Oct 2008

OTHER AWARDS 2008-2009

CONTINUED



GRANTS AND FUNDING

Major New Grants Awarded 2008-2009 (over $100,000)

SOURCE CHIEF INVESTIGATOR & PROJECT TITLE TERM PERIOD

TOTAL FUNDS OR

QIMR COMPONENT

OF FUNDS

ACH2SUHRBIER A Use of Chaperonin 10 to ameliorate endtoxin induced immune

activation and HIV replication2 yrs 2008 - 2009 $165,000

ACH2 HARRICH D – Null Basis: A Novel HIV 1 Inhibitor 2 yrs 2008 - 2009 $ 147,125

ACH2 WARRILOW D – DNA oligomers to block HIV 1 nucleic acid replication 2 yrs 2008 - 2009 $137,625

ARC BURROWS S – Noncanonical epitope recognition by CD8+I lymphocytes 3 yrs 2009 - 2011 $481,214

ARC

GREEN A C et al – Evaluation of an instrument to Assess needs of Indigenous

Patients with Cancer (Administered by University of Southern Queensland; QIMR

Investigator Assoc Prof Gail Garvey)

2 Yrs 2009 - 2010 $185,000

ARC

LAVIN M et al – A novel role for SMG 1 protein kinase in stress granule and the

stress response (Administered by University of Queensland; QIMR Investigator

Prof M Lavin)

1 yr 2009 $ 110,000

FLU

WADE T et al – Identifying endophenotypes for eating disorders and their

relationship to specifi c genotypes and environments (Administered by Flinders

University; QIMR Investigator Dr G Montgomery)

3 Yrs 2009 - 2011 $131,209

LFQJONES K – New Strategies for the treatment and prevention of Hodgkin’s

Lymphoma3 Yrs 2009 - 2011 $120,000

MACQ

COOKE, B et al – Bioinformatics aspect of NCRIS Programme via Murdoch

BPA Agreement (Administered by Macquarie University; QIMR Investigator

Prof J Gorman)

2 yrs 2009 - 2011 $400,000

MRAHAYWARD N et al – A Genome Wide Association Study to Identify Melanoma

Predisposition Genes3 yrs 2008 - 2011 US$1,000,000

NBCF

NEWMAN B – Pathologic & molecular investigations of the ABC breast cancer

‘cluster’; (Administered by Qld University of Technology; QIMR Investigator Dr. G.

Chenevix-Trench)

1 yr 2008 - 2009 $100,221

NHF GOOD M et al – Design and analysis of an improved vaccine candidate against

rheumatic heart disease2 yrs 2009 - 2010 $129,000

NHMRCGREEN et al – Gynaecological, oesophageal and skin cancer in Australia.

Developing the evidence-base for prevention and control5 yrs 2009 - 2013 $5,902,320

NHMRCWHITELAW E et al – A saturation screen for modifi ers of epigenetic reprogramming

in the mouse; Phase II5 yrs 2009 - 2013 $1,298,750

NHMRC SPURDLE A et al – A genome wide association study of endometrial cancer 2 yrs 2009 - 2010 $1,035,200

NHMRCMARTIN N et al – Investigating the role of pigmentation pathway genes in moliness

& melanoma risk2 yrs 2009 - 2010 $906,900

NHMRCMARTIN N et al – Validation and replication of genes associated with common

human diseases using Australian Twin Families5 yrs 2009 - 2013 $901,880

NHMRCWHITFIELD J et al – A genome wide association study for alcohol & nicotine

addiction susceptibility genes3 yrs 2009 - 2011 $846,000

NHMRCKHANNA,K et al – Genome maintenance and hSSB1, a novel player in the DNA

damage response pathway3 yrs 2009 - 2011 $622,000

NHMRCGARDINER D et al – Plasmodium falciparum neutral aminopeptidases: structure-

function analysis for the discovery of anti-malarial drugs3 Yrs 2009 - 2011 $ 608,660

NHMRC TRENHOLME K et al – Analysis of the P. falciparum M18 aspartyl aminopeptidase 3 yrs 2009 - 2011 $ 590,250

NHMRCLAVIN M – ATM activation and its functional importance in DNA damage response

(Administered by University of Queensland)3 yrs 2009 - 2011 $ 533,750


TOTAL FUNDS OR

QIMR COMPONENT

OF FUNDS

NHMRCWALKER G et al – Interaction of Mc1r with pRb and p53 pathways in UVR-induced

melanoma development3 yrs 2009 - 2011 $531,750

NHMRC HILL et al – IL 17 as a regulator of treatment outcome 3 yrs 2009 - 2011 $521,250

NHMRC VALERY P et al – Closing the divide: Aboriginal and TSI people and cancer survivorship 3 yrs 2009 - 2011 $520,263

NHMRCANDERSON G et al – Mechanisms of intestinal iron absorption and consequences

of iron supplementation during the perinatal period3 yrs 2009 - 2011 $514,500

NHMRC HARRICH D et al– Regulation of HIV-1Tat traffi cking in cells 3 yrs 2009 - 2011 $475,200

NHMRC TRENCH G – Collaborative ovarian, prostate and breast gene-environment study, EU 4 yrs 2009 - 2012 $441,500

NHMRCDOOLAN D et al – Application of protein microarrays to develop a cross-species

malaria vaccine3 yrs 2009 - 2011 $434,250

NHMRCHAYWARD N – Identifi cation of novel low penetrance genes associated with

melanoma risk3 yrs 2009 - 2011 $389,500

NHMRC BOYD A et al – Targeting Eph receptors as anti-cancer therapy in malignant glioma 3 yrs 2009 - 2011 $387,750

NHMRCGANDHI M et al – EBV-specifi c T-cells as therapy for relapsed/refactory EBV-

positive lymphomas2 yrs 2009 - 2011 $312,000

NHMRCNYHOLT D et al – Genome-wide association study of migraine in women with

endometriosis2 yrs 2009 - 2010 $310,450

NHMRC WHITEHALL V et al – Tubulovillous adenomas in colorectal tumorigenesis 3 yrs 2009 - 2011 $284,250

NHMRCWALLACE D – Non-HFE haemochromatosis in Australia: natural history and

molecular character2 yrs 2009 - 2010 $174,500

PCFASPURDLE A et al – Role of Kallikrein gene variants in prostate cancer etiology,

Detection and Disease Progression2 yrs 2009 - 2010 $249,847

RISS KHANNA R – Funding for HCMV Trial 3 Yrs 2009 - 2011 $100,000

SANDLER JONES M et al – Profi ling gene expression of female germinal tissues of schistosomes 1 yr 2008 - 2009 $118,598

CAWEBB P et al – Improving Outcomes for women with endometrial cancer: Follow

up, Survival and Quality of Life4 yrs 2009 - 2012 $596,788

CA TRENCH G et al – Response to chemotherapy in ovarian cancer 4 yrs 2009 - 2012 $568,750

CA NANCARROW D et al – Towards new screening tests for oesophageal adenocarcinoma 4 yrs 2009 - 2012 $465,750

TCCQ BOYD A et al – Elk4 regulation of Mc1 1: a therapeutic target in malignant glioma 2 yrs 2009 - 2010 $164,000

TCCQ HAYWARD N – The role of miR 211 in melanoma 2 yrs 2009 - 2010 $164,000

GRANTS AND FUNDING CONTINUEDMajor New Grants Awarded 2008-2009 (over $100,000)




TOTAL FUNDS OR

QIMR COMPONENT

OF FUNDS

TCCQ LOPEZ A – Breast cancer stem cells as a model for therapy 2 yrs 2009 - 2010 $164,000

TCCQTONKS I – The role of pocket proteins in melanocyte homeostasis and

transformation to melanoma2 yrs 2009 - 2010 $164,000

TCCQGANDHI M et al – Biomolecular profi ling in PET/CT directed diffuse large B cell

lymphoma 2 yrs 2009 - 2010 $164,000

TCCQAURET M – Tissue specifi c microRNA and the endocrine bias of Men-1related

tumorgenesis 2 yrs 2009 - 2010 $164,000

TCCQ PARSONS P – Sending cancer to sleep: Drug-induced senescence in solid tumours 2 yrs 2009 - 2010 $163,500

TCCQ SCHMIDT C – Immunological determinants of clinical outcome in metastatic melanoma 2 yrs 2009 - 2010 $159,600

UBSMcMANUS D et al – Impact of educational videotapes on soil transmitted helminth

risk behaviour2 Yrs 2009 - 2010 CHF200,000

WCRF VAN DER POLS J – Vitamin D and Skin Cancer Risk: an 11 year prospective study 2 Yrs 2009 - 2011 GBP90,751

LEGEND FOR SOURCE OF FUNDS

ACH2 Australian Centre for HIV and Hepatitis Virology Research

ARC Australian Research Council

CA Cancer Australia

FLU Flinders University

LFQ Leukaemia Foundation of Queensland

MACQ Macquarie University

MRA Melanoma Research Alliance

NBCF National Breast Cancer Foundation

NHF National Heart Foundation

NHMRC National Health and Medical Research Council

NIH National Institutes of Health (USA)

PCFA Prostate Cancer Foundation of Australia

RISS NCRIS - Research Infrastructure Support Services Limited

SANDLER University of California - San Francisco

TCCQ The Cancer Council Queensland

UBS UBS Optimus Foundation

WCRF World Cancer Research Fund International

Agrawal A, Lynskey MT, Pergadia ML, Bucholz KK, Heath

AC, Martin NG and Madden PA. Early cannabis use and

DSM-IV nicotine dependence: a twin study. Addiction 103(11):

1896-1904, 2008

Agrawal A, Morley KI, Hansell NK, Pergadia ML,

Montgomery GW, Statham DJ, Todd RD, Madden PA, Heath

AC, Whitfi eld J, Martin NG and Lynskey MT. Autosomal

linkage analysis for cannabis use behaviors in Australian adults.

Drug and Alcohol Dependence 98: 185-190, 2008

Agrawal A, Pergadia ML, Balasubramanian S, Saccone

SF, Hinrichs AL, Saccone NL, Breslau N, Johnson EO,

Hatsukami D, Martin NG, Montgomery GW, Goate AM,

Rice JP, Bierut LJ and Madden PA. Further evidence for an

association between the gamma-aminobutyric acid receptor

A, subunit 4 genes on chromosome 4 and Fagerstrom test for

nicotine dependence. Addiction 104(3): 471-477, 2009

Ahmed S, Thomas G, Ghoussaini M, Healey CS,

Humphreys MK, Platte R, Morrison J, Maranian M, Pooley

KA, Luben R, Eccles D, Evans DG, Fletcher O, Johnson

N, dos Santos Silva I, Peto J, Stratton MR, Rahman N,

Jacobs K, Prentice R, Anderson GL, Rajkovic A, Curb JD,

Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS,

Calle EE, Thun MJ, Diver WR, Bojesen S, Nordestgaard

BG, Flyger H, Dörk T, Schürmann P, Hillemanns P,

Karstens JH, Bogdanova NV, Antonenkova NN, Zalutsky

IV, Bermisheva M, Fedorova S, Khusnutdinova E, Kang

D, Yoo KY, Noh DY, Ahn SH, Devilee P, van Asperen CJ,

Tollenaar RA, Seynaeve C, Garcia-Closas M, Lissowska

J, Brinton L, Peplonska B, Nevanlinna H, Heikkinen

T, Aittomäki K, Blomqvist C, Hopper JL, Southey MC,

Smith L, Spurdle AB, Schmidt MK, Broeks A, van Hien

RR, Cornelissen S, Milne RL, Ribas G, González-Neira

A, Benitez J, Schmutzler RK, Burwinkel B, Bartram CR,

Meindl A, Brauch H, Justenhoven C, Hamann U, Chang-

Claude J, Hein R, Wang-Gohrke S, Lindblom A, Margolin

S, Mannermaa A, Kosma VM, Kataja V, Olson JE, Wang X,

Fredericksen Z, Giles GG, Severi G, Baglietto L, English

DR, Hankinson SE, Cox DG, Kraft P, Vatten LJ, Hveem

K, Kumle M, Sigurdson A, Doody M, Bhatti P, Alexander

BH, Hooning MJ, van den Ouweland AM, Oldenburg RA,

Schutte M, Hall P, Czene K, Liu J, Li Y, Cox A, Elliott G,

Brock I, Reed MW, Shen CY, Yu JC, Hsu GC, Chen ST,

Anton-Culver H, Ziogas A, Andrulis IL, Knight JA, Beesley

J, Goode EL, Couch F, Chenevix-Trench G, Hoover

RN, Ponder BA, Hunter DJ, Pharoah PD, Dunning AM,

Chanock SJ and Easton DF. Newly discovered breast cancer

susceptibility loci on 3p24 and 17q23.2. Nature Genetics

41(5): 585-590, 2009. Letter

Anderson CA, Zhu G, Falchi M, van den Berg SM, Treloar

SA, Spector TD, Martin NG, Boomsma DI, Visscher PM

and Montgomery GW. A genome-wide linkage scan for age at

menarche in three populations of European descent. Journal of

Clinical Endocrinology and Metabolism 93(10): 3965-3970, 2008

Anderson GJ. Things that go BMP in the liver: Bone

morphogenetic protein 6 and the control of body iron

homeostasis. Hepatology 50(1): 316-319, 2009

Anderson GJ, Frazer DM and McLaren GD. Iron absorption

and metabolism. Current Opinion in Gastroenterology 25(2):

129-135, 2009

Andrews KT, Tran TN, Wheatley NC and Fairlie DP.

Targeting histone deacetylase inhibitors for anti-malarial therapy.

Current Topics in Medicinal Chemistry 9(3): 292-308, 2009

Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R,

Waddell N, Simms L, Locandro B, Fereday S, Trafi cante

N, Russell P, Sharma R, Birrer MJ; AOCS Study Group,

deFazio A, Chenevix-Trench G and Bowtell DD. Mutation

of ERBB2 provides a novel alternative mechanism for the

ubiquitous activation of RAS-MAPK in ovarian serous low

malignant potential tumors. Molecular Cancer Research 6(11):

1678-1690, 2008

Anttila V, Nyholt DR, Kallela M, Artto V, Vepsalainen S,

Jakkula E, Wennerstrom A, Tikka-Kleemola P, Kaunisto

MA, Hamalainen E, Widen E, Terwilliger J, Merikangas K,

Montgomery GW, Martin NG, Daly M, Kaprio J, Peltonen

L, Farkkila M, Wessman M and Palotie A. Consistently

Replicating Locus Linked to Migraine on 10q22-q23. American

Journal of Human Genetics 82(5): 1051-1063, 2008

Apte SH, Baz A, Groves P, Kelso A and Kienzle N.

Interferon-gamma and interleukin-4 reciprocally regulate

CD8 expression in CD8+ T cells. Proceedings of the National

Academy of Science USA 105(45): 17475-17480, 2008

Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ,

Bell MJ, Brennan RM, Beddoe T, Wilce MC, Clements

CS, Purcell AW, McCluskey J, Burrows SR, and Rossjohn

J. Natural micropolymorphism in human leukocyte antigens

provides a basis for genetic control of antigen recognition.

Journal of Experimental Medicine 206(1): 209-219, 2009

Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh

MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown

MA, Tavtigian SV, Goldgar DE, Young JP and Spurdle AB.

Classifying MLH1 and MSH2 variants using bioinformatic

prediction, splicing assays, segregation, and tumor

characteristics. Human Mutation 30(5): 757-770, 2009

2008-2009 SCIENTIFIC

PUBLICATIONS


Ashe A, Morgan DK, Whitelaw NC, Bruxner TJ, Vickaryous

NK, Cox LL, Butterfi eld NC, Wicking C, Blewitt ME, Wilkins

SJ, Anderson GJ, Cox TC and Whitelaw E. A genome-wide

screen for modifi ers of transgene variegation identifi es genes

with critical roles in development. Genome Biology 9(12):

R182, 2008

Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid

IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson

JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio

J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U,

Campbell H, Rudan I, Johansson A, Marroni F, Hayward C,

Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler

I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus,

Montgomery GW, Whitfi eld J, Magnusson P, Saharinen J,

Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden

AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A,

Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring

A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM

and Peltonen L. Loci infl uencing lipid levels and coronary

heart disease risk in 16 European population cohorts. Nature

Genetics 41: 47-55, 2009

Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar

CB and Aitken JF. Factors associated with the number of

lesions excised for each skin cancer: a study of primary care

physicians in Queensland, Australia. Archives of Dermatology

144(11): 1468-76, 2008

Banovic T, MacDonald KP, Markey KA, Morris ES,

Kuns RD, Varelias A and Hill GR. Donor treatment with

a multipegylated G-CSF maximizes graft-versus-leukemia

effects. Biology of Blood and Marrow Transplantation 15(1):

126-30, 2009

Banovic T, Markey KA, Kuns RD, Olver SD, Raffelt NC, Don

AL, Degli-Esposti MA, Engwerda CR, MacDonald KP and

Hill GR. Graft-versus-host disease prevents the maturation of

plasmacytoid dendritic cells. Journal of Immunology 182(2):

912-920, 2009

Barnes TS, Li J, Coleman GT and McManus DP.

Development and evaluation of immunoblot-based

serodiagnostic tests for hydatid infection in macropodids.

Journal of Wildlife Diseases 44(4): 1036-1040, 2008

Bates TC, Luciano M, Lind PA, Wright MJ, Montgomery

GW and Martin NG. Recently-derived variants of brain-size

genes ASPM, MCPH1, CDK5RAP and BRCA1 not associated

with general cognition, reading or language. Intelligence

36(6):689-693, 2008

Battaglia M, Pesenti-Gritti P, Medland SE, Ogliari A, Tambs

K and Spatola CAM. A genetically informed study of the

association between childhood separation anxiety, sensitivity to

CO2, panic disorder, and the effect of childhood parental loss.

Archives of General Psychiatry 66(1): 64-71, 2009

Beadle G, Baade P and Fritschi L. Acute myeloid leukemia

after breast cancer: a population-based comparison with

hematological malignancies and other cancers. Annals of

Oncology 20(1): 103-109, 2008

Beaumont KA, Shekar SN, Cook AL, Duffy DL and Sturm

RA. Red hair is the null phenotype of MC1R. Human Mutation

29(8): E88-94, 2008

Beddoe T, Chen Z, Clements CS, Ely LK, Bushell SR,

Vivian JP, Kjer-Nielsen L, Pang SS, Dunstone MA, Liu YC,

Macdonald WA, Perugini MA, Wilce MC, Burrows SR,

Purcell AW, Tiganis T, Bottomley SP, McCluskey J and

Rossjohn J. Antigen ligation triggers a

conformational change within the constant domain of the

alpha-beta T cell receptor. Immunity 30(6): 777-788, 2009

Beesley VL, Eakin EG, Janda M and Battistutta D.

Gynecological cancer survivors’ health behaviours and their

associations with quality of life. Cancer Causes

and Control 19(7): 775-782, 2008

Beeson JG, Osier FH and Engwerda CR. Recent

insights into humoral and cellular immune responses against

malaria. Trends in Parasitology 24(12): 578-584, 2008

Bell MJ, Abbott RJ, Croft NP, Hislop AD and Burrows SR.

An HLA-A2-restricted T cell epitope mapped to the BNLF2a

immune evasion protein of EBV that inhibits TAP. Journal of

Virology 83(6): 2783-2788, 2009

Bell MJ, Burrows JM, Brennan R, Miles JJ, Tellam J,

McCluskey J, Rossjohn J, Khanna R and Burrows SR. The

peptide length specifi city of some HLA class I alleles is very

broad and includes peptides of up to 25 amino acids in length.

Molecular Immunology 46(8-9): 1911-1917, 2009

Benyamin B, McRae AF, Zhu G, Gordon S, Henders

AK, Palotie A, Peltonen L, Martin NG, Montgomery GW,

Whitfi eld JB and Visscher PM. Variants in TF and HFE

explain approximately 40% of genetic variation in Serum-

Transferrin Levels. American Journal of Human Genetics 84(1):

60-65, 2009

Benyamin B, Visscher PM and McRae AF. Family-based

genome-wide association studies. Pharmacogenomics 10(2):

181-190, 2009 Review


Bergquist R and McManus DP. Strategy for the development

of a vaccine against schistosomiasis. In: Important Helminth

Infections in Southeast Asia. RNAS+, UNICEF/UNDP/World

Bank/WHO Special Programme for Research and Training in

Tropical Diseases (TDR), pp 98-108, 2008

Bergström FC, Reynolds S, Johnstone M, Pike RN,

Buckle AM, Kemp DJ, Fischer K and Blom AM. Scabies

mite inactivated serine protease paralogs inhibit the human

complement system. Journal of Immunology 182(12): 7809-

7817, 2009

Birley AJ, James MR, Dickson PA, Montgomery GW, Heath

AC, Martin NG and Whitfi eld JB. ADH SNP associations with

alcohol metabolism in vivo. Human Molecular Genetics 18(8):

1533-1542, 2009

Bloethner S, Mould A, Stark M and Hayward NK.

Identifi cation of ARHGEF17, DENND2D, FGFR3, and RB1

mutations in melanoma by inhibition of nonsense-mediated

mRNA decay. Genes Chromosomes and Cancer 47(12): 1076-

1085, 2008

Blokland GA, McMahon KL, Hoffman J, Zhu G, Meredith

M, Martin NG, Thompson PM, de Zubicaray GI and Wright

MJ. Quantifying the heritability of task-related brain activation

and performance during the N-back working memory task: a

twin fMRI study. Biological Psychology 79(1): 70-79, 2008

Bolderson E, Richard DJ, Edelmann W and Khanna KK.

Involvement of Exo1b in DNA damage-induced apoptosis.

Nucleic Acids Research 37(10): 3452-3463, 2009

Bonazzi VF, Irwin D and Hayward NK. Identifi cation of

candidate tumor suppressor genes inactivated by promoter

methylation in melanoma. Genes Chromosomes and Cancer

48(1):10-21, 2008

Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton

GM, Brown DA, Breit SN and Parsons PG. Macrophage

inhibitory cytokine-1 is overexpressed in malignant melanoma

and is associated with tumorigenicity. Journal of Investigative

Dermatology 129(2): 383-391, 2009

Brennan RM and Burrows SR. A mechanism for the HLA-

A*01-associated risk for EBV+ Hodgkin lymphoma and

infectious mononucleosis. Blood 112(6): 2589-2590, 2008.

Letter

Brooker S and Clements ACA. Spatial heterogeneity

of parasite co-infection: Determinants and geostatistical

prediction at regional scales. International Journal for

Parasitology 39(5): 591–597, 2009

Brown KM, MacGregor S, Montgomery G, Craig DW, Zhao

ZZ, Iyadurai K, Henders A, Homer N, Campbell M, Stark

M, Thomas S, Schmid H, Holland EA, Gillanders EM, Duffy

DL, Maskiell JA, Jetann J, Ferguson M, Stephan DA, Cust

AE, Whiteman D, Green A, Olsson H, Puig S, Ghiorzo P,

Hansson J, Bressac-de Paillerets B, Goldstein AM, Gruis

NA, Elder DE, Newton Bishop J, Kefford RF, Giles GG,

Armstrong BK, Aitken JF, Hopper JL, Martin NG, Trent JM,

Mann GJ and Hayward NK. Common sequence variants on

20q11.22 confer melanoma susceptibility. Nature Genetics

40(7): 838-840, 2008

Brun C, Leporé N, Pennec X, Chou YY, Lee AD, Barysheva

M, de Zubicaray G, Meredith M, McMahon K, Wright MJ,

Toga AW and Thompson PM. A tensor-based morphometry

study of genetic infl uences on brain structure using a new fl uid

registration method. Medical Image Computing and Computer

Assisted Intervention 11(2): 914-21, 2008

Buchanan D and Young J. A Perspective on bi-allelic MUTYH

mutations in patients with Hyperplastic Polyposis Syndrome.

Gastroenterology 136(7): 2407-2408, 2009

Burke ML, Jones MK, Gobert G, Li YS, Ellis MK and McManus

DP. Immunopathogenesis of human schistosomiasis. Parasite

Immunology 31(4): 163-176, 2009. Review

Buttini MJ, Jordan SJ and Webb PM. The effect of the

levonorgestrel releasing intrauterine system on endometrial

hyperplasia: An Australian study and systematic review.

Australian and NZ Journal of Obstetrics and Gynaecology

49(3): 316-322, 2009

Byrne EM, McRae AF, Zhao ZZ, Martin NG, Montgomery

GW and Visscher PM. The use of common mitochondrial

variants to detect and characterise population structure in

the Australian population: implications for genome-wide

association studies. European Journal of Human Genetics

16(11): 1396-1403, 2008

Campbell BE, Nisbet AJ, Mulvenna J, Loukas A and

Gasser RB. Molecular and phylogenetic characterization

of cytochromes c from Haemonchus contortus and

Trichostrongylus vitrinus (Nematoda: Trichostrongylida). Gene

424(1-2): 121-129, 2008

Cantacessi C, Campbell BE, Visser A, Geldhof P, Nolan

MJ, Nisbet AJ, Matthews JB, Loukas A, Hofmann A,

Otranto D, Sternberg PW and Gasser RB. A portrait of the

“SCP/TAPS” proteins of eukaryotes--developing a framework

for fundamental research and biotechnological outcomes.

Biotechnology Advances 27(4): 376-388, 2009

2008-2009 SCIENTIFIC PUBLICATIONS

CONTINUED


Cantacessi C, Loukas A, Campbell BE, Mulvenna J, Ong

EK, Zhong W, Sternberg PW, Otranto D and Gasser RB.

Exploring transcriptional conservation between Ancylostoma

caninum and Haemonchus contortus by oligonucleotide

microarray and bioinformatic analyses. Molecular and Cellular

Probes 23(1): 1-9, 2009

Carless MA, Kraska T, Lintell N, Neale R, Green AC and

Griffi ths LR. Polymorphisms of the VDR gene are associated

with presence of solar keratosis on the skin. British Journal of

Dermatology 159(4): 804-10, 2008

Chambers SK, Ferguson M, Gardiner RA, Nicol D, Gordon

L, Occhipinti S and Aitken JF. ProsCan for men: randomised

controlled trial of decision support intervention for men with

localised prostate cancer. BioMed Central Cancer 8: 207, 2008

Chambers SK, Schover L, Halford K, Clutton S, Ferguson

M, Gordon L, Gardiner RA, Occhipinti S and Dunn J.

ProsCan for couples: randomised controlled trial of a couples-

based sexuality intervention for men with localised prostate

cancer who receive radical prostatectomy. BioMed Central

Cancer 8: 226, 2008

Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK,

Bataille V, Bergman W, Berwick M, Bracci PM, Elwood

JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar

C, Kanetsky PA, Karagas MR, Marchand LL, Mackie RM,

Olsson H, Osterlind A, Rebbeck TR, Reich K, Sasieni P,

Siskind V, Swerdlow AJ, Titus-Ernstoff, L, Zens MS, Ziegler

A and Barrett JH. A pooled analysis of melanocytic nevus

phenotype and the risk of cutaneous melanoma at different

latitudes. International Journal of Cancer 124(2): 429-428, 2009

Chen CCM, Mengersen KL, Keith JM, Martin NG and

Nyholt DR. Linkage and heritability analysis of migraine symptom

groupings: a comparison of three different clustering methods

on twin data. Human Genetics 12595-6): 591-604, 2009

Chenoweth SF and Visscher PM. Association mapping in

outbred populations: power and effi ciency when genotyping

parents and phenotyping progeny. Genetics 181(2):755-765,

2009

Chiang MC, Barysheva M, Lee AD, Madsen S, Klunder

AD, Toga AW, Mcmahon KL, de Zubicaray GI, Meredith M,

Wright MJ, Srivastava A, Balov N and Thompson PM. Brain

fi ber architecture, genetics, and intelligence: a high angular

resolution diffusion imaging (HARDI) study. Medical Image

Computing and Computer Assisted Intervention 11(1):1060-

1067, 2008

Chiang MC, Barysheva M, Shattuck DW, Lee AD, Madsen

SK, Avedissian C, Klunder AD, Toga AW, McMahon KL,

de Zubicaray GI, Wright MJ, Srivastava A, Balov N and

Thompson PM. Genetics of brain fi ber architecture and

intellectual performance. Journal of Neuroscience 29(7): 2212-

24, 2009

Chircop M, Oakes V, Graham ME, Ma MP, Smith CM,

Robinson PJ and Khanna KK. The actin-binding and

bundling protein, EPLIN, is required for cytokinesis. Cell Cycle

8(5): 757-764, 2009. Report

Chou YY, Leporé N, Chiang MC, Avedissian C, Barysheva

M, McMahon KL, de Zubicaray GI, Meredith M, Wright

MJ, Toga AW and Thompson PM. Mapping genetic

infl uences on ventricular structure in twins. Neuroimage 44(4):

1312-1323, 2009

Clarke RA, Zhao Z, Guo A, Roper K, Teng L, Fang Z,

Samaratunga H, Lavin MF and Gardiner RA. New genomic

structure for prostate cancer specifi c gene PCA3 within

BMCC1: Implications for prostate cancer detection and

progression. PLoS ONE. 4(3): e4995, 2009

Clements ACA, Bosque-Oliva E, Sacko M, Landoure A,

Dembele R, Traore M, Fenwick A and Brooker S.

A comparative study of the spatial distribution of

schistosomiasis in Mali in 1984–1989 and 2004–2006. PLoS

Neglected Tropical Diseases 3(5): e431, 2009

Colgrave ML, Kotze AC, Kopp S, McCarthy JS, Coleman

GT and Craik DJ. Anthelmintic activity of cyclotides: In vitro

studies with canine and human hookworms. Acta Tropica

109(2): 163-166, 2009

Collaborative Group on Epidemiological Studies of

Ovarian Cancer. Ovarian cancer and oral contraceptives:

collaborative reanalysis of data from 45 epidemiological studies

including 23 257 women with ovarian cancer and 87 303

controls. Lancet 371(9609): 303-314, 2008

Cook AL, Chen W, Thurber AE, Smit DJ, Smith AG,

Bladen TG, Brown DL, Duffy DL, Pastorino L, Bianchi-

Scarra G, Leonard JH, Stow JL and Sturm RA. Analysis of

Cultured Human Melanocytes Based on Polymorphisms within

the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P Loci.

Journal of Investigative Dermatology 129(2): 392-405, 2009

Cornes BK, Lind PA, Medland SE, Montgomery GW, Nyholt

DR and Martin NG. Replication of the association of common

rs9939609 variant of FTO with increased BMI in an Australian

adult twin population but no evidence for gene by environment

(G x E) interaction. International Journal of Obesity (Lond) 33(1):

75-79, 2009


Cornes BK, Medland SE, Lind PA, Nyholt DR, Montgomery

GW and Martin NG. Genetic variation in female BMI increases

with number of children born but failure to replicate association

between GNbeta3 variants and increased BMI in parous females.

Twin Research and Human Genetics 12(3): 276-285, 2009

Cozen W and Ferreira MA. Understanding the asthma

epidemic: can twin studies help? Twin Research and Human

Genetics 11(2): 111, 2008

Crawford DH, Fletcher LM and Anderson GJ. Tissue

specifi c action of Hfe – It’s the ‘cyte that matters Hepatology.

48:336-338, 2009

Crawford DHG, Murphy TL, Ramm LE, Fletcher LM,

Clouston AD, Anderson GJ, Subramaniam VN, Powell LW

and Ramm GA. Serum hyaluronic acid with serum ferritin

accurately predicts cirrhosis and reduces the need for liver

biopsy in C282Y hemochromatosis. Hepatology 49(2): 418-

425, 2009

Crawford DHG and Ramm GA. Utility of platelets and AST vs

serum ferritin and serum hyaluronic acid as markers of cirrhosis

in hemochromatosis. Hepatology, 49(5):1781-1782, 2009

Crough T and Khanna R. Immunobiology of human

cytomegalovirus: from bench to bedside. Clinical Microbiology

Reviews 22(1): 76-98, 2009. Review

Dale PER, Knight J, Kay BH, Chapman H, Ritchie SA and

Brown MD. Habitat characteristics and eggshell distribution

of the salt marsh mosquito Aedes vigilax in marshes in

subtropical eastern. Australian Journal of Insect Science 8(25):

1-5, 2008

Darbro JM and Thomas MB. Spore persistence and

likelihood of aeroallergenicity of entomopathogenic fungi used

for mosquito control. American Journal of Tropical Medicine

and Hygiene 80(6): 992-997, 2009

Darshan D and Anderson GJ. Interacting signals in the control

of hepcidin expression. Biometals 22(1): 77-87, 2009

Datu BJ, Loukas A, Cantacessi C, O’Donoghue P and

Gasser RB. Investigation of the regulation of transcriptional

changes in Ancylostoma caninum larvae following serum

activation, with a focus on the insulin-like signalling pathway.

Veterinary Parasitology 159(2): 139-148, 2008

Dave KA, Whelan F, Bindloss C, Furness SG, Chapman-

Smith A, Whitelaw ML and Gorman JJ. Sulfonation and

phosphorylation of regions of the dioxin receptor susceptible to

methionine modifi cations. Molecular and Cellular Proteomics 8:

706-719, 2009

Davies MR, Shera J, Van Domselaar GH, Sriprakash KS

and McMillan DJ. A novel integrative conjugative element

mediates genetic transfer from group G streptococcus to other

beta-haemolytic streptococci. Journal of Bacteriology 191(7):

2257-2265, 2009

Davis AJ, Carr JM, Bagley CJ, Powell J, Warrilow D,

Harrich D, Burrell CJ and Li P. Human immunodefi ciency

virus type-1 reverse transcriptase exists as post-translationally

modifi ed forms in virions and cells. Retrovirology 5: 115, 2008

de Zubicaray, Chiang MC, McMahon KL, Shattuck DW,

Toga AW, Martin NG, Wright MJ and Thompson PM.

Meeting the Challenges of Neuroimaging Genetics. Brain

Imaging and Behavior 2: 258-263, 2008

Dirani M, Shekar SN and Baird PN. Adult-onset myopia:

the Genes in Myopia (GEM) twin study. Investigative

Ophthalmology and Visual Science 49(8): 3324-3327, 2008

Dirani M, Shekar SN and Baird PN. Evidence of shared

genes in refraction and axial length: the Genes in Myopia

(GEM) twin study. Investigative Ophthalmology and Visual

Science 49(10): 4336-4339, 2008

Dirani M, Shekar SN and Baird PN. The role of educational

attainment in refraction: the Genes in Myopia (GEM) twin study.

Investigative Ophthalmology and Visual Science 49(2): 534-

538, 2008

Distel MA, Rebollo-Mesa I, Willemsen G, Derom CA, Trull

TJ, Martin NG and Boomsma DI. Familial resemblance of

borderline personality disorder features: genetic or cultural

transmission? PLoS ONE 4(4): e5334, 2009

Dixon MW, Peatey CL, Gardiner DL and Trenholme KR.

A green fl uorescent protein-based assay for determining

gametocyte production in Plasmodium falciparum. Molecular

and Biochemical Parasitology 163(2): 123-126, 2008

Dixon WMA, Spielmann T, Hawthorne PL, Anderson

KL, Trenholme KR and Gardiner DL. Targeting of the Ring

Exported Protein 1 to the Maurer’s clefts is mediated by a two

phase process. Traffi c 9(8): 1316-1326, 2008

Dobaño C, Sedegah M, Rogers WO, Kumar S, Zheng

H, Hoffman SL and Doolan DL. Plasmodium: mammalian

codon optimization of malaria plasmid DNA vaccines enhances

antibody responses but not T cell responses nor protective

immunity. Experimental Parasitology 122(2):112-123, 2009


CONTINUED


Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M,

Green AC, Hayward NK, Webb PM and Whiteman DC.

Polymorphisms in MGMT and DNA repair genes and the risk of

esophageal adenocarcinoma. International Journal of Cancer

123(1): 174-180, 2008

Dolezal M, Schwarzenbacher H, Soller M, Sölkner J and

Visscher PM. Multiple-marker mapping for selective DNA

pooling within large families. Journal of Dairy Science 91:

2864-2873, 2008

Don TA, Bethony JM and Loukas A. Saposin-like proteins

are expressed in the gastrodermis of Schistosoma mansoni

and are immunogenic in natural infections. International Journal

of Infectious Diseases 12(6): e39-47, 2008

Dong L, Gordon VA, Grange RL, Johns J, Parsons PG,

Porzella A, Reddell P, Schill H and Williams CM. Structure

and absolute stereochemistry of the anticancer agent EBC-

23 from the Australian rainforest. Journal of the American

Chemical Society 130(46): 15262-15263, 2008

Doolan DL. The path of discovery. Human Vaccines 4(5): 324-

327, 2008

Doolan DL, Dobao C and Baird JK. Acquired immunity to

malaria. Clinical Microbiology Reviews 22(1): 13-36, 2009. Review

Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C,

Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair

PL, Aguiar JC, Baldi P, Davies DH and Felgner PL. Profi ling

humoral immune responses to P. falciparum infection with

protein microarrays. Proteomics 20(22): 4680-4694, 2008

Dow GS, Chen Y, Andrews KT, Caridha D, Gerena

L, Gettayacamin M, Johnson J, Li Q, Melendez V,

Obaldia N, Tran TN and Kozikowski AP. Antimalarial

activity of phenylthiazolyl-bearing hydroxamate-based

histone deacetylase inhibitors. Antimicrobial Agents and

Chemotherapy 52(10): 3467-3477, 2008

Dowty JG, Lose F, Jenkins MA, Chang J-H, Chen X,

Beesley J, Dite GS, Southey MC, Byrnes GB, Giles G.G,

Tesoriero A, kConFaB, ABCFS, Hopper JL and Spurdle AB.

The Rad51D E233G variant and breast cancer risk: population-

based and clinic-based family studies of Australasian women.

Breast Cancer Research and Treatment 112(1): 35-39, 2008

Doyle AE, Ferreira MA, Sklar PB, Lasky-Su J, Petty C,

Fusillo SJ, Seidman LJ, Willcutt EG, Smoller JW, Purcell

S, Biederman J and Faraone SV. Multivariate genomewide

linkage scan of neurocognitive traits and ADHD symptoms:

suggestive linkage to 3q13. American Journal of Medical

Genetics B Neuropsychiatric Genetics 147B(8):1399-1411,

2008. Erratum in: 150B(5): 751, 2009

Duffy SL, Coulthard MG, Spanevello MD, Herath NI,

Yeadon TM, McCarron JK, Carter JC, Tonks ID, Kay GF,

Phillips GE and Boyd AW. Generation and characterization

of EphA1 receptor tyrosine kinase reporter knockout mice.

Genesis 46(10): 553-561, 2008

Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S,

Vega A, Rodríguez R, Barbosa-Morais NL, Ponder BA,

Low YL, Bingham S, Haiman CA, Le Marchand L, Broeks

A, Schmidt MK; ABCS, Hopper J, Southey M, Beckmann

MW, Fasching PA; BBCC, Peto J, Johnson N; BBCS,

Bojesen SE, Nordestgaard B; CGPS, Milne RL, Benitez

J; CNIO-BCS, Hamann U, Ko Y; GENICA, Schmutzler RK,

Burwinkel B; GC-HBOC, Schürmann P, Dörk T; HABCS,

Heikkinen T, Nevanlinna H, Lindblom A, Margolin S;

KARBAC, Mannermaa A, Kosma VM, Chen X, Spurdle A,

Change-Claude J, Flesch-Janys D, Couch FJ, Olson JE;

for MCBCS, Severi G, Baglietto L; MCCS, Børresen-Dale

AL, Kristensen V, Hunter DJ, Hankinson SE, Devilee P,

Vreeswijk M; ORIGO, Lissowska J, Brinton L, Liu J, Hall P,

Kang D, Yoo KY, Shen CY, Yu JC, Anton-Culver H, Ziogoas

A, Sigurdson A, Struewing J, Easton DF, Garcia-Closas M,

Humphreys MK, Morrison J, Pharoah PD, Pooley KA and

Chenevix-Trench G. Association of ESR1 gene tagging SNPs

with breast cancer risk. Human Molecular Genetics 18(6):

1131-1139, 2009

Ehlers CL, Gilder DA, Slutske WS, Lind PA and Wilhelmsen

KC. Externalizing disorders in American Indians: Comorbidity

and a genome wide linkage analysis. American Journal of

Medical Genetics B, Neuropsychiatric Genetics 147B(6): 690-

698, 2008

Ellis MK and McManus DP. Familial aggregation of human

helminth infection in the Poyang lake area of China with a

focus on genetic susceptibility to Schistosomiasis japonica and

associated markers of disease. Parasitology 136(7): 699-712,

2009. Review

Ely LK, Burrows SR, Purcell AW, Rossjohn J and

McCluskey J. T-cells behaving badly: structural insights into

alloreactivity and autoimmunity. Current Opinion in Immunology

20(5): 575-580, 2008

Engwerda CR and Good MF. Disarming the malaria parasite.

Nature Medicine 14(9): 912-913, 2008

Fan J, Yang W and Brindley PJ. Lysophospholipase from

the human blood fl uke, Schistosoma japonicum. International

Journal of Infectious Diseases 12(2): 143-151, 2008

Fang ZM, Tse RV, Marjoniemi VM, Kozlov S, Lavin

MF, Chen H, Kearsley JH, Graham PH and Clarke RA.

Radioresistant malignant myoepithelioma of the breast with


high level of ataxia telangiectasia mutated protein. Journal of

Medical Imaging and Radiation Oncology 53(2): 234-239, 2009

Ferreira MA, O’Donovan MC, Meng YA, Jones IR, Ruderfer

DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller

JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere

ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S,

Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel

SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M,

Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R,

Macintyre DJ, Maclean AW, St Clair D, Robinson M, Van

Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier

DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin

A, Farmer A, Curtis D, Scolnick EM, McGuffi n P, Daly MJ,

Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen

MJ, Purcell SM, Sklar P and Craddock N. Collaborative

genome-wide association analysis supports a role for ANK3

and CACNA1C in bipolar disorder. Nature Genetics 40(9):

1056-1058, 2008

Finnegan EJ and Whitelaw E. Leaving the past behind. PLoS

Genetics 4(10): e1000248, 2008

Fischer K, Bergström F, Reynolds S, Beckham S, Willis

C, Law R, Langendorf C, Blom A, Buckle A, Pike R and

Kemp DJ. Scabies mite inactivated protease paralogues inhibit

human complement. Molecular Immunology 45(16): 4171-

4172, 2008. Abstract

Fischer K, Langendorf CG, Irving JA, Reynolds S, Willis

C, Beckham S, Law RH, Yang S, Bashtannyk-Puhalovich

TA, McGowan S, Whisstock JC, Pike RN, Kemp DJ and

Buckle AM. Structural mechanisms of inactivation in scabies

mite serine protease paralogues. Journal of Molecular Biology,

390(4): 635-645, 2009

Flight SM, Johnson LA, Du QS, Warner RS, Trabi M, Gaffney

PJ, Lavin MF, de Jersey J and Masci PP. Textilinin-1, an

alternative anti-bleeding agent to aprotinin: Importance of

plasmin inhibition in controlling blood loss. British Journal of

Haematology 145(2): 207-211, 2009

Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM,

Hayward NK, Whiteman DC, Florin TH, Montgomery GW,

Cavanaugh JA and Radford-Smith GL. ATG16L1 T300A

shows strong associations with disease subgroups in a large

Australian IBD population: further support for signifi cant

disease heterogeneity. American Journal of Gastroenterology

103(10): 2519-26, 2008

Francis GD, Jones MA, Beadle GF and Stein SR. Bright-

fi eld in situ hybridization for HER2 gene amplifi cation in

breast cancer using tissue microarrays: Correlation between

chromogenic (CISH) and automated silver-enhanced (SISH)

methods with patient outcome. Diagnostic Molecular

Pathology 18(2): 88-95, 2009

Frazer DM and Anderson GJ. Hepcidin compared with

prohepcidin: an absorbing story. American Journal of Clinical

Nutrition 89: 475-476, 2009. Editorial

Frazer DM, Anderson GJ, Ramm GA, Subramaniam VN

and Powell LW. How much iron is too much? Expert Review

of Gastroenterology and Hepatology 2(3): 287-290, 2008

Fujita Y, Abdel-Aal A-BM, Wimmer N, Batzloff MR, Good

MF and Toth I. Synthesis and immunological evaluation

of self-adjuvanting glycolipopeptide vaccine candidates.

Bioorganic and Medicinal Chemistry 16(19): 8907-8913, 2008

Gandhi MK. What changes are needed to the current direction

and interpretation of clinical cancer research to meet the needs

of the 21st century? Medical Journal of Australia 190(8): 461,

2009. Letter

Garcia-Closas M, Hall P, Nevanlinna H, Pooley K,

Morrison J, Richesson DA, Bojesen SE, Nordestgaard

BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-

Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C,

Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann

P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH,

Fagerholm R, Aaltonen K, Aittomäki K, von Smitten K,

Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M,

Tengström M, Kosma VM, Kataja V, Chenevix-Trench G,

Spurdle AB, Beesley J, Chen X, Australian Ovarian Cancer

Management Group, Kathleen Cuningham Foundation

Consortium For Research Into Familial Breast Cancer,

Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts

PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-

Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S,

Couch F, Goode EL, Olson JE, Vachon C, Fredericksen

ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English

DR, Southey MC, Haiman CA, Henderson BE, Kolonel

LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE,

Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ,

Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning

MJ, Meijers-Heijboer H, Collee JM, van den Ouweland

A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K,

Czene K, Cox A, Balasubramanian SP, Cross SS, Reed

MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA,

Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V,

Sigurdson A, Doody M, Struewing JP, Alexander B, Easton

DF and Pharoah PD. Heterogeneity of breast cancer

associations with fi ve susceptibility loci by clinical and pathological

characteristics. PLoS Genetics 4(4): e1000054, 2008

Gardiner DL, Woodcroft BJ, Dixon MW, Ralph SA and

Trenholme KR. REX1 and Pf62: are they one and the same?

Parasitology Research 104(5): 967-968, 2009


CONTINUED


Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL,

Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi

G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X,

Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R,

Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin

S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H,

Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram

CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H,

Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI,

Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto

J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching

PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt

MK, van Leeuwen FE, Van’t Veer LJ, Southey MC, Hopper

JL, Apicella C, Haiman CA, Henderson BE, Le Marchand

L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter

DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk

MP, Tollenaar RA, Devilee P, Chanock S, Lissowska

J, Brinton L, Peplonska B, Czene K, Hall P, Li Y, Liu J,

Balasubramanian S, Rafi i S, Reed MW, Pooley KA, Conroy

D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SH, Shen

CY, Wang HC, Yu JC, Wu PE, Anton-Culver H, Ziogoas

A, Egan K, Newcomb P, Titus-Ernstoff L, Trentham Dietz

A, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K,

Cannon-Albright LA, Wong J, Chenevix-Trench G, Spurdle

AB, Beesley J, Pharoah PD, Easton DF, and Garcia-Closas

M. Five polymorphisms and breast cancer risk: results from the

Breast Cancer Association Consortium. Cancer Epidemiology

Biomarkers and Prevention 18(5): 1610-1616, 2009

Georgousakis MM, McMillan DJ, Batzloff MR and

Sriprakash KS. Moving forward: a mucosal vaccine against

group A streptococcus. Expert Review of Vaccines 8(6): 747-

760, 2009

Gillespie NA, Zhu G, Evans DM, Medland SE, Wright

MJ and Martin NG. A genome-wide scan for eysenckian

personality dimensions in adolescent twin sibships:

psychoticism, extraversion, neuroticism, and lie. Journal of

Personality 76(6): 1415-46, 2008

Gobert GN and Jones MK. Discovering new schistosome

drug targets: the role of transcriptomics. Current Drug Targets

9(11): 922-930, 2008

Gobert GN, Moertel L, Brindley PJ and McManus DP.

Developmental gene expression profi les of the human pathogen

Schistosoma japonicum. BMC Genomics 10: 128, 2009

Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen

ES and Greenblatt MS. Genetic evidence and integration of

various data sources for classifying uncertain variants into a

single model. Human Mutation 29(11):1265-1272, 2008. Review

Good MF. The hope but challenge for developing a vaccine

that might control malaria. European Journal of Immunology

39(4): 939-943, 2009

Gordon LG, Hirst NG, Gies PH and Green AC. What impact

would effective solarium regulation have in Australia? Medical

Journal of Australia 189(7): 375-378, 2008

Gordon L, Lynch BM and Newman B. Transitions in work

participation after a diagnosis of colorectal cancer. Australia

and N Z Journal of Public Health 32(6): 569-74, 2008

Gorton D, Govan B, Olive C, and Ketheesan N. B and T cell

responses in group A streptococcal M protein/peptide induced

experimental carditis. Infection and Immunity 77(5): 2177-

2183, 2009

Gras S, Burrows SR, Kjer-Nielsen L, Clements CS, Liu YC,

Sullivan LC, Bell MJ, Brooks AG, Purcell AW, McCluskey J

and Rossjohn J. The shaping of T cell receptor recognition by

self-tolerance. Immunity 30(2): 193-203, 2009

Gray DJ, Forsyth SJ, Li RS, McManus DP, Li Y, Chen

H, Zheng F and Williams GM. An innovative database for

epidemiological fi eld studies of neglected tropical diseases.

PLoS Neglected Tropical Diseases 3(5):e413, 2009

Gray DJ, Williams GM, Li Y and McManus DP. Transmission

dynamics of Schistosoma japonicum in the lakes and

marshlands of China. PLoS ONE 3(12): e4058, 2008

Gray DJ, Williams GM, Li YS, Chen H-G, Forsyth SJ,

Li, RS, Barnett AG, Guo JG, Ross AG, Zheng F and

McManus DP. A cluster-randomised intervention trial against

Schistosoma japonicum in the Peoples’ Republic of China:

bovine and human transmission. PLoS ONE 4(6): e5900, 2009

Green AC, van der Pols J and Hunter D. Epidemiology of

cancer of the skin. In: A textbook of cancer epidemiology

and control, 2nd Edition. Adami A, Trichopoulos D, Hunter D

(Eds). Oxford University Press, New York pp 378-394, 2008

Green M, Camilleri E, Gandhi MK and Griffi ths L. Genetic

susceptibility to complex traits: moving towards informed

analysis of whole-genome screens. In: Human Genome:

Features, Variations and Genetic Disorders. F Columbus (Ed).

Hauppage New York, Nova Science Publishers, 2009

Green M, Gandhi MK, Camilleri E, Marlton P, Lea R and

Griffi ths L. High levels of BACH2 associated with lower

levels of BCL2 transcript abundance in t(14;18)(q21;q34)

translocation positive non-Hodgkin’s lymphoma. Leukemia

Research 33(5): 731-734, 2009


Greenblatt MS, Brody LC, Foulkes WD, Genuardi

M, Hofstra RMW, Olivier M, Plon SE, Sijmons RH,

Sinilnikova O and Spurdle AB. Locus-specifi c databases

and recommendations to strengthen their contribution to the

classifi cation of variants in cancer susceptibility genes. Human

Mutation 29(11): 1273-1281, 2008. Review

Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ,

Constantine CC, McLaren CE, English DR, Gertig DM,

Delatycki MB, Nicoll AJ, Southey MC, Hopper JL, Giles

GG, Anderson GJ, Olynyk JK, Powell LW and Allen KJ.

HFE C282Y/H63D compound heterozygotes are at low risk of

hemochromatosis-related morbidity. Hepatology 50(1): 94-101,

2009

Gurrin LC, Osborne NJ, Constantine CC, McLaren CE,

English DR, Gertig DM, Delatycki MB, Anderson GJ, Olynyk

JK, Powell LW and Allen KJ. The natural history of serum iron

indices for HFE C282Y homozygosity associated with hereditary

hemochromatosis. Gastroenterology 135(6): 1945-1952, 2008

Hacker E and Hayward NK. Germline MC1R variants and

BRAF mutant melanoma. Journal of Investigative Dermatology

128(10): 2354-2356, 2008

Hacker E, Muller HK, Whiteman D, Pavey S, Hayward N

and Walker G. Reduced expression of IL18 in the pathway to

ultraviolet radiation induced melanoma. International Journal of

Cancer 123(1): 227-231, 2008. Report

Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A,

Hankinson SE, Hu FB, Duffy DL, Zhao ZZ, Martin NG,

Montgomery GW, Hayward NK, Thomas G, Hoover RN,

Chanock S and Hunter DJ. A genome-wide association

study identifi es novel alleles associated with hair color and skin

pigmentation. PLoS Genetics 4(5): e1000074, 2008

Hanh TT, Hill PS, Kay BH and Quy TM. Development of a

framework for evaluating the sustainability of community-based

dengue control projects. American Journal of Tropical Medicine

and Hygiene 80(2): 312-318, 2009

Hansell NK, Agrawal A, Whitfi eld JB, Morley KI, Gordon

SD, Lind PA, Pergadia ML, Montgomery GW, Madden

PA, Todd RD, Heath AC and Martin NG. Can we identify

genes for alcohol consumption in samples ascertained

for heterogeneous purposes? Alcoholism – Clinical and

Experimental Research 33(4): 729-739, 2009

Hanssen E, Hawthorne P, Dixon MW, Trenholme KR,

McMillan P, Spielman T, Gardiner DL and Tilley L. Targeted

mutagenesis of the ring exported protein-1 of Plasmodium

falciparum disrupts the architecture of Maurer’s cleft organelles.

Molecular Microbiology 69(4): 938-953, 2008

Harrich D, Apolloni A and Warrilow D. HIV-1 Tat implicated as a

key factor in viral spread. Future HIV Therapy 2(4): 323-326, 2008

Hasselbalch AL, Benyamin B, Visscher PM, Heitmann BL,

Kyvik KO and Sørensen TI. Common Genetic Components

of Obesity Traits and Serum Leptin. Obesity 16(12): 2723-

2729, 2008

Hausdorf, Eakin E, Whiteman D, Rogers C, Aitken J and

Newman B. Prevalence and correlates of multiple cancer risk

behaviours in an Australian population-based survey: Results

from the Queensland Cancer Risk Study. Cancer Causes and

Control 19(10): 1339-1347, 2008

Haworth CM, Wright MJ, Martin NW, Martin NG, Boomsma

DI, Bartels M, Posthuma D, Davis OS, Brant AM, Corley

RP, Hewitt JK, Iacono WG, McGue M, Thompson LA, Hart

SA, Petrill SA, Lubinski D and Plomin R. A Twin Study of the

Genetics of High Cognitive Ability Selected from 11,000 Twin

Pairs in Six Studies from Four Countries. Behavior Genetics

39(4): 359-370, 2009

Hayes BJ, Visscher PM and Goddard ME. Increased

accuracy of artifi cial selection by using the realized relationship

matrix. Genetics Research 91: 47-60, 2009

Hayward NK. Mouse pigmentation mutants help identify

a uveal melanoma oncogene. Pigment Cell and Melanoma

Research 22(1): 2-3, 2009

Herath NI, Doecke J, Spanevello MD, Leggett BA and

Boyd AW. Epigenetic silencing of EphA1 expression in

colorectal cancer is correlated with poor survival. British

Journal of Cancer, 100(7): 1095-1102, 2009

Hewett DG, Watson BM, Gallois C, Ward M and Leggett

BA. Communication in Medical Records – Intergroup

Language and Patient Care. Journal of Language and Social

Psychology 28(2): 119-138, 2009

Hill GR. Infl ammation and bone marrow transplantation.

Biology of Blood and Marrow Transplantation 15 (1 Suppl):

139-41, 2008

Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S,

Steffens M, Flaquer A, Herms S, Becker T, Kortum AK, Nyholt

DR, Zhao ZZ, Montgomery GW, Martin NG, Muhleisen TW,

Alblas MA, Moebus S, Jockel KH, Brocker-Preuss M, Erbel

R, Reinartz R, Betz RC, Cichon S, Propping P, Baur MP,

Wienker TF, Kruse R and Nothen MM. Susceptibility variants for

male-pattern baldness on chromosome 20p11. Nature Genetics

40(11): 1279-1281, 2008

Hinojosa-Juarez AC, Sandoval-Balanzario M, McManus

DP and Monroy-Ostria A. Genetic similarity between

cysticerci of Taenia solium isolated from human brain and from

pigs. Infection, Genetics and Evolution 8(5): 653-656, 2008


CONTINUED


Hirst N, Gordon L, Gies P and Green AC. Estimation of

avoidable skin cancers and cost-savings to government

associated with regulation of the solarium industry in Australia.

Health Policy 89(3): 303-311, 2009

Ho SK, Kovacevic N, Henkelman RM Boyd A, Pawson

T, Henderson JT. EphB2 and EphA4 receptors regulate

formation of the principal inter-hemispheric tracts of the

mammalian forebrain. Neuroscience 160(4): 744-95, 2009

Hoang-Le D, Smeenk L, Anraku I, Pijlman GP, Wang XJ,

de Vrij J, Liu WJ, Le TT, Schroder WA, Khromykh AA and

Suhrbier A. A Kunjin replicon vector encoding granulocyte

macrophage colony-stimulating factor for intra-tumoral gene

therapy. Gene Therapy 16(2): 190-199, 2009

Hoekstra C, Willemsen G, van Beijsterveldt TC,

Montgomery GW and Boomsma DI. Familial twinning and

fertility in Dutch mothers of twins. American Journal of Medical

Genetics: Part A 146A: 3147-3156, 2008

Hofstra RMW, Spurdle AB, Eccles D, Foulkes W, Goldgar

D, de Wind N, Hoogerbrugge N, and Hogervorst F. Tumor

characteristics as an analytic tool for classifying variants of

unknown clinical signifi cance. Human Mutation 29(11): 1292-

1303, 2008. Review

Holliday EG, Mowry BJ and Nyholt DR. A reanalysis of

409 European-Ancestry and African American schizophrenia

pedigrees reveals signifi cant linkage to 8p23.3 with evidence of

locus heterogeneity. American Journal of Medical Genetics B -

Neuropsychiatric Genetics 147B(7): 1080-1088, 2008

Holliday EG, Nyholt DR, Tirupati S, John S, Ramachandran

P, Ramamurti M, Ramadoss AJ, Jeyagurunathan A,

Kottiswaran S, Smith HJ, Filippich C, Nertney DA,

Nancarrow DJ, Hayward NK, Watkins WS, Jorde LB, Thara

R and Mowry BJ. Strong evidence for a novel schizophrenia

risk locus on chromosome 1p31.1 in homogeneous pedigrees

from Tamil Nadu, India. American Journal of Psychiatry 166(2):

206-215, 2009 Erratum in: 166(2): 238, 2009

Hou X-Y, McManus DP, Gray DJ, Balen J, Luo X-S, He Y-K,

Ellis M, Williams GM and Li Y-S. A randomized, double-

blind, placebo-controlled trial on the safety and effi cacy of

combined praziquantel and artemether treatment for acute

schistosomiasis japonica in China. Bulletin of the World Health

Organisation 86(10): 788-795, 2008

Houlihan LM, Harris SE, Luciano M, Gow AJ, Starr JM,

Visscher PM and Deary IJ. Replication study of candidate

genes for cognitive abilities: the Lothian Birth Cohort 1936.

Genes Brain and Behaviour 8(2): 238-247, 2009

Hughes MC, Williams GM, Fourtanier A and Green AC.

Food intake, dietary patterns, and actinic keratoses of the

skin: a longitudinal study. American Journal of Clinical Nutrition

89(4): 1246-1255, 2009

Hur YM, Kaprio J, Iacono WG, Boomsma DI, McGue M,

Silventoinen K, Martin NG, Luciano M, Visscher PM, Rose

RJ, He JH, Ando J, Ooki S, Nonaka K, Lin CCH, Lajunen

HR, Cornes BK, Bartels M, van Beijsterveldt CEM, Cherny

SS and Mitchell K. Genetic infl uences on the difference in

variability of height, weight and body mass index between

Caucasian and East Asian adolescent twins. International

Journal of Obesity 32(10):1455-1467, 2008

Ibiebele TI and van der Pols JC. Dietary pattern predicts

breast cancer risk- evidence from the EPIC-Potsdam study.

British Journal of Nutrition 100(5): 925-926, 2008

Ibiebele TI, Hughes MC, O’Rourke P, Webb PM and

Whiteman DC. Cancers of the oesophagus and carbonated

beverage consumption: a population-based case-control

study. Cancer Causes and Control 19(6): 577-84, 2008

Jeske YW, So A, Kelemen L, Sukor N, Willys C, Bulmer

B, Gordon RD, Duffy D and Stowasser M. Examination of

chromosome 7p22 candidate genes RBaK, PMS2 and GNA12

in familial hyperaldosteronism type II. Clinical and Experimental

Pharmacology and Physiology 35(4): 380-385, 2008

Johnatty SE, Beesley J, Chen X, Hopper JL, Southey MC,

Giles GG, Goldgar DE, Chenevix-Trench G, Spurdle AB

and the Kathleen Cuningham Consortium for Research

in Familial Breast Cancer. The BARD1 Cys557Ser

polymorphism and breast cancer risk: an Australian case-

control and family analysis. Breast Cancer Research and

Treatment 115(1): 145-50, 2009

Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB,

Webb PM, Byth K, Marsh S, McLeod H; AOCS Study

Group; Harnett PR, Brown R, DeFazio A and Chenevix-

Trench G. ABCB1 (MDR 1) polymorphisms and progression-

free survival among women with ovarian cancer following

paclitaxel/carboplatin chemotherapy. Clinical Cancer Research

14(17): 5594-5601, 2008

Johnatty SE, Beesley J, Chen X, Spurdle AB, DeFazio

A, Webb PM, Australian Ovarian Cancer Study Group,

Australian Cancer Study (Ovarian Cancer), Goode EL,

Rider DN, Vierkant RA, Anderson S, Wu AH, Pike M, Van

Den Berg D, Moysich K, Ness R, Doherty J, Rossing M-A,

Pearce CL and Chenevix-Trench G. Polymorphisms in the

FGF2 gene and risk of serous ovarian cancer: Results from the

Ovarian Cancer Association Consortium. Twin Research and

Human Genetics 12(3): 269-275, 2009


Jones AL, Holliday EG, Mowry BJ, McLean DE, McGrath

JJ, Pender MP and Greer JM. CTLA-4 single-nucleotide

polymorphisms in a Caucasian population with schizophrenia.

Brain Behaviour and Immunity 23(3): 347-350, 2009

Jones GN, Tep C, Towns WH 2nd, Mihai G, Tonks ID,

Kay,GF, Schmalbrock PM, Stemmer-Rachamimov AO,

Yoon SO and Kirschner LS. Tissue-specifi c ablation

of Prkar1a causes schwannomas by suppressing

neurofi bromatosis protein production. Neoplasia 10(11):1213-

1221, 2008

Jones MK, Lustigman S and Loukas A. Tracking the odysseys

of juvenile schistosomes to understand host interactions. PLoS


Jones MK, Bong SH, Green KM, Holmes P, Duke M, Loukas

A and McManus DP. Correlative and dynamic imaging of the

hatching biology of Schistosoma japonicum from eggs prepared

by high pressure freezing. PLoS Neglected Tropical Diseases

2(11): e334, 2008

Jones K and Gandhi MK. Epstein-Barr virus DNA as a

biomarker for Epstein-Barr virus-positive lymphomas: are we

there yet? Leukemia and Lymphoma 50(5): 684-686, 2009

Jonsson J, Barrie HD, O’Rourke P, Clouston AD and

Powell EE. Obesity and steatosis infl uence serum and hepatic

infl ammatory markers in chronic hepatitis C. Hepatology 48(1):

80-87, 2008

Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GH, Wong AH,

Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, McRae AF,

Visscher PM, Montgomery GW, Gottesman II, Martin NG

and Petronis A. DNA methylation profi les in monozygotic and

dizygotic twins. Nature Genetics 41(2): 240-245, 2009. Letter

Kaneva R, Milanova V, Angelicheva D, MacGregor

S, Kostov C, Vladimirova R, Aleksiev S, Angelova M,

Stoyanova V, Loh A, Hallmayer J, Kalaydjieva and

Jablensky A. Bipolar disorder in the Bulgarian Gypsies:

Genetic heterogeneity in a young founder population. American

Journal of Medical Genetics B - Neuropsychiatric Genetics

150B(2): 191-201, 2009

Kay BH. Biological control of dengue vectors - promises from

the past. In: Dengue (Halstead SB Ed), Imperial College Press,

London, pp 389 – 405, 2008

Keith JM, McRae A, Duffy D, Mengersen K and Visscher

PM. Calculation of IBD probabilities with dense SNP or

sequence data. Genetic Epidemiology 32(6): 513-519, 2008

Khomenko T, Szabo S, Deng X, Ishikawa H, Anderson

GJ and McLaren GD. Role of iron in the pathogenesis of

cysteamine-induced duodenal ulceration in rats. American

Journal of Physiology – Gastrointestinal and Liver Physiology

296(6): G1277-1286, 2009

Kim M, Taylor J, Sidney J, Mikloska Z, Bodsworth

N, Lagios K, Dunckley H, Byth-Wilson K, Denis M,

Finlayson R, Khanna R, Sette A and Cunningham AL.

Immunodominant epitopes in herpes simplex virus Type 2

glycoprotein D Are recognized by CD4 Lymphocytes from

both HSV-1 and HSV-2 seropositive subjects. Journal of

Immunology 181(9): 6604 – 6615, 2008

Kines KJ, Morales ME, Mann VH, Gobert GN, and Brindley

PJ. Integration of reporter transgenes into Schistosoma

mansoni chromosomes mediated by pseudotyped murine

leukemia virus. FASEB Journal 22(8): 2936-2948, 2008

Knaapila A, Tuorila H, Kyvik KO, Wright MJ, Keskitalo K,

Hansen J, Kaprio J, Perola M and Silventoinen K. Self-

ratings of olfactory function refl ect odor annoyance rather than

olfactory acuity. Laryngoscope. 118(12): 2212-2217, 2008

Knaapila A, Tuorila H, Silventoinen K, Wright MJ, Kyvik

KO, Keskitalo K, Hansen J, Kaprio J and Perola M.

Environmental effects exceed genetic effects on perceived

intensity and pleasantness of several odors: a three-population

twin study. Behavior Genetics 38(5): 484-492, 2008

Kolahdooz F, Ibiebele TI, van der Pols JC and Webb PM.

Dietary patterns and ovarian cancer risk. American Journal of

Clinical Nutrition 89(1): 297-304, 2008

Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M,

Mangino M, Albrecht E, Wallace C, Farrall M, Johansson

A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S,

Bochud M, Brown M, Campbell H, Connell J, Dominiczak

A, Homuth G, Lamina C, McCarthy MI, Meitinger T,

Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo

P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker

U, Waeber G, Waterworth D, Wang-Sattler R, Wright

AF, Adamski J, Whitfi eld JB, Gyllensten U, Wilson JF,

Rudan I, Pramstaller P, Watkins H, Doering A, Wichmann

HE, Spector TD, Peltonen L, Völzke H, Nagaraja R,

Vollenweider P, Caulfi eld M; WTCCC, Illig T and Gieger

C. Meta-Analysis of 28,141 Individuals Identifi es Common

Variants within Five New Loci That Infl uence Uric Acid

Concentrations. PLoS Genetics 5(6): e1000504, 2009

Kopp SR, Coleman GT, McCarthy JS and Kotze AC.

Phenotypic characterization of two Ancylostoma caninum isolates

of different susceptibility to the anthelmintic pyrantel. Antimicrobial

Agents and Chemotherapy 52(11): 3980-3986, 2008

Kopp SR, Coleman GT, Traub RJ, McCarthy JS and Kotze

AC. Acetylcholine receptor subunit genes from Ancylostoma


CONTINUED


caninum: altered transcription patterns associated with

pyrantel resistance. International Journal for Parasitology

39(4): 435- 41, 2009

Kopp SR, Kotze AC, McCarthy JS, Traub RJ and Coleman

GT. Pyrantel in small animal medicine: 30 years on. Veterinary

Journal 178(2):177-184, 2008

Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA,

Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T,

Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W,

Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A,

Steginga S, John EM, Giles G, Hopper J, Chappuis PO,

Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners

JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL,

Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer

A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu

JF, O’Mara T, Gardiner RA, Aitken J, Joshi AD, Severi

G, English DR, Southey M, Edwards SM, Al Olama AA

and Eeles RA. Multiple novel prostate cancer predisposition

loci confi rmed by an international study: the PRACTICAL

Consortium. Cancer Epidemiology Biomarkers and Prevention

17(8): 2052-2061, 2008

Kovac S, Smith K, Anderson GJ, Burgess JR, Shulkes

A and Baldwin GS. Interrelationships between circulating

gastrin and iron status in mice and humans. American Journal

of Physiology – Gastrointestinal and Liver Physiology 295(4):

G855-G861, 2008

Kuns RD, Morris ES, Macdonald KP, Markey KA, Morris

HM, Raffelt NC, Banovic T, Don AL, Rowe V, Burman AC,

Clouston AD, Farah C, Besra GS, Illarionov PA, Smyth MJ,

Porcelli SA and Hill GR. Invariant NKT - NK cell interactions

dictate transplant outcome following alpha-galactosylceramide

administration. Blood 113(22): 5644-5649, 2009

Kuphal S, Martyn AC, Pedley J, Crowther LM, Bonazzi VF,

Parsons PG, Bosserhoff AK, Hayward NK and Boyle GM.

H-Cadherin expression reduces invasion of malignant melanoma.

Pigment Cell Melanoma Research 22(3): 296-306, 2009

Laha T, Sripa J, Sripa B, Pearson M, Tribolet L, Kaewkes

S, Sithithaworn P, Brindley PJ and Loukas A. Asparaginyl

endopeptidase from the carcinogenic liver fl uke, Opisthorchis

viverrini, and its potential for serodiagnosis. International

Journal of Infectious Diseases 12(6): e49-59, 2008

Landers KA, McKinnon BD, Li H, Subramaniam VN,

Mortimer RH and Richard K. Carrier mediated thyroid hormone

transport into placenta by placental transthyretin. Journal of

Clinical Endocrinology and Metabolism 94(7): 2610-2616, 2009

Lavin MF. Ataxia-telangiectasia: from a rare disorder to a

paradigm for cell signalling and cancer. Nature Reviews

Molecular Cell Biology 9(10): 759-769, 2008. Review

Lavin MF, Gueven, N, and Grattan-Smith P. Defective

responses to DNA single and double-strand breaks in

spinocerebellar ataxia. DNA Repair 7(7): 1061-1076, 2008

Le TT, Gardner J, Hoang-Le D, Schmidt CW, Macdonald

KP, Lambley E, Schroder WA, Ogbourne SM and Suhrbier

A. Immunostimulatory cancer chemotherapy using local

ingenol-3-angelate and synergy with immunotherapies.

Vaccine 27(23): 3053-62, 2009

Lee SH, van der Werf JH, Hayes BJ, Goddard ME and

Visscher PM. Predicting unobserved phenotypes for complex

traits from whole-genome SNP data. PLoS Genetics 4(10):

e1000231, 2008

Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-

Adams TS, Nosten F, Gardiner DL, Boonma P, Piera

KA, Andrews KT, Machunter B, McCarthy JS, Anstey

NM, Price RN and Russell B. Stronger activity of human

immunodefi ciency virus type 1 protease inhibitors against

clinical isolates of Plasmodium vivax than against those of P.

falciparum. Antimicrobial Agents and Chemotherapy 52(7):

2435-2441, 2008

Leow AD, Zhu S, Zhan L, McMahon K, de Zubicaray GI,

Meredith M, Wright MJ, Toga AW and Thompson PM. The

tensor distribution function. Magnetic Resonance in Medicine

61(1): 205-214. 2009

Ligthart L, Nyholt DR, Hottenga JJ, Distel MA, Willemsen

G and Boomsma DI. A genome-wide linkage scan provides

evidence for both new and previously reported loci infl uencing

common migraine. American Journal of Medical Genetics B -

Neuropsychiatric Genetics147B(7): 1186-1195, 2008

Lind PA, Eriksson CJP and Wilhelmsen KC. The role of

aldehyde dehydrogenase-1 (ALDH1A1) polymorphisms in

harmful alcohol consumption in a Finnish population. Human

Genomics 3(1): 24-35, 2008

Lind PA, Eriksson CJP and Wilhelmsen KC. Association

between harmful alcohol consumption behavior and

the dopamine transporter gene (DAT1) in a male Finnish

population. Psychiatric Genetics 19(3): 117-125, 2009

Lind PA, Macgregor S, Agrawal A, Montgomery GW,

Heath AC, Martin NG and Whitfi eld JB. The role of GABRA2

in alcohol dependence, smoking, and illicit drug use in

an Australian population sample. Alcoholism Clinical and

Experimental Research 32(10): 1721-1731, 2008

Liu XQ, Hart DN, MacPherson GG, Good MF and Wykes

MN. Soluble CD38 signifi cantly prolongs the lifespan of

memory B-cell responses. Immunology 125(1): 14-20, 2008


Loehlin JC, Medland SE and Martin NG. Relative fi nger

lengths, sex differences, and psychological traits. Archives of

Sexual Behavior 38(2): 298-305, 2008

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB,

Australian Ovarian Cancer Study Management Group.

Skewed X chromosome inactivation and breast and ovarian

cancer status: evidence for X-linked modifi ers of BRCA1. Journal

of the National Cancer Institute 100(21): 1519-1529, 2008

Loughrey BT, Healy PC, Parsons PG and Williams

ML. Selective Cytotoxic Ru(II) Arene Cp* Complex Salts

[R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).

Inorganic Chemistry 47(19): 8589-8591, 2008

Luciano M, Gow AJ, Taylor MD, Hayward C, Harris SE,

Campbell H, Porteous DJ, Starr JM, Visscher PM and

Deary IJ. Apolipoprotein E is not Related to Memory Abilities

at 70 Years of Age. Behavior Genetics 39: 6-14, 2009

Luciano M, Lind PA, Deary IJ, Payton A, Posthuma D,

Butcher LM, Bochdanovits Z, Whalley LJ, Visscher PM,

Harris SE, Polderman TJ, Davis OS, Wright MJ, Starr JM,

de Geus, Bates TC, Montgomery GW, Boomsma DI, Martin

NG and Plomin R. Testing replication of a 5-SNP set for

general cognitive ability in six population samples. European


Luciano M, Miyajima F, Lind PA, Bates TC, Horan M,

Harris SE, Wright MJ, Ollier WE, Hayward C, Pendleton

N, Gow AJ, Visscher PM, Starr JM, Deary IJ, Martin NG

and Payton A. Variation in the Dysbindin gene and normal

cognitive function in three independent population samples.

Genes Brain and Behaviour 8(2): 218-227, 2009

Lundmark PE, Liljedahl U, Boomsma DI, Mannila H, Martin

NG, Palotie A, Peltonen L, Perola M, Spector TD and

Syvanen AC. Evaluation of HapMap data in six populations

of European descent. European Journal of Human Genetics

16(9): 1142-1150, 2008

Lutzky VP, Moss DJ, Chin D, Coman WB, Parsons PG and

Boyle GM. Biomarkers for cancers of the head and neck.

Clinical Medicine: Ear, Nose and Throat. 1: 5-15, 2008

Macgregor S, Hottenga JJ, Lind PA, Suchiman HE,

Willemsen G, Slagboom PE, Montgomery GW, Martin NG,

Visscher PM and Boomsma DI. Vitamin D receptor gene

polymorphisms have negligible effect on human height. Twin

Research and Human Genetics 11(5): 488-494, 2008

Macgregor S, Lind PA, Bucholz KK, Hansell NK, Madden

PA, Richter MM, Montgomery GW, Martin NG, Heath AC

and Whitfi eld JB. Associations of ADH and ALDH2 gene

variation with self report alcohol reactions, consumption

and dependence: an integrated analysis. Human Molecular

Genetics 18(3): 580-593, 2009

Maes HH, Neale MC, Medland SE, Keller MC, Martin NG,

Heath AC and Eaves LJ. Flexible mx specifi cation of various

extended twin kinship designs. Twin Research and Human

Genetics 12(1): 26-34, 2009

Major L, Linn ML, Slade RW, Schroder WA, Hyatt AD,

Gardner J, Cowley J and Suhrbier A. Ticks associated with

Macquarie Island penguins carry arboviruses from four genera.

PLoS ONE 4(2): e4375, 2009

Maric S, Donnelly SM, Robinson MW, Skinner-Adams

TS, Trenholme KR, Gardiner DL, Dalton JP, Stack CM

and Lowther J. The M17 leucine aminopeptidase of the

malaria parasite Plasmodium falciparum: importance of active

site metal ions in the binding of substrates and inhibitors.

Biochemistry 48(23):5435-5439, 2009

Markey KA, Macdonald KP and Hill GR. Impact of cytokine

gene polymorphisms on graft-vs-host disease. Tissue Antigens

72(6): 507-516, 2008

Markey K, MacDonald KP and Hill GR. Recipient

plasmacytoid DC are not required to prime allogeneic T cell

responses after BMT. Blood 113(23): 6038-6039, 2009. Letter

Markey KA, Banovic T, Kuns RD, Olver SD, Don AL, Raffelt

NC, Wilson YA, Raggatt LJ, Pettit AR, Bromberg JS, Hill

GR and Macdonald KP. Conventional dendritic cells are the

critical donor APC presenting alloantigen after experimental

BMT. Blood 113(22): 5644-5649, 2009

Martin JH, Coory M, Valery PC and Green AC. Association

of diabetes with survival among cohorts of Indigenous and

non-Indigenous Australians with cancer. Cancer Causes and

Control 20(3): 355-360, 2009

Martin NG. Introduction. In: Statistical Genetics: Gene

Mapping through Linkage and Association. Neale BM, Ferreira

MAR, Medland SE, Posthuma D(Eds) Taylor & Francis Group,

NY. pp 1-5, 2008.

Martin NW, Hansell NK, Wainwright MA, Shekar SN,

Medland SE, Bates TC, Burt JS, Martin NG and Wright

MJ. Genetic covariation between the author recognition test

and reading and verbal abilities: What can we learn from the

analysis of high performance? Behavior Genetics 39(4): 417-

426, 2009

McCullen MA, Fletcher LM, Dimeski G, Pink A, Powell LW,

Crawford DH and Hickman PE. Patient-focused outcomes

following detection in a hospital-based screening programme

for C282Y haemochromatosis. Internal Medicine Journal 38(8):

651-656, 2008


CONTINUED


McCutcheon VV, Heath AC, Nelson EC, Bucholz KK,

Madden PA and Martin NG. Accumulation of trauma over

time and risk for depression in a twin sample. Psychological

Medicine 39(3): 431-441, 2009

McEvoy BP, Montgomery GW, McRae AF, Ripatti S,

Perola M, Spector TD, Cherkas L, Ahmadi KR, Boomsma

D, Willemsen G, Hottenga JJ, Peterson NL, Magnusson

PK, Ohm Kyvik K, Christensen K, Kaprio J, Heikkila K,

Palotie A, Widen E, Muilu J, Syvanen AC, Liljedahl U,

Hardiman O, Cronin S, Peltonen L, Martin NG and Visscher

PM. Geographical structure and differential natural selection

amongst North European populations. Genome Research

19(5): 804-814, 2009

McGowan S, Porter C, Lowther J, Stack C, Golding S,

Skinner-Adams TS, Trenholme KR, Teuscher F, Donnelly

S, Grembecka J, Mucha A, Kafarski P, DeGori R, Buckle

A, Gardiner DL, Whisstock J, and Dalton JP. Structural

basis for the inhibition of the essential Plasmodium falciparum

M1 neutral aminopeptidase: a new route for antimalarial

compounds. Proceedings of the National Academy of

Sciences of the USA 106(8): 2537-2542, 2009

McManus DP, Li Y, Gray DJ and Ross AG. Conquering ‘snail

fever’: schistosomiasis and its control in China. Expert Review

of Anti Infective Therapy 7(4): 473-85, 2009

McManus DP and Yang YR. Helminthic diseases:

Echinococcosis. In: International Encyclopedia of Public

Health. Heggenhougen, HK and Quah SR(Eds). Academic

Press, San Diego, Vol 3, pp 311-316, 2008

McPherson S, Jonsson JR, Barrie HD, O’Rourke P,

Clouston AD and Powell EE. Investigation of the role of

SREBP-1c in the pathogenesis of HVC-related steatosis.

Hepatology 49(6): 1046-1054, 2008

Medland SE and Loehlin JC. Multivariate genetic analyses

of the 2D:4D ratio: examining the effects of hand and

measurement technique in data from 757 twin families. Twin


Medland SE, Loehlin JC and Martin NG. No effects of

prenatal hormone transfer on digit ratio in a large sample

of same- and opposite-sex dizygotic twins. Personality and

Individual Differences 44(5): 1225-1234, 2008

Medland SE, Loehlin JC, Willemsen G, Hatemi PK, Keller

MC, Boomsma DI, Eaves LJ and Martin NG. Males do not

reduce the fi tness of their female co-twins in contemporary samples.


Medland SE, Duffy DL, Wright MJ, Geffen GM, Hay DA,

Levy F, van-Beijsterveldt CE, Willemsen G, Townsend

GC, White V, Hewitt AW, Mackey DA, Bailey JM, Slutske

WS, Nyholt DR, Treloar SA, Martin NG and Boomsma

DI. Genetic infl uences on handedness: Data from 25,732

Australian and Dutch twin families. Neuropsychologia 47(2):

330-337, 2009

Medland SE and Keller MC. Modeling extended twin family

data II: Power associated with different family structures. Twin


Medland SE, Neale MC, Eaves LJ and Neale BM. A note on

the parameterization of Purcell’s G x E model for ordinal and

binary data. Behavior Genetics 39(2): 220-229, 2009

Medland SE, Schmitt JE, Webb BT, Kuo PH and Neale MC.

Effi cient calculation of empirical P-values for genome-wide

linkage analysis through weighted permutation. Behavioral

Genetics 39(1): 91-100, 2009

Meier MH, Slutske WS, Heath AC and Martin NG. The role

of harsh discipline in explaining sex differences in conduct

disorder: A study of opposite-sex twin pairs. Journal of

Abnormal Psychology 37(5): 653-664, 2009

Middeldorp CM, Sullivan PF, Wray NR, Hottenga JJ, de

Geus, van den, Montgomery GW, Coventry WL, Statham

DJ, Andrews G, Slagboom PE, Boomsma DI and Martin

NG. Suggestive linkage on chromosome 2, 8, and 17 for

lifetime major depression. American Journal of Medical Genetics

Part B: Neuropsychiatric Genetics 150B(3): 352-358, 2009

Middelberg RP, Gordon SD, Zhu G, McRae A, Montgomery

GW, Martin NG and Whitfi eld JB. Linkage and association

analyses of longitudinally measured lipid phenotypes in adolescence.


Miles JJ, Brennan RM and Burrows SR. T cell receptor bias in

humans. Current Immunology Reviews 5(1): 10-21, 2009. Review

Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E,

Kenangalem E, Price RN, Engwerda CR, Anstey NM and

Plebanski M. Parasite-dependent expansion of TNF receptor

II-positive regulatory T cells with enhanced suppressive activity in

adults with severe malaria. PLoS Pathogens 5(4): e1000402, 2009

Mitchell GK, Del Mar CB, O’Rourke PK and Clavarino

AM. Do case conferences between general practitioners

and specialist palliative care services improve quality of life?

A randomised controlled trial (ISRCTN 52269003). Palliative

Medicine 22(8): 904-912, 2008

Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter

JN, Missmer SA, Kennedy SH and Zondervan KT. The

search for genes contributing to endometriosis risk. Human

Reproduction Update 14(5): 447-572, 2008. Review


Morgan DK and Whitelaw E. The case for transgenerational

epigenetic inheritance in humans. Mammalian Genome 19(6):

394-397, 2008. Review

Morris ES, Macdonald KP, Kuns RD, Morris HM, Banovic

T, Don AL, Rowe V, Wilson YA, Raffelt NC, Engwerda CR,

Burman AC, Markey KA, Godfrey DI, Smyth MJ and Hill

GR. Induction of natural killer T cell-dependent alloreactivity

by administration of granulocyte colony-stimulating factor after

bone marrow transplantation. Nature Medicine 15(4): 436-441,

2009. Letter

Morrison BJ, Andera L, Reynolds BA, Ralph SJ and Neuzil

J. Future use of mitocans against tumour-initiating cells?

Molecular Nutrition and Food Research 53(1): 147-153, 2009

Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA and

Lopez JA. Breast cancer stem cells: implications for therapy

of breast cancer. Breast Cancer Research 10(4): 210, 2008.

Review

Morrison BJ, Steel JC, Gregory M, Morris JC, and

Malyguine AM. Genetically modifi ed dendritic cells in cancer

immunotherapy. Chapter 23 in Dendritic Cells in Cancer. Shurin

MR and Salter R (Eds) Springer, New York, pp 347-363, 2009

Mould AW, Duncan R, Serewko-Auret M, Loffl er KA, Biondi

C, Gartside M, Kay GF and Hayward NK. Global expression

profi ling of sex cord stromal tumors from Men1 heterozygous

mice identifi es altered TGF-beta signaling, decreased Gata6

and increased Csf1r expression. International Journal of

Cancer 124(5): 1122-1132, 2008

Mulvenna J, Hamilton B, Nagaraj S, Smyth D, Loukas A

and Gorman J. Proteomic analysis of the excretory/secretory

component of the blood-feeding stage of the hookworm,

Ancylostoma caninum. Molecular and Cellular Proteomics 8(1):

109-121, 2009

Nagle CM, Bell TA, Purdie DM, Treloar SA, Olsen CM,

Grover S and Green AC. Relative weight at ages 10 and

16 years and risk of endometriosis: a case-control analysis.

Human Reproduction 1(1): 1-6, 2009

Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC

and Green AC. Endometrioid and clear cell ovarian cancers

- A comparative analysis of risk factors. European Journal of

Cancer 44(16): 2477-2484, 2008

Nakagawa H, Nagasaka T, Cullings HM, Notohara K,

Hoshijima N, Young J, Lynch HT, Tanaka N and Matsubara

N. Effi cient molecular screening of Lynch syndrome by specifi c

3’ promoter methylation of the MLH1 or BRAF mutation in

colorectal cancer with high-frequency microsatellite instability.

Oncology Reports 21(6): 1577-83, 2009

Naumann SC, Roos WP, Jöst E, Belohlavek C, Lennerz V,

Schmidt CW, Christmann M and Kaina B. Temozolomide-

and fotemustine-induced apoptosis in human malignant

melanoma cells: response related to MGMT, MMR, DSBs, and

p53. British Journal of Cancer 100(2): 322-333, 2009

Neale RE, Cariere P, Murphy MFG and Badde PD. Testicular

cancer in twins: A meta-analysis. British Journal of Cancer

98(1): 171-173, 2008

Neale RE, Doecke JD, Pandeya N, Sadhegi S, Green AC,

Webb PM and Whiteman DC. Does type 2 diabetes infl uence

the risk of oesophageal adenocarcinoma? British Journal of

Cancer 100(5): 795-798, 2009

Neale RE, Webb PM and van der Pols JC. Vitamin D for

prevention of chronic disease: the need for continued research.

Internal Medicine Journal 38(11): 813-815, 2008

Neale RE, Youlden DR, Krnjacki L, Kimlin MG and van der

Pols JC. Latitude variation in pancreatic cancer mortality in

Australia. Pancreas 38(4): 387-390, 2009

Neller MA, López JA, Schmidt CW. Antigens for cancer

immunotherapy. Seminars in Immunology 20(5): 286-295,

2008. Review

Nelson EC, Agrawal A, Pergadia ML, Lynskey MT, Todorov

AA, Wang JC, Todd RD, Martin NG, Heath AC, Goate AM,

Montgomery GW and Madden PA. Association of childhood

trauma exposure and GABRA2 polymorphisms with risk of

posttraumatic stress disorder in adults. Molecular Psychiatry

14(3): 234-235, 2009. Letter

Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ,

Crabb BS, Heath WR, Engwerda CR, Hickey MJ, Schofi eld

L and Hansen DS. 2009. IP-10-mediated T cell homing

promotes cerebral infl ammation over splenic immunity to

malaria infection. PLoS Pathogens 5(4): e1000369, 2009

Nourse J, Jones K and Gandhi MK. The role of Epstein-Barr

virus in Richter syndrome. British Journal of Haematology

144(4): 613, 2009

Nyholt DR, Yu CE and Visscher PM. On Jim Watson’s APOE

status: genetic information is hard to hide. European Journal of

Human Genetics 17(2): 147-149, 2008. Letter

Nyholt DR, Gillespie NG, Merikangas KR, Treloar SA,

Martin NG and Montgomery GW. Common genetic

infl uences underlie comorbidity of migraine and endometriosis.

Genetic Epidemiology 33(2): 105-113, 2008

Nyholt DR, LaForge KS, Kallela M, Alakurtti K, Anttila V,

Färkkilä M, Hämaläinen E, Kaprio J, Kaunisto MA, Heath

AC, Montgomery GW, Göbel H, Todt U, Ferrari MD, Launer


CONTINUED


LJ, Frants RR, Terwindt GM, de Vries B, Verschuren WM,

Brand J, Freilinger T, Pfaffenrath V, Straube A, Ballinger

DG, Zhan Y, Daly MJ, Cox DR, Dichgans M, van den

Maagdenberg AM, Kubisch C, Martin NG, Wessman M,

Peltonen L and Palotie A. A high-density association screen

of 155 ion transport genes for involvement with common

migraine. Human Molecular Genetics 17(21): 3318-3331, 2008

O’Connor DT, Zhu G, Rao F, Taupenot L, Fung MM, Das M,

Mahata SK, Mahata M, Wang L, Zhang K, Greenwood TA,

Shih PA, Cockburn MG, Ziegler MG, Stridsberg M, Martin

NG and Whitfi eld JB. Heritability and genome-wide linkage

in US and Australian twins identify novel genomic regions

controlling chromogranin A: implications for secretion and

blood pressure. Circulation 118:247-257, 2008

O’Donovan MC, Craddock N, Norton N, Williams H, Peirce

T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva

L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie

B, Leung HT, Hartmann AM, Möller HJ, Morris DW, Shi

Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier

W, Rietschel M, Zammit S, Schumacher J, Quinn EM,

Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M,

Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson

DF, Gejman PV; Molecular Genetics of Schizophrenia

Collaboration, Gejman PV, Sanders AR, Duan J, Levinson

DF, Buccola NG, Mowry BJ, Freedman R, Amin F, Black

DW, Silverman JM, Byerley WF, Cloninger CR, Cichon

S, Nöthen MM, Gill M, Corvin A, Rujescu D, Kirov G and

Owen MJ. Identifi cation of loci associated with schizophrenia

by genomewide association and follow-up. Nature Genetics

40(9): 1053-1055, 2008

O’Donovan MC, Norton N, Williams H, Peirce T, Moskvina

V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer

S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung

HT, Giegling I, Hartmann AM, Möller HJ, Morris DW, Shi

Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W,

Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze

TG, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J,

Sanders AR, Levinson DF, Adolfsson R, Osby U, Terenius

L, Jönsson EG, Cichon S, Nöthen MM, Gill M, Corvin AP,

Rujescu D, Gejman PV, Kirov G, Craddock N, Williams

NM, Owen MJ Molecular Genetics of Schizophrenia

Collaboration. Analysis of 10 independent samples provides

evidence for association between schizophrenia and a

SNP fl anking fi broblast growth factor receptor 2. Molecular

Psychiatry 14(1): 30-36, 2009

Oldmeadow C, Mengersen K, Martin NG and Duffy DL.

Heritability and linkage analysis of appendicitis utilizing age

at onset. Twin Research and Human Genetics 12(2): 50-157,

2009

Oldmeadow C, Wood I, Mengersen K, Visscher PM, Martin

NG and Duffy DL. Investigation of the relationship between

smoking and appendicitis in Australian twins. Annals of

Epidemiology 18(8): 631-636, 2008

O’Leary CA, He X, Bolton JA, Gobe G and Duffy D.

Haplotype sharing excludes orthologous COL4A3, COL4A4

or MYH9 loci in hereditary nephritis in bull terriers. Animal

Genetics 40(2): 252-253, 2009

Olsen C, Green A, Nagle C, Jordan S, Whiteman D, Bain C

and Webb P. Epithelial ovarian cancer: testing the androgens

hypothesis. Endocrine Related Cancer 15(4): 1061-1068, 2008

Olsen CM, Parsons PG and Green AG. If you can see the

sunlight, seek shade. Skin Cancer Foundation Journal Vol 27:

44-45, 2009

Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM,

Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA,

Kirkpatrick C, Mack T, Bishop JN, Osterlind A, Swerdlow

AJ, Zanetti R, Green AC, Karagas MR and Whiteman DC.

Nevus density and melanoma risk in women: A pooled analysis

to test the divergent pathway hypothesis. International Journal

of Cancer 124(4): 937-944, 2008

Olynyk JK, Trinder D, Ramm GA, Britton RS and Bacon

BR. Hereditary hemochromatosis: Recent developments.

Hepatology, 48(3):991-1001, 2008

Owen SJ, Batzloff M, Chehrehasa F, Meedeniya A, Casart

Y, Logue CA, Hirst RG, Peak IR, Mackay-Sim A and

Beacham IR. Nasal-associated lymphoid tissue and olfactory

epithelium as portals of entry for Burkholderia pseudomallei

in murine melioidosis. Journal of Infectious Diseases

199(12):1761-70, 2009

Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert

B, Moorman PG, Poole CL, Anderson AR, Anderson

S, Anton-Culver H, Beesley J, Hogdall E, Brewster W,

Carney ME, Chen X, Chenevix-Trench G, Chang-Claude

J, Cunningham JM, DiCioccio RA, Doherty JA, Easton DF,

Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL,

Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison

EL, Blaaker J, Lurie G, McGuire V, Menon U, Moysich

KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus

SJ, Rossing MA, Song H, Terada KY, Van Den Berg D,

Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS,

Wu AH, Ziogas A, Berchuck A, Schildkraut JM, on behalf

of the Ovarian Cancer Association Consortium; Australian

Cancer Study (Ovarian Cancer Group); Australian Ovarian

Cancer Study Group. Polymorphism in the IL18 gene and

epithelial ovarian cancer in non-Hispanic white women. Cancer

Epidemiology Biomarkers and Prevention 17(12): 3567-3572,

2008


Pandey M, Batzloff MR and Good MF. Mechanism of

protection induced by group A Streptococcus vaccine

candidate J8-DT: contribution of B and T-cells towards

protection. PLoS ONE 4(4): e5147, 2009

Pandeya N, Williams G, Green AC, Webb PM and

Whiteman DC. Alcohol consumption and the risks of

adenocarcinoma and squamous cell carcinoma of the

esophagus. Gastroenterology 136(4): 1215-1224, 2009

Papp LV, Wang J, Kennedy D, Boucher D, Zhang Y,

Gladyshev VN, Singh RN and Khanna KK. Functional

characterization of alternatively spliced human SECISBP2

transcript variants. Nucleic Acids Research 36(22): 7192-7206,

2008

Pasay C, Arlian L, Morgan M, Gunning R, Rossiter L, Holt

D, Walton S, Beckham S and McCarthy J. The effect of

insecticide synergists on the response of scabies mites to

pyrethroid acaricides. PLoS Neglected Tropical Disease 3(1):

e354, 2009

Pearce CL, Near A, Van Den Berg D, Ramus SJ, Gentry-

Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund

CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen

C, Doherty J, Rossing MA, Whittemore AS, McGuire V,

DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens

LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer-

Kruger S, Hogdall E, Hogdall CK, Goode EL, Sellers TA,

Vierkant RA, Cunningham JC, Schildkraut JM, Berchuck

A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis

AF, Titus-Ernstoff L, Song H, Pharoah P, Spurdle AB,

Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V and

Chenevix-Trench G, Australian Cancer Study (Ovarian

Cancer) and Australian Ovarian Cancer Study Group on

behalf of the Ovarian Cancer Association Consortium.

Validating genetic risk associations for ovarian cancer through

the International Ovarian Cancer Association Consortium

British Journal of Cancer 100(2): 412-420, 2009

Pender MP, Csurhes PA, Lenarczyk A, Pfl uger CM and

Burrows SR. Decreased T cell reactivity to Epstein-Barr virus

infected lymphoblastoid cell lines in multiple sclerosis. Journal

of Neurology Neurosurgery and Psychiatry 80(5): 498-505, 2009

Peters K, Wiltshire S, Henders AK, Dragovic M, Badcock

JC, Chandler D, Howell S, Ellis C, Bouwer S, Montgomery

GW, Palmer LJ, Kalaydjieva L and Jablensky A.

Comprehensive analysis of tagging sequence variants in

DTNBP1 shows no association with schizophrenia or with its

composite neurocognitive endophenotypes. American Journal

of Medical Genetics B - Neuropsychiatric Genetics 147B(7):

1159-66, 2008

Pinheiro CS, Staub O, Loukas A, Jones MK and Rabelo

EM. SmLANP: a new Schistosoma mansoni gene member of

the ANP32 family. Molecular and Biochemical Parasitology,

165(2): 95-102, 2009

Pinlaor P, Kaewpitoon N, Laha T, Sripa B, Kaewkes S,

Morales ME, Mann VH, Parriott SK, Suttiprapa S, Robinson

MW, To J, Dalton JP, Loukas A and Brindley PJ. Cathepsin

F Cysteine Protease of the Human Liver Fluke, Opisthorchis

viverrini. PLoS Neglected Tropical Diseases 3(3): e398, 2009

Pinzon-Charry A and López J.A. Tumor-derived Factors

Responsible for DC dysfunction. Chapter 7 in Dendritic Cells in

Cancer. Shurin MR and Salter R (Eds) Springer, New York,pp

103-117, 2009

Pleydell D, Yang YR, Danson FM, Raoul F, Craig,PS,

McManus DP, Vuitton D, Wang Q and Giraudoux P.

Landscape composition and spatial prediction of alveolar

echinococcosis in southern Ningxia, China. PLoS Neglected

Tropical Diseases 2(9): e287, 2008

Plon S, Eccles D, Easton D, Foulkes WD, Genuardi

M, Greenblatt MS, Hogervorst FBL, Hoogerbrugge N,

Foulkes WD, Spurdle AB and Tavtigian S. Sequence variant

classifi cation and reporting: Recommendations for improving

the interpretation of cancer susceptibility genetic test results.

Human Mutation 29(11): 1282-129, 2008. Review

Poynter JN, Siegmund KD, Weisenberger DJ, Long TI,

Thibodeau SN, Lindor N, Young J, Jenkins MA, Hopper JL,

Baron JA, Buchanan D, Casey G, Levine AJ, Le Marchand

L, Gallinger S, Bapat B, Potter JD, Newcomb PA, Haile RW

and Laird PW. Molecular characterization of MSI-H colorectal

cancer by MLHI promoter methylation, immunohistochemistry,

and mismatch repair germline mutation screening. Cancer

Epidemiology Biomarkers and Prevention 17(11): 3208-3215,

2008

Pritchard AL, Pritchard CW, Bentham P and Lendon

CL. Investigation of the role of the Dopamine transporter in

susceptibility to behavioural and psychological symptoms of

patients with probable Alzheimer’s Disease. Dementia and

Geriatric Cognitive Disorders 26(3): 257-260, 2008

Rabelo EM, Hall RS, Loukas A, Cooper L, Hu M,

Ranganathan S and Gasser RB. Improved insights into the

transcriptomes of the human hookworm Necator americanus -

fundamental and biotechnological implications. Biotechnology

Advances 27(2): 122-132, 2009

Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney

AD, Pereira TN, Bridle KR, Doecke JD, Meikle PJ, Turlin

B and Lewindon PJ. Fibrogenesis in pediatric cholestatic

liver disease: Role of taurocholate and hepatocyte-derived


CONTINUED



monocyte chemotaxis protein-1 in hepatic stellate cell

recruitment. Hepatology 49(2): 533-544, 2009

Randall LM, Amante FH, Zhou Y, Stanley AC, Haque

A, Rivera F, Pfeffer K, Scheu S, Hill GR, Tamada K and

Engwerda CR. Cutting edge: selective blockade of LIGHT-

lymphotoxin beta receptor signaling protects mice from

experimental cerebral malaria caused by Plasmodium berghei

ANKA. Journal of Immunology 181(11): 7458-7462, 2008

Ranjit N, Zhan B, Hamilton B, Stenzel D, Lowther J,

Pearson M, Gorman J, Hotez P and Loukas A. Proteolytic

degradation of hemoglobin in the intestine of the human

hookworm Necator americanus. Journal of Infectious Diseases

199(6): 904-912, 2009

Ranjit N, Zhan B, Stenzel DJ, Mulvenna J, Fujiwara

R, Hotez PJ, Loukas A. A family of cathepsin B cysteine

proteases expressed in the gut of the human hookworm,

Necator americanus. Molecular and Biochemical Parasitology

160(2): 90-99, 2008

Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H,

Aittomäki K, Simard J, Spurdle AB kConFab, Couch FJ,

Pereira LHM, Greene M, Andrulis IL, OCGN, Pasche B,

Kaklamani V, BCFR, Hamann U, Szabo C, Peock S, Cook

M, Harrington PA, Donaldson A, Male AM, Gardiner CA,

Gregory H, Side LE, Robinson AC, Emmerson L, Ellis I,

EMBRACE, Peyrat J-P, Fournier J, Vennin P, Adenis C,

Muller D, Fricker J-P, Longy M, Sinilnikova OM, Stoppa-

Lyonnet D, GEMO, Schmutzler, RK, Versmold B, Engel

C, Meindl A, Kast K, Schaefer D, Froster UG, Chenevix-

Trench G, Easton DE. No association of TGFB1 genotypes

and breast cancer risk in BRCA1 and BRCA2 mutation

carriers: A multi-center cohort study. Breast Cancer Research

and Treatment 115(1): 185-92, 2009

Reid DW, Anderson GJ and Lamont IL. Cystic fi brosis:

ironing out the problem of infection? American Journal of

Physiology - Lung Cellular and Molecular Physiology 295(1):

L23-L24, 2008

Reiersen AM, Constantino JN, Grimmer M, Martin NG

and Todd RD. Evidence for shared genetic infl uences on

self-reported ADHD and autistic symptoms in young adult

Australian twins. Twin Research and Human Genetics 11(6):

579-585, 2008

Richard DJ, Bolderson E and Khanna KK. Multiple human

single-stranded DNA binding proteins function in genome

maintenance: structural, biochemical and functional analysis.

Critical Reviews in Biochemistry and Molecular Biology 14:

1-19, 2009

Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE,

Williams GM, van der Pols JC and Green AC. Incidence

of basal cell carcinoma multiplicity and detailed anatomic

distribution: Longitudinal study of an Australian population.


Richmond-Sinclair NM, Lee E, Cummings MC, Williamson

R, Muller K, Green AC, Hayward NK, Whiteman DC.

Histologic and epidemiologic correlates of P-MAPK, Brn-2,

pRb, p53, and p16 immunostaining in cutaneous melanomas.

Melanoma Research 18(5): 336-345, 2008

Rogers PA, D’Hooghe TM, Fazleabas A, Gargett CE,

Giudice LC, Montgomery GW, Rombauts L, Salamonsen

LA and Zondervan KT. Priorities for endometriosis research:

recommendations from an international consensus workshop.

Reproductive Sciences 16(4): 335-346, 2009

Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS,

Piva TJ, Watters DJ, Santambrogio P, Arosio P and Ramm

GA. Ferritin functions as a proinfl ammatory cytokine via iron-

independent protein kinase C zeta/nuclear factor kappaB-

regulated signaling in rat hepatic stellate cells. Hepatology

49(3): 887-900, 2008

Ruddell RG, Knight B, Tirnitz-Parker JEE, Akhurst B,

Summerville L, Subramaniam VN, Olynyk JK and Ramm

GA. Lymphotoxin-beta receptor signaling regulates hepatic

stellate cell function and wound healing in a murine model of

chronic liver injury. Hepatology, 49(1): 227-239, 2009

Russell TL, Gatton ML, Ryan PA and Kay BH. Quality

assurance of aerial applications of larvicides for mosquito

control: effects of granule and catch tray size on fi eld

monitoring programs. Journal of Economic Entomology 102(2):

507-514, 2009

Russell TL and Kay BH. Biologically based insecticides for the

control of immature Australian mosquitoes: a review. Australian

Journal of Entomology 47(3): 232-242, 2008. Review

Ruyssers NE, De Winter BY, De Man JG Loukas A, Herman

AG, Pelckmans PA and Moreels TG. Worms and the treatment

of infl ammatory bowel disease: are molecules the answer?

Clinical and Developmental Immunology 567314, 2008

Ruyssers NE, De Winter BY, De Man JG, Loukas A,

Pearson MS, Weinstock JV, Van den Bossche RM,

Martinet W, Pelckmans PA and Moreels TG. Therapeutic

potential of helminth soluble proteins in TNBS-induced colitis

in mice. Infl ammatory Bowel Diseases 15(4): 491-500, 2009

Schermer JA, Feather NT, Zhu G and Martin NG.

Phenotypic, genetic, and environmental properties of the

portrait values questionnaire. Twin Research and Human

Genetics 11(5): 531-537, 2008

Schildkraut JM, Goode EL, Clyde MA, Iversen ES,

Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton

L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN,

Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan

C, Sutphen R, Sellers TA, Pearce L, Wu AH, Van Den Berg

D, Conti D, Elund CK, Anderson R, Goodman MT, Lurie

G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ,

Jacobs I, Krüger Kjaer S, Hogdall E, Blaakaer J, Hogdall C,

Easton DF, Song H, Pharoah PD, Whittemore AS, McGuire

V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer

DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock

S, Sherman M, Garcia-Closas M; Australian Cancer

Study (Ovarian Cancer); Australian Ovarian Cancer Study

Group. Single nucleotide polymorphisms in the TP53 region

and susceptibility to invasive epithelial ovarian cancer. Cancer

Research 69(6): 8993-8997, 2009

Senter L, Clendenning M, Sotamaa K, Hampel H, Green

J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN,

Lindor NM, Young J, Winship I, Dowty JG, White DM,

Hopper JL, Baglietto L, Jenkins MA and de la Chapelle A.

The clinical phenotype of Lynch syndrome due to germ-line

PMS2 mutations. Gastroenterology 135(2): 419-28, 2008

Shattuck DW, Chiang MC, Barysheva M, McMahon KL,

de Zubicaray GI, Meredith M, Wright MJ, Toga AW and

Thompson PM. Visualization tools for high angular resolution

diffusion imaging. Medical Image Computing and Computer

Assisted Intervention 11(2):298-305, 2008

Shekar SN, Duffy DL, Frudakis T, Sturm RA, Zhao ZZ,

Montgomery GW and Martin NG. Linkage and Association

Analysis of Spectrophotometrically Quantifi ed Hair Color in

Australian Adolescents: the Effect of OCA2 and HERC2.

Journal of Investigative Dermatology 128(12): 2807-2814,

2008

Shi J, Misso NL, Kedda MA, Horn J, Welch MD, Duffy DL,

Williams C and Thompson PJ. Cyclooxygenase-2 gene

polymorphisms in an Australian population: association of the

-1195G > A promoter polymorphism with mild asthma. Clinical

and Experimental Allergy 38(6): 913-920, 2008

Shin SJ, Simpson PT, Da Silva L, Jayanthan J, Reid

L, Lakhani SR and Rosen PP. Molecular Evidence for

Progression of Microglandular Adenosis (MGA) to Invasive

Carcinoma. American Journal of Surgical Pathology 33(4):

496-504, 2008

Simerska P, Abdel-Aal A-BM, Fujita Y, Batzloff MR, Good

MF and Toth I. Synthesis and In Vivo of Carbohydrate-

Based Vaccines Against Group A Streptococcus. Biopolymers

(Peptide Science) 90(5): 611-616, 2008

Simerska P, Moyle P, Olive C and Toth I. Strategies in Oral

Immunisation. In: Oral Delivery of Macromolecular Drugs:

Barriers, Strategies and Future Trends. Bernkop-Schnürch A

(Ed). Springer, NY, USA, Chapter 11, pp 195-222, 2009

Sims A-M, Timms AE, Bruges-Armas J, Burgos-Vargas

R, Chou C-T, Doan T, Dowling A, Fialho RN, Gergely P,

Gladman DD, Inman R, Kauppi M, Kaarela K, Laiho K,

Maksymowych W, Pointon JJ, Rahman P, Reveille, JD,

Sorrentino R, Tuomilehto J, Vargas-Alarcon G, Wordsworth

BP, Xu H, Brown MA on behalf of the International

Genetics of Ankylosing Spondylitis. Prospective meta-

analysis of interleukin 1 gene complex polymorphisms confi rms

associations with ankylosing spondylitis. Annals of Rheumatic

Diseases 67 (9) 1305-1309, 2008

Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH,

Chambert K, Nimgaonkar VL, McQueen MB, Faraone

SV, Kirby A, de Bakker PI, Ogdie MN, Thase ME, Sachs

GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C,

Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir

WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M,

McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A,

Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling

HM and Purcell SM. Whole-genome association study of

bipolar disorder. Molecular Psychiatry 13(6): 558-69. 2008

Slutske WS, D’Onofrio BM, Turkheimer E, Emery RE,

Harden KP, Heath AC and Martin NG. Searching for an

environmental effect of parental alcoholism on offspring alcohol

use disorder: a genetically informed study of children of

alcoholics. Journal of Abnormal Psychology 117(3): 534-551,

2008

Slutske WS, Meier MH, Zhu G, Statham DJ, Blaszczynski

A and Martin NG. The Australian Twin Study of Gambling

(OZ-GAM): Rationale, Sample Description, Predictors of

Participation, and a First Look at Sources of Individual

Differences in Gambling Involvement. Twin Research and

Human Genetics 12(1): 63-78, 2009

Smith C, Beagley L and Khanna R. Acquisition of

polyfunctionality by Epstein-Barr virus-specifi c CD8+ T cells

correlates with increased resistance to galectin-1 mediated

suppression. Journal of Virology 83(12): 6192-6198, 2009

Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook

AL, Boyle GM, Parsons PG, Sturm RA and Muscat GEO.

PPARgamma agonists attenuate proliferation and modulate

Wnt/beta-catenin signalling in melanoma cells. International

Journal of Biochemistry and Cell Biology 41(4): 844-852, 2009


CONTINUED



Smith S, Martinez M, Cooper L, Rist M, Zhong J and

Khanna R. Generating functional CD8+ T-cell memory

response under transient CD4+ T-cell defi ciency: implications

for vaccination of immunocompromised individuals. European

Journal of Immunology 38(7): 1857-1866, 2008

Smith C, Wakisaka N, Crough T, Peet J, Yoshizaki T,

Beagley L and Khanna R. Discerning regulation of cis- and

trans-presentation of CD8+ T-cell epitopes by EBV-encoded

oncogene LMP-1 through self aggregation. Blood 113(24):

6148-6152, 2009

Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow

DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR,

Clouston AD, Gotley DC, Devitt PG, Jamieson GG and

Drew PA. Similarity of aberrant DNA methylation in Barrett’s

esophagus and esophageal adenocarcinoma. Molecular

Cancer 7: 75, 2008

Solares CA, Brown I, Boyle GM, Parsons PG and Panizza

B. Neural cell adhesion molecule expression: No correlation

with perineural invasion in cutaneous squamous cell carcinoma

of the head and neck. Head & Neck 31(6): 802-806, 2009

Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-

Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire

V, Hogdall C, Blaakaer J, Wu AH, Van Den Berg DJ,

Stram DO, Menon U, Gentry-Maharaj A, Jacobs IJ,

Webb PM, Beesley J, Chen X, Rossing MA, Doherty JA,

Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G,

Thompson PJ, Carney ME, Ness RB, Moysich K, Goode

EL, Vierkant RA, Cunningham JM, Anderson S, Schildkraut

JM, Berchuck A, Iversen ES, Moorman PG, Garcia-Closas

M, Chanock S, Lissowska J, Brinton L, Anton-Culver H,

Ziogas A, Brewster WR, Ponder BA, Easton DF, Gayther

SA and Pharoah PD. Association between invasive ovarian

cancer susceptibility and 11 best candidate SNPs from breast

cancer genome-wide association study. Human Molecular

Genetics 18(12): 2297-2304, 2009

Spurdle AB, Couch FJ, Hogervorst FB, Radice P and

Sinilnikova OM. Prediction and assessment of splicing

alterations: implications for clinical testing. Human Mutation

29(11): 1304-1313, 2008. Review

Spurdle AB, Deans AJ, Duffy D, Goldgar DE, Chen X,

Beesley J, Easton DF, Antoniou AC, Peock S, Cook

M, Nathanson KL, Domchek SM, MacArthur GA and

Chenevix-Trench G. No evidence that CDKN1B (p27)

polymorphisms modify breast cancer risk in BRCA1 and

BRCA2 mutation carriers. Breast Cancer Research and

Treatment 115(2): 307-313, 2009

Stanley AC, Dalton JE, Rossotti SH, Macdonald KP, Zhou

Y, Rivera F, Schroder WA, Maroof A, Hill GR, Kaye PM and

Engwerda CR. VCAM-1 and VLA-4 modulate dendritic cell IL-

12p40 production in experimental visceral leishmaniasis. PLoS

Pathogens 4(9): e1000158, 2008

Steer AC, Jenney AW, Kado J, Batzloff MR, La Vincente

S, Waqatakirewa L, Mulholland EK and Carapetis JR. High

burden of impetigo and scabies in a tropical country. PLoS


Steer AC, Jenney AW, Kado J, Good MF, Batzloff M, Magor

G, Ritika R, Mulholland KE and Carapetis JR. Prospective

surveillance of streptococcal sore throat in a tropical country.

Pediatric Infectious Diseases Journal 28(6): 477-482, 2009

Steer AC, Jenney A, Kado J, Good MF, Batzloff M,

Waqatakirewa L, Mullholland EK and Carapetis JR.

Prospective surveillance of invasive Group A streptococcal

disease, Fiji, 2005-2007. Emerging Infectious Diseases 15(2):

216-222, 2009.

Steer AC, Kado J, Jenney AW, Batzloff M, Waqatakirewa L,

Mulholland EK and Carapetis JR. Acute rheumatic fever and

rheumatic heart disease in Fiji: prospective surveillance, 2005-

2007. Medical Journal of Australia 190(3): 133-135, 2009

Steer AC, Kado J, Wilson N, Tuiketei T, Batzloff M,

Waqatakirewa L, Mulholland EK and Carapetis JR.

High prevalence of rheumatic heart disease by clinical and

echocardiographic screening among children in Fiji. Journal of

Heart Valve Disease 18(3): 327-35, 2009

Steer AC, Vidmar S, Ritika R, Kado J, Batzloff M,

Jenney AW, Carlin JB and Carapetis JR. Normal ranges

of streptococcal antibody tests are similar in streptococcal-

endemic and non-endemic settings. Clinical and Vaccine

Immunology 16(2): 172-175, 2009

Stone JL, O’Donovan MC, Gurling H, Kirov GK, Blackwood

DH, Corvin A, Craddock NJ, Gill M, Hultman CM,

Lichtenstein P, McQuillin A, Pato CN, Ruderfer DM, Owen

MJ, St Clair D, Sullivan PF, Sklar P, Purcell Leader SM;

Data analysis; Stone JL, Ruderfer DM, Korn J, Kirov GK,

Macgregor S, McQuillin A, Morris DW, O’Dushlaine CT,

Daly MJ, Visscher PM, Holmans PA, O’Donovan MC,

Sullivan PF, Sklar P, Purcell Leader SM, Gurling H, Corvin

A, Blackwood DH, Craddock NJ, Gill M, Hultman CM,

Kirov GK, Lichtenstein P, McQuillin A, O’Donovan MC,

Owen MJ, Pato CN, Purcell SM, Scolnick EM, St Clair

D, Stone JL, Sullivan PF, Sklar Leader P, O’Donovan

MC, Kirov GK, Craddock NJ, Holmans PA, Williams NM,

Georgieva L, Nikolov I, Norton N, Williams H, Toncheva

D, Milanova V, Owen MJ, Hultman CM, Lichtenstein P,

Thelander EF, Sullivan P, Morris DW, O’Dushlaine CT,

Kenny E, Waddington JL, Gill M, Corvin A,McQuillin A,

Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V,

Krasucki R, Lawrence J, Quested D, Bass N, Curtis D,

Gurling H, Crombie C, Fraser G, Leh Kwan S, Walker N, St

Clair D, Blackwood DH, Muir WJ, McGhee KA,

Pickard B, Malloy P, Maclean AW, Van Beck M, Visscher

PM, Macgregor S, Pato MT, Medeiros H, Middleton F,

Carvalho C, Morley C, Fanous A, Conti D, Knowles JA,

Paz Ferreira C, Macedo A, Helena Azevedo M, Pato CN,

Stone JL, Ruderfer DM, Korn J, McCarroll SA, Daly M,

Purcell SM, Sklar P, Purcell SM, Stone JL, Chambert K,

Ruderfer DM, Korn J, McCarroll SA, Gates C, Gabriel SB,

Mahon S, Ardlie K, Daly MJ, Scolnick EM and Sklar P.

Rare chromosomal deletions and duplications increase risk of

schizophrenia. Nature 455(7210): 237-241, 2008. Letter

St Pierre L, Earl S, Filippovich I, Sorokina S, Masci P,

de Jersey J and Lavin MF. Common evolution of waprin

and kunitz-like toxin families in Australian venomous snakes.

Cellular and Molecular Life Sciences 65(24): 4039-4054, 2008

Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello

C, Kelemen L, Jeske Y, Veglio F and Stowasser M. Further

evidence for linkage of familial hyperaldosteronism type II at

chromosome 7p22 in Italian as well as Australian and South

American families. Journal of Hypertension (8): 1577-1582, 2008

Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit

JH, Zandbelt T, Arolt V, Baune BT, Blackwood D, Cichon S,

Coventry WL, Domschke K, Farmer A, Fava M, Gordon SD,

He Q, Heath AC, Heutink P, Holsboer F, Hoogendijk WJ,

Hottenga JJ, Hu Y, Kohli M, Lin D, Lucae S, Macintyre DJ,

Maier W, McGhee KA, McGuffi n P, Montgomery GW, Muir

WJ, Nolen WA, Nothen MM, Perlis RH, Pirlo K, Posthuma

D, Rietschel M, Rizzu P, Schosser A, Smit AB, Smoller JW,

Tzeng JY, van Dyck R, Verhage M, Zitman FG, Martin NG,

Wray NR, Boomsma DI and Penninx BW. Genome-wide

association for major depressive disorder: a possible role for

the presynaptic protein piccolo. Molecular Psychiatry 14(4):

359-375, 2009

Suttiprapa S, Loukas A, Laha T, Wongkham S, Kaewkes

S, Gaze S, Brindley PJ and Sripa B. Characterization of

the antioxidant enzyme, thioredoxin peroxidase, from the

carcinogenic human liver fl uke, Opisthorchis viverrini. Molecular

and Biochemical Parasitology 160(2): 116-122, 2008

Sved JA, McRae AF and Visscher PM. Divergence between

human populations Estimated from linkage disequilibrium.

American Journal of Human Genetics 83(6):7 37-743, 2008

Tabrizi JS, Wilson AJ and O’Rourke P. Customer quality in

health care. Patient Education and Counselling 74(1): 130-131,

2009. Letter to Editor

Teixeira-Carvalho A, Fujiwara RT, Stemmy E, Olive D,

Damsker JM, Loukas AC, Corrêa-Oliveira R, Constant SL

and Bethony JM. Binding of excreted/secreted products of

adult Necator americanus to human NK cells in hookworm

infected individuals from Brazil. Infection and Immununity

76(12): 5810-5816, 2008

Tellam J, Smith C, Rist M, Webb N, Cooper L, Vuocolo

T, Connolly G, Tscharke DC, Devoy MP and Khanna R.

Regulation of protein translation through mRNA structure

infl uences MHC class I loading and T cell recognition.

Proceedings of the National Academy of Science USA.

105(27): 9319-24, 2008

Thara R, Srinivasan T, John S, Nancarrow D, Chant D,

Holliday E and Mowry B. Design and clinical characteristics

of a homogeneous schizophrenia pedigree sample from Tamil

Nadu, India. The Australian and New Zealand Journal of

Psychiatry 43(6):561-570, 2009

Theurl M, Theurl I, Hochegger K, Obrist P, Subramaniam

N, van Rooijen N, Schuemann K and Weiss G. Kupffer cells

modulate iron homeostasis in mice via regulation of hepcidin

expression. Journal of Molecular Medicine 86(7): 825-835, 2008

Thomsen SF, Ferreira MA, Kyvik KO, Fenger M and Backer

V. A quantitative genetic analysis of intermediate asthma

phenotypes. Allergy 64(3): 427-30, 2009

Thomsen SF, van der Sluis S, Stensballe LG, Posthuma D,

Skytthe A, Kyvik KO, Duffy DL, Backer V and Bisgaard H.

Exploring the association between severe respiratory syncytial

virus infection and asthma: a registry-based twin study.

American Journal of Respiratory and Critical Care Medicine

179(12): 1091-1097, 2009

Ting M and Boyd AW. The role of Eph receptor tyrosine

kinases and ephrin ligands in hematopoietic cell development

and function. The Open Hematology Journal 2: 103-110, 2008

Tonks ID, Mould A, Nurcombe V, Cool SM, Walker GJ,

Hacker E, Keith P, Schroder WA, Cotterill A, Hayward

NK and Kay GF. Dual loss of Rb1 and Trp53 in melanocytes

perturbs melanocyte homeostasis and genetic stability in vitro

but does not cause melanoma or pigmentation defects in vivo.

Pigment Cell Melanoma Research 22(3): 328-330, 2009. Letter

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S,

Johnson DS, Trivett MK, Etemadmoghadam D, Locandro

B, Trafi cante N, Fereday S, Hung JA, Chiew YE, Haviv

I, AOCS Study Group (Green AC, member), Gertig DM,

deFazio A and Bowtell DDL. Novel molecular subtypes of

serous and endometrioid ovarian cancer linked to clinical

outcome. Clinical Cancer Research 14(16): 5198-208, 2008

Turlin B, Ramm GA, Purdie DM, Lainé F, Perrin M, Deugnier

Y and Macdonald GA. Assessment of hepatic steatosis:

comparison of quantitative and semi-quantitative methods in


CONTINUED



108 liver biopsies. Liver International 29(4): 530-535, 2009

Utuk AE, Simsek S, McManus DP and Koroglu E. Molecular

genetic characterization of Turkish isolates of Echinococcus

granulosus. Acta Tropica 107(2): 192-194., 2008

Valery PC, Moloney A, Cotterill A, Harris M, Sinha AK and

Green AC. Prevalence of obesity and metabolic syndrome in

Indigenous Australian youths. Obesity Reviews 10(3): 255-261,

2008

Valle AM, Radic Z, Rana BK, Whitfi eld JB, O’Connor DT,

Martin NG and Taylor P. The cholinesterases: Analysis by

pharmacogenomics in man. Chemico-Biological Interactions

175(1-3): 343-345, 2008

van der Pols JC, Heinen MM, Hughes MC, Ibiebele TI,

Marks GC and Green AC. Serum antioxidants and skin cancer

risk: An 8-Year community-based follow-up study. Cancer

Epidemiology Biomarkers and Prevention 18(4): 1167-1173, 2009

Vaughan K, Blythe M, Greenbaum J, Zhang Q, Peters

B, Doolan DL and Sette A. Meta-analysis of immune

epitope data for all Plasmodia: overview and applications for

malarial immunobiology and vaccine-related issues. Parasite

Immunology 31(2):78-97, 2009

Verweij KJ, Zietsch BP, Bailey JM and Martin NG. Shared

aetiology of risky sexual behaviour and adolescent misconduct:

genetic and environmental infl uences. Genes Brain and

Behavior 8(1): 107-13, 2009

Vink JM, Smit AB, de Geus EJC, Sullivan P, Willemsen

G, Hottenga JJ, Smit JH, Hoogendijk WJ, Zitman FG,

Peltonen L, Kaprio J, Pedersen NL, Magnusson P,

Spector TD, Kyvik KO, Morley KI, Heath AC, Martin NG,

Westendorp RGJ, Slagboom PE, Tiemeier H, Hofman

A, Uitterlinden AG, Aulchenko YS, Amin N, van Duijn C,

Penninx BW and Boomsma DI. Genome-wide association

study of smoking initiation and current smoking. American


Visscher PM. Whole genome approaches to quantitative

genetics Genetica 136(2): 351-358, 2009

Waddell N. Microarray-based DNA profi ling to study genomic

aberrations. IUBMB Life 60(7): 437-440, 2008. Review

Wade TD, Treloar SA and Martin NG. Shared and unique risk

factors between lifetime purging and objective binge eating: a

twin study. Psychological Medicine 38(10): 1455-1464, 2008

Waldron M, Heath AC, Bucholz KK, Madden PAF and

Martin NG. Alcohol dependence and reproductive onset:

Findings in two Australian twin cohorts. Alcoholism: Clinical

and Experimental Research 32(11): 1865-1874, 2008

Walker G. Cutaneous melanoma: how does ultraviolet light

contribute to melanocyte transformation? Future Oncology

4(6): 841-56, 2008. Review

Walker G and Box N. Ribosomal stress, p53 activation

melanocyte and the tanning response. Expert Reviews in

Dermatology 3(6):649-656, 2008. Review

Walker NA, Crawford DH, Subramaniam VN and Wallace

DF. Juvenile iron overload--advances, but no answers. Journal

of Pediatrics 153(4): 588, 2008

Walker GJ, Kimlin MG, Hacker E, Ravishankar S, Muller

HK, Beermann F and Hayward NK. Murine Neonatal

Melanocytes Exhibit a Heightened Proliferative Response to

Ultraviolet Radiation and Migrate to the Epidermal Basal Layer.


Walker LC, Waddell N, Ten Haaf A, kConFab Investigators,

Grimmond S and Spurdle AB. Use of expression data and

the CGEMS genome-wide breast cancer association study

to identify genes that may modify risk in BRCA1/2 mutation

carriers. Breast Cancer Research and Treatment 112(2): 229-

236, 2008

Wallace DF and Subramaniam VN. Co-factors in liver

disease: The role of HFE-related hereditary hemochromatosis

and iron. Biochimica et Biophysica Acta – General Subjects

1790(7): 663-670, 2008

Walsh MD, Young J, Spurdle A and Obermair A. Lynch

syndrome in women less than 50 years of age with endometrial

cancer. Obstetrics and Gynecology 112(4): 943, 2008. Letter

Walsh MD, Dent OF, Young JP, Wright CM, Barker

MA, Leggett BA, Bokey L, Chapuis PH, Jass JR and

Macdonald GA. HLA-DR expression is associated with better

prognosis in sporadic Australian clinicopathological Stage C

colorectal cancers. International Journal of Cancer 125(5):

1231-1237, 2009. Report

Waltes R, Kalb R, Gatei M, Kijas A, Stumm M, Sobeck A,

Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D

and Dork T. Human Rad50 defi ciency in a Nijmegen-Breakage

Syndrome-like disorder. American Journal of Human Genetics

84(5): 605-616, 2009

Wang X, Gobert GN, Feng X, Fu Z, Yuan C, Jin Y, Han H

and Lin JJ. Analysis of early hepatic stage schistosomula gene

expression by subtractive expressed sequence tags library.

Molecular and Biochemical Parasitology. 166(1):62-69, 2009

Watkins WS, Thara R, Mowry BJ, Zhang Y, Witherspoon

DJ, Tolpinrud W, Bamshad MJ, Tirupati S, Padmavati R,

Smith H, Filippich C, and Jorde LB. Genetic variation

in South Indian castes: evidence from Y-chromosome,

mitochondrial, and autosomal polymorphisms. BMC Genetics

9: 86, 2008

Webb N, Connolly G, Tellam J, Yap AS and Khanna R.

Epstein-Barr virus associated modulation of Wnt pathway

is not dependent on latent membrane protein-1. PLoS ONE

3(9):e3254, 2008

Webbink HD, Posthuma D, Boomsma DI, Eco J.C. de

Geus EJC and Visscher PM. Do twins have lower cognitive

ability than singletons? Intelligence 36: 539-547, 2008

Webster J, Courtney M, O’Rouke P, Marsh N, Gale C,

Abbott B, McRae P and Mason K. Should elderly patients

be screened for their “falls risk”? Validity of the STRATIFY falls

screening tool and predictors of falls in a large acute hospital.

Age and Ageing 37(6): 702-706, 2008

Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal

R, Saemundsen E, Stefansson H, Ferreira MA, Green T,

Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti

A, Tanzi RE, Stefansson K, Santangelo SL, Gusella

JF, Sklar P, Wu BL and Daly MJ. Association between

microdeletion and microduplication at 16p11.2 and autism.

New England Journal of Medicine 358(7): 667-675, 2008

Whisstock JC, McGowan S, Trenholme KR, Gardiner DL,

and Dalton JP. Intracellular processing of the membrane-

bound PfA-M1 neutral aminopeptidase, a target for new

antimalarials Proceedings of the National Academy of Sciences

of the USA 106(22): E56, 2009

Whitelaw NC and Whitelaw E. Transgenerational epigenetic

inheritance in health and disease. Current Opinion on Genetics

and Development 18(3): 227-284, 2008

Whiteman DC. Hot tea and increased risk of oesophageal

cancer (invited editorial). British Medical Journal 338: 841-842,

2009

Whitfi eld JB, Dy V, Madden PA, Heath AC, Martin NG

and Montgomery GW. Measuring carbohydrate-defi cient

transferrin by direct immunoassay: factors affecting diagnostic

sensitivity for excessive alcohol intake. Clinical Chemistry 54(7):

1158-1165, 2008

Wilkins SE, Hyvärinen J, Chicher J, Gorman JJ, Daniel

J, Peet DJ, Bilton RL and Koivunen P. Differences

in hydroxylation and binding of Notch and HIF-1alpha

demonstrate substrate selectivity for factor inhibiting HIF-1

(FIH-1) International Journal of Biochemistry and Cell Biology

41(7): 1563-1571, 2009

Winning A, Braslins P and McCarthy JS. Case report:

nitazoxanide for treatment of refractory bony hydatid disease.

American Journal of Tropical Medicine and Hygiene 80(2):176-

178, 2009

Wipasa J, Xu H, Liu X, Hirunpetcharat C, Stowers A

and Good MF. Effect of Plasmodium yoelii exposure on

vaccination with the 19-kilodalton carboxyl terminus of

merozoite surface protein 1 and vice versa and implications

for the application of a human malaria vaccine. Infection and

Immunity 77(2): 817-824, 2009

Woo J, Tone S, Campbell MJ, Wallace L, Meagher S,

Montgomery GW, Chao F, Chan W and Vollenhoven B.

Two corpora lutea seen at 6–13 weeks’ gestation infers

dizygosity among spontaneous same-sexed dichorionic twins.


Woodberry T, Pinzon-Charry A, Piera KA, Panpisutchai

Y, Engwerda CR, Doolan DL, Salwati E, Kenangalem

E, Tjitra E, Price RN, Good MF and Anstey NM. Human

T cell recognition of the blood stage antigen Plasmodium

hypoxanthine guanine xanthine phosphoribosyl transferase

(HGXPRT) in acute malaria. Malaria Journal 8: 122, 2009

Worthley DL, Johnson DF, Eisen DP, Dean MM, Heatley

SL, Tung JP, Scott J, Padbury RT, Harley HA, Bardy PG,

Angus PW and Mullighan CG. Donor mannose-binding

lectin defi ciency increases the likelihood of clinically signifi cant

infection after liver transplantation. Clinical Infectious Diseases

48(4): 410-417, 2009

Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-

Smith I, Bik To L, Browett P, Western R, Durrant S, So

J, Young GP, Mullighan CG, Bardy PG, and Michael MZ.

Human gastrointestinal neoplasia-associated myofi broblasts

can develop from bone marrow-Derived Cells Following

Allogeneic Stem Cell Transplantation. Stem Cells 27(6):

1463-1468, 2009

Worthley DL, Suthers G and Lipton L. Management of

MUTYH-associated neoplasia in Australia. International

Medical Journal 38(8): 644-650, 2008

Wray NR, James MR, Handoko HY, Dumenil T, Lind PA,

Montgomery GW and Martin NG. Association study of

candidate variants from brain-derived neurotrophic factor

and dystrobrevin-binding protein 1 with neuroticism, anxiety,

and depression. Psychiatric Genetics 18(5): 219-225 2008

Wray NR, James MR, Dumenil T, Handoko HY, Lind

PA, Montgomery GW and Martin NG. Association study


CONTINUED



of candidate variants of COMT with neuroticism, anxiety,

and depression. American Journal of Medical Genetics -

Neuropsychiatric Genetics 147B(7): 1314-1318, 2008

Wray NR, Goddard ME and Visscher PM. Prediction of

individual genetic risk of complex disease. Current Opinion in

Genetics and Development 18(3): 257-263, 2008

Wright MJ, Gillespie NA, Luciano M, Zhu G and Martin

NG. Genetics of personality and cognition in adolescents. In:

Development Psychopathology and Wellness : Genetic and

Environmental Infl uences (J Hudziak Ed) American Psychiatric

Publishing Inc, Washington. Pp 85-107, 2008

Wykes MN and Good MF. What really happens to dendritic

cells during malaria? Nature Reviews Microbiology 6(11): 864-

870, 2008. Review

Yang YR, Craig PS, Vuitton DA, Williams GM, Sun T, Liu

TX, Boufana B, Giraudoux P, Teng J, Li Y, Huang L, Zhang

W, Jones MK and McManus DP. Serological prevalence of

echinococcosis and risk factors for infection amongst children

in rural communities of southern Ningxia, China. Tropical

Medicine and International Health 13(8): 1086-1094, 2008

Yang YR, McManus DP, Huang Y and Heath DD.

Echinococcus granulosus infection and options for control

of cystic echinococcosis in Tibetan communities of Western

Sichuan Province, China. PLoS Neglected Tropical Diseases

3(4): e426, 2009

Yin M, Hu W, Mo X, Wang S, Brindley PF, McManus

DP, Davis GM, Feng Z and Blair D. Multiple near-identical

genotypes of Schistosoma japonicum can occur in snails and

have implications for population-genetic analyses. International

Journal for Parasitology 38(14): 1681-1691, 2008

Yong M, Mitchell D, Caudron A, Toth I and Olive C.

Expression of maturation markers on murine dendritic cells

in response to group A streptococcal lipopeptide vaccines.

Vaccine 27(25-26): 3313-3318, 2009

Youl PH, Coxeter PD, Whiteman DC and Aitken J.

Screening for skin cancer in Queensland: who attends, and

why and where do they attend? Medical Journal of Australia

190(1): 45-45, 2009. Letter

Youngson NA and Whitelaw E. Transgenerational epigenetic

effects. Annual Review of Genomics and Human Genetics 9:

233-257, 2008. Review

Zhang W and McManus DP. Advances in the immunology

and diagnosis of echinococcosis. In: Advances in Hydatid

Disease Diagnosis and Treatment. Filppou DK (Ed). Pashalidis

Medical Publishing, Athens, Greece. Chapter 8 pp 125-146, 2009

Zhang W and McManus DP. Vaccination of dogs against

Echinococcus granulosus: a means to control hydatid

disease? Trends in Parasitology 24(9): 419-424, 2008. Review

Zhang W, Ross AG and McManus DP. Mechanisms

of immunity in hydatid disease: implications for vaccine

development. Journal of Immunology 181(10):6679-85, 2008.

Review

Zhao ZZ, Duffy DL, Thomas SA, Martin NG, Hayward NK

and Montgomery GW. Polymorphisms in the syntaxin 17

gene are not associated with human cutaneous malignant

melanoma. Melanoma Research 19(2): 80-86, 2009

Zhao ZZ, Painter JN, Palmer JS, Webb PM, Hayward NK,

Whiteman DC, Boomsma DI, Martin NG, Duffy DL and

Montgomery GW. Variation in bone morphogenetic protein 15

is not associated with spontaneous human dizygotic twinning.

Human Reproduction 23(10): 2372-2379, 2008

Zhao ZZ, Nyholt DR, Thomas S, Treloar SA and

Montgomery GW. Polymorphisms in the vascular endothelial

growth factor gene and the risk of familial endometriosis.

Molecular Human Reproduction 14(9): 531-538, 2008

Zhao ZZ, Nyholt DR, Le L, Treloar SA and Montgomery

GW. Common variation in the CYP17A1 and IFIT1 genes

on Chromosome 10 does not contribute to the risk of

Endometriosis. The Open Reproductive Science Journal 1:

35-40, 2008

Zhong J, Rist M, Cooper L, Smith C and Khanna R.

Induction of pluripotent protective immunity following

immunisation with a chimeric vaccine against human

cytomegalovirus. PLoS ONE 3(9): e3256, 2008

Zhong W, Skwarczynski M, Simerska P, Good MF and Toth

I. Development of highly pure α-helical lipoglycopeptides as

self-adjuvanting vaccines. Tetrahedron 65(17): 3459-3464,

2009

B. P. Zietsch, K. I. Morley, S. N. Shekar, K. J. H. Verweij,

M. C. Keller, S. Macgregor, M. J. Wright, J. M. Bailey and

N. G. Martin. Genetic factors predisposing to homosexuality

may increase mating success in heterosexuals. Evolution and

Human Behavior 29(6): 424-433, 2008

DR FIONA AMANTE

A Role for plasmacytoid dendritic cells in controlling parasite

burden and cerebral pathology during malaria infection

Brisbane Immunology Group, Sunshine Coast, Aug 2008

PROF GREG ANDERSON

Interacting signals in the control of hepcidin expression Biometals 2008 Symposium, Santiago de Compostela, Spain, Jul 2008

Hepatic iron metabolism in health and disease: Iron metabolism

for clinicians

Roche Hepatology Masterclass, Sydney, Jul 2008

Regulation of mammalian iron transport Curtin Conference on Ion Channels and Transporters, Canberra, Apr 2009

1. Regulating mammalian iron homeostasis

2. Metabolism and diseases

Second Australia-China Biomedical Research Conference, Tianjin, China,

Apr 2009

Opportunities for novel therapeutics for disorders of iron

homeostasis

Symposium on Biomedicine and Drug Development, Guangzhou, China,

Apr 2009

PROF ANDREW BOYD

EphA4 in spinal cord injury Queensland Brain Institute Conference, Noosa Heads, Aug 2008

Eph receptors as targets for therapy in cancer and spinal cord injury Hanson Institute, IMVS, Adelaide, Oct 08

Novel targets for therapy in malignant glioma AHMRC, Brisbane, Nov 2008

Eph kinases as tumour markers and potential targets for therapy HSANZ conference, Brisbane, Mar 2009

Cell membrane protein targets for therapy in leukaemia and

other cancers

Haematology Oncology Department, Princess Alexandra Hospital,

Brisbane, Jun 2009

DR GLEN BOYLE

1. Induction of senescence by diterpene esters in melanoma

2. A novel therapeutic target for metastatic melanoma

The Australian Health and Medical Research Congress, Brisbane, Nov 2008.

ASSOC PROF SCOTT BURROWS

Mapping of an immunodominant viral CD8+ T cell epitope with a

minimal length of 16 residues illustrates the broad peptide length

specifi city of some MHC class I molecules

Frontiers in Immunology Research International Conference, Florence,

Italy, Jul 2008

New Insights into allorecognition 22nd International Congress of the Transplantation Society, Sydney, Aug 2008

Epitope selection in the CD8+ T cell response to Epstein-Barr virus:

The infl uence of a new immune evasion protein and a fussy HLA allele

Brisbane Immunology Group Annual Retreat, Sunshine Coast, Aug 2008

The impact of polymorphism in HLA and TCR Vbeta genes on the

T cell response to herpesviruses

Department of Microbiology and Immunology, University of Melbourne,

Dec 2008

PROF GEORGIA CHENEVIX-TRENCH

Genetic susceptibility to breast cancer NZ Society of Oncology, Christchurch, New Zealand, Nov 2008

Finding breast and ovarian cancer SNPs and the implications for

public health

Australian Health and Medical Research Council, Brisbane, Nov 2008

Current trends in ovarian cancer research International Ovarian Cancer Forum, Montreal, Canada, Sep 2008

Towards an understanding of the genetic architecture of

breast cancer

University of Queensland Diamantina Institute for Cancer, Immunology

and Metabolic Medicine, Brisbane, Nov 2008 and Murdoch Children’s

Research Institute, Melbourne, Nov 2008

Predictors of outcome in the Australian Ovarian Cancer Study University of Chicago, Chicago, USA, Jun, 2009

INVITED LECTURES AND

PRESENTATIONS 2008-2009


DR QIN CHENG

Dissecting drug resistance in Plasmodium vivax Plasmodium vivax and Beyond, Panama city, Panama, May 2009

DR SUYINN CHONG

Modifi ers of epigenetic reprogramming display paternal effects ComBio, Canberra, Sept 2008

A mouse model of fetal alcohol syndrome Griffi th Medical Research College Retreat, Brisbane, May 2009

DR ARCHIE CLEMENTS

Mapping to support malaria elimination in the Asia-Pacifi c region. Asia-Pacifi c Malaria Elimination Network Inaugural Meeting, Brisbane, Feb 2009

Application of spatial epidemiological tools in the era of renewed

neglected tropical disease control: the example of schistosomiasis.

2nd International Symposium on Geospatial Health, New Orleans, USA,

Dec 2008

Geostatistical risk maps as tools for enhanced planning of large-

scale schistosomiasis control in Africa

17th International Congress on Tropical Medicine and Malaria, Jeju, South

Korea, Oct 2008

Spatial heterogeneity of parasite co-infection: determinants and

geostatistical prediction at regional scales

Australian Health and Medical Research Congress, Brisbane, Nov 2008

Spatial epidemiological research: An analytical framework for using

GIS tools – examples from infectious disease modelling in Africa

NSW Health, Epidemiology Special Interest Group meeting, Sydney,

Apr 2009

Malaria mapping Oxford University Malaria Atlas Project Workshop, Oxford, UK, Jul 2008

Bayesian methods in spatial epidemiology London School of Hygiene and Tropical Medicine, London, UK, Mar 2009

Mapping tropical parasitic diseases, relevance to malaria in the Pacifi c Pacifi c Malaria Initiative Meeting, Honiara, Solomon Islands, Aug 2008

DR MARK CLENDENNING

Using MLPA in a research setting HGSA workshop on MLPA and arrayCGH, Brisbane, Apr 2009

DR BRYAN DAY

EphA3 regulates cancer progenitor cell self-renewal and

proliferation in glioma neurosphere cultures

World Federation of Neuro-oncologists, Yokohama, Japan, May 2009

DR DENISE DOOLAN

The role of of immunomics in vaccine development – what and why? Australian Health and Medical Research Congress, Brisbane, Nov 2008

Genome credentialing and vaccine development Griffi th Medical Research College 2009 Retreat, Brisbane, 28 Apr 2009

DR DAVID DUFFY

Faculty Teaching - Computational biology workshop Faculty Teaching - Computational Biology Workshop, Muscat, Oman, Jan 2009

DR CHRISTIAN ENGWERDA

The pathogenesis of experimental cerebral malaria during

Schistosoma mansoni infection

Keystone Symposium, Malaria: Immunology, Pathogenesis and Vaccine

Perspectives, Alpbach, Austria, Jun 2008

Sites of T cell activation in experimental visceral leishmaniasis Comparative Genomics Centre, JCU, Townsville, Nov 2008

The pathogenesis of experimental cerebral malaria Centenary Institute, Sydney, Apr 2009

DR MANUEL FERREIRA

Large-scale genetic approaches to dissect asthma aetiology MEGA Epidemiology, University of Melbourne, Melbourne, Feb 2009

Genetic principles for linkage and association studies Invited Faculty: 22nd International Workshop on Methodology of Twin and

Family Studies, Boulder, Colorado, Mar 2009

Copy number variations: detection and analysis Invited Faculty: 22nd International Workshop on Methodology of Twin and

Family Studies, Boulder, Colorado, Mar 2009


DR KATJA FISCHER

Scabies mite inactivated protease paralogues inhibit human

complement

3rd Annual Conference of the Australian Society for Parasitology and

the ARC/NHMRC Research Network for Parasitology, Glenelg, South

Australia, Jul 2008

Towards a scabies mite genome project Inaugural Scabies Workshop, Darwin, Aug 2008

Scabies mite inactivated protease paralogues inhibit human

complement

22nd International Complement Conference, Basel, Switzerland, Nov

2008

ASSOC PROF MAHER GANDHI

Lymphoma (Chair) Haematology Society of Australia and New Zealand National Conference,

Perth, Oct 2008

Lymphoma biomarkers Haematology / Oncology Targeted Therapies, Melbourne, Sydney, May 2009

DR DON GARDINER

HIV and malaria Australian Society for Microbiology Annual Conference, Melbourne, Jul 2008

The aspartyl aminopeptidase of Plasmodium falciparum Griffi th Medical Research College - 2009 Retreat, Brisbane, Apr 2009

ASSOC PROF GAIL GARVEY

The AMC’s Standards for Indigenous Health: an assessor’s

perspective

Australian Medical Council, Melbourne, Sept 2008

DR MICHELLE GATTON

A biological approach to modeling malaria transmission Swiss Tropical Institute seminar, Basel, Switzerland, 25 Jun 2009

DR MELINA GEORGOUSAKIS

Commensal bacteria as a mucosal delivery system for vaccines

against group A streptococcus

Indian Institute of Science, Bangalore, India, Sept 2008

The science of vaccine development, from bench top to bedside QUT, Pharmacy Undergraduate Students, Brisbane, Aug 2008

The development of a live vaccine against group A streptococcus Australian Heart Foundation, Brisbane, 16 May 2009

A live delivery system for a minimal epitope vaccine against GAS XVII Lancefi eld International Symposium on streptococci and

streptococcal diseases, Porto Heli, Greece, Jul 2008

DR GEOFF GOBERT

Gene expressional changes during the Schistosoma japonicum

lifecycle

Shanghai Veterinary Research Institute, Chinese Academy of Agricultural

Sciences, Shanghai, China, Oct 2008 and

China Human Genome Centre, Shanghai, China, Oct 2008

PROF MICHAEL GOOD

Translating Research into Policy: the role of the National Health and

Medical Research Council

Clinical Research Excellence Conference (CRX08), Brisbane, 7 Aug, 2008

Malaria parasite escape mechanisms and strategies to induce

immunity

ASI IgV-Mitenyi Winter Seminar fo the Peter MacCallum Cancer Centre,

WEHI, Melbourne, Aug 2008

The challenges to control malaria: progress towards a vaccine Australasian Medical Writers Association 25th Anniversary Conference,

Brisbane, Oct, 2008

Translation of public health knowledge into policy: the low cost

option to reduce chronic illness’

APHA 28th National Congress 2008, Adelaide, Oct, 2008

Challenges beyond the subunit paradigm for blood stage malaria

vaccination

NIH, Bethesda, USA, Nov 2008

INVITED LECTURES AND PRESENTATIONS

2008-2009 CONTINUED


Challenges beyond the subunit paradigm for blood stage malaria

vaccination

University of Hawaii, Hawaii, USA, Nov 2008

2020 Australia: priorities for health research and policy Sax Institute Health Policy and Research Exchange, Sydney, Nov 2008

Malaria parasite escape mechanisms and strategies to induce immunity ASI 2008, Canberra, 7-10 Dec 2008

Contributions of women to the research efforts and support of

research at QIMR

International Women’s Day Luncheon hosted by the Queensland Police

Service, Brisbane, Mar 2009

Progress with malaria vaccines – are we learning from history? NIAID Workshop: Immunology of Malaria, Washington, USA, Mar 2009

Early development of a GMP grade whole blood challenge facility Malaria Blood-Stage Challenge Workshop, Bethesda, Washington, USA,

Mar 2009

Welcome and overview Public Forum - Mosquito and Man: an unhealthy relationship, Brisbane,

Apr 2009

Promises and challenges in developing new vaccines, with a focus

on diseases of the developing world

Public Lecture, World Day of Immunology 2009, ANU, Canberra, Apr 2009

Rationale and strategy for a whole organism vaccine for the blood

stages of malaria

MALVAC 2009 Meeting – WHO Scientifi c Forum on Malaria Vaccines:

Progress and Challenges in Development of Whole Organism Malaria

Vaccines for Endemic Countries, Dakar, Senegal, Jun 2009

Manufacture and testing of a whole blood stage vaccine MALVAC 2009 Meeting – WHO Scientifi c Forum on Malaria Vaccines:

Progress and Challenges in Development of Whole Organism Malaria

Vaccines for Endemic Countries, Dakar, Senegal, Jun 2009

PROF JEFF GORMAN

Analysis of post-translational modifi cations on signal-activated

transcription factors

St Vincent’s Institute, Melbourne, May 2009

Post-Translational Surprises on Mammalian Signal Activated

Transcription Factors

CSIRO Health and Molecular Technologies, Melbourne, May 2009 and

American Society for biochemistry and Molecular Biology, Special Symposium

on Post-Translational Modifi cations, Granlibakken, USA, Oct 2008

PROF ADÈLE GREEN

1. Ganesapillai Memorial Lecture, Diet and photoprotection

2. Skin Cancer and other protection measures

3. Melanoma – causes and prevention

33rd Dermatological Society of Malaysia Dermatology Congress, Kuala

Lumpur, Malaysia, Aug 2008

Assessing sun exposure as a cause of skin cancer Dermatology Dept , Leiden University Medical Center, Leiden, The

Netherlands, Apr 2009

1. Sunscreens- do they have a role in photoprotection?

2. Overview of skin cancer incidence and association with sun exposure

World Congress of Cancers of the Skin, Tel Aviv, Israel, May 2009

1. 20 year Australian study of skin cancer and the role of

sunscreen and foods

2. 20 year Australian study of skin cancer and Photoageing

L’Oreal Research, Paris, France, May 2009

Obesity and Cancer and Illustration: Oesophageal cancer University of Manchester, Manchester, UK, May 2009

Photoprotection and actinic skin tumours L’Oreal Research, Paris, France, May 2009

DR ELKE HACKER

The adventures of science High School Awards Night, Cooroy, Nov 2008

My journey so far Orientation Welcome, Sunshine Coast, Feb 2009


PROF DAVID HARRICH

The repressor of reverse transcription is critical for HIV-1 infectivity

and replication

HIV and Hepatitis Meeting, Terrigal, NSW, Jun 2009

PROF NICK HAYWARD

Finding new low penetrance melanoma predisposition genes: is it

all about pigmentation?

Hunter Medical Research Institute Conference on Translational Cancer

Research: Pathways to Tailored Therapies, Newcastle, Sept 2008

Identifying new low penetrance melanoma predisposition genes: is

it all about skin phenotypes?

Lorne Cancer Conference, Lorne, Australia, Feb 2009

Molecular genetics of melanoma: are all low penetrance

susceptibility genes related to skin phenotypes?

12th World Congress on Cancers of the Skin, Tel Aviv, Israel, May 2009

PROF GEOFF HILL

Infl ammation in transplantation American Society of Bone Marrow Transplantation, Tampa Bay, USA,

Feb 2009

NKT cell activation in transplantation Invited Lecture, Memorial Sloan Kettering Cancer Center, New York City,

USA, May 2009

Cytokine dependent manipulation of GVHD and GVL responses World Transplant Congress, Plenary speaker. Sydney, Aug 2008

DR MALCOLM JONES

Tissue specifi c profi ling of the human pathogen Schistosoma

japonicum by integrated laser microdissection microscopy and

microarray analysis

International Congress of Tropical Medicine and Malaria, Jeju, Korea, Oct

2008

PROF BRIAN KAY

Astounding success in controlling Aedes aegypti using community-

based biological control in Vietnam

XXIII International Congress of Entomology, Durban, South Africa, Aug 2008

Chair, PMSEIC Expert Working Group on Epidemics in a

changing world

Prime Minister’s Scientifi c, Engineering and Innovation Council, Canberra,

Jun 2009

Grand Challenges for Global Health Third Annual meeting- Grand Challenges for Global Health, Bangkok,

Thailand, Oct 2008

Astounding success in controlling Aedes aegypti using community-

based biological control in Vietnam- an update on progress

Second international Conference on Dengue and Dengue Haemorrhagic

Fever, Phuket, Thailand, Oct 2008

PROF DAVE KEMP

Molecular work on scabies Inaugural Scabies Workshop, Darwin, Aug 2008

DR KUM KUM KHANNA

Evolutionary conserved single stranded DNA binding proteins

critical for genomic stability

Tolmac Symposium: early steps in DNA damage detection, St Louis, USA,

Oct 2008

hSSB1 and genome maintenance International Conference in Radiation Biology & Translational Research in

Radiation Oncology, India, Jaipur, Nov 2008

Signalling and repair of DNA damage Australian Health and Medical Research Congress, Brisbane, Nov 2008

Defective DNA damage Response and cancer susceptibility Seminars at Institute of Molecular and Cell Biology, Singapore, Nov 2008 and

Hong Kong University of Science and Technology, Hong Kong, Apr 2009

Coping with DNA damage to maintain genomic stability Second Australia-China Biomedical Research Conference, Tianjin, China,

24-27 Apr 2009

ASSOC PROF RAJIV KHANNA

Host cellular defence against EBV NIH/NCI, Bethesda, USA, Sep 8-9 2008


2008-2009 CONTINUED


Vaccines and diagnostics International CMV consensus meeting for Solid Organ Transplant patients,

Paris, France, Dec 2008

Collaborative research in medical biotechnology Queensland Government Delegation for Queensland-India Dialogue, New

Delhi, India, April 6-9, 2009

Translation of herepesvirus immunology from bench to bedside John Curtin School of Medical Research, Canberra, Apr 2009

PROF MARTIN LAVIN

A central role for ATM in the DNA damage response St Vincents Medical Research Institute Conference, Melbourne, Jun 2008

ATM/Rad50/SMC-1: A novel signalling pathway for DNA repair and

cell cycle checkpoint control”

International Conference on Genome Stability in Health and Disease,

Jerusalem, Israel, Sept 2008

Mitochondrial defects in autosomal recessive ataxias AussieMit Workshop, Melbourne, Nov 2008

Rad50 mediates the DNA damage response Friedrich Ataxia Research Association, Melbourne, Nov 2008

Role of ATM in the DNA damage response to minimise the risk of

cancer and neurodegenerative disease

Australian Chinese Association for Biomedical Sciences 2009, Tianjin,

China, Apr 2009

Rad50 mediates the DNA damage response 11th International Wolfsberg Meeting on Molecular Radiation Biology/

Oncology, Wolfsberg, Switzerland, Jun 2009

PROF BARBARA LEGGETT

Prophylactic vaccine for human cytomegalovirus MedImmune, San Jose, California, USA, May 2009

Colorectal Cancer: understanding the pathways of tumourigenesis

to improve prevention and treatment

Inaugural Queensland Institutes of Health Forum, Caloundra, Aug 2008

Genetics of colorectal cancer Asia Pacifi c Digestive Week, New Delhi, India, Sep 2008

Molecular pathogenesis of serrated polyps Digestive Diseases Week, Chicago, USA, Jun 2009

Assoc Prof Alejandro López

Células Madres Cancerígenas en Inmunoterapia contra el Cáncer

del Seno

Universidad de Antioquia, Medellin, Colombia, Dec 2008

Breast cancer stem cells as targets for immunotherapy Griffi th Medical Research College Retreat, Brisbane, Apr 2009

DR KELLI MACDONALD

Bone marrow transplantation, where are we in 2009? Capricornia Medical Conference, Rockhampton, Jun 2009

SOCS3 regulates GVHD Tolerance and Autoimmunity, Antigua, West Indies, May 2009

DR STUART MACGREGOR

Effect and admixture on Norfolk Island Gold Coast Health and Medical Research Congress, Gold Coast, Nov 2008

Prof James McCarthy

Anthelmintic resistance in soil transmitted helminths American Society for Tropical Medicine and Hygiene, New Orleans, USA,

Dec 2008

Helminth infections: What’s new in treatment Interscience Conference of Antimicrobial Agents and Chemotherapy,

Washington DC, USA, Oct 2008

Operational research priorities for malaria elimination Australian Health and Medical Research Congress, Brisbane, Nov 2008

PROF DON MCMANUS

Current status of Schistosomiasis Vaccine Program. XV11th International Congress for Tropical Medicine and Malaria, Jeju,

Korea, Sept/Oct 2008

Dog vaccination against echinococcosis Workshop on Current Diagnosis, Treatment and Control of Cystic

Echinococcosis, University of Peru, Lima, Peru, Mar 2009


DR DAVID MCMILLAN

Vaccines for group A streptococcus JCU undergraduate students, Townsville, Jul 2008

A mucosal vaccine for group A streptococcus QUT undergraduate students, Brisbane, Sept 2008

MS KATE MARKEY

Conventional dendritic cells are the critical donor APC presenting

alloantigen after experimental BMT.

European Bone Marrow Transplantation Society Annual Meeting,

Gothberg, Sweden, Mar 2009

PROF NICK MARTIN

Genetics of complex diseases Human Genetics Society of Australasia, Adelaide, Aug 2008

GWAS for moliness 21st Twin Analysis Workshop, Leuven, Belgium, Aug 2008

G x E for depression? David Hay Festschrift Symposium, Perth, Nov 2008

Genetic approaches to anorexia and bulimia Butterfl y Foundation, Eating Disorders Symposium, Sydney, Nov 2008

The GWAS revolution Australian Academy of Science, Queensland Branch, Brisbane, Nov 2008

GWAS for CVD risk factors Nordic Countries Biobank Consortium, Groningen, Holland, Dec 2008

Genetics of quality of life indicators Faculty Mayo Clinic – Wellbeing Consortium Meeting, Rochester, MN, Feb 2009

Hunting QTLs Invited Faculty : 22nd International Workshop on Methodology of Twin &

Family Studies, Boulder, Colorado, Feb 2009

The GWAS revolution Australian Academy of Science, Queensland Branch, Townsville, Mar 2009

GWAS for depression and alcoholism Royal Australian College of Psychiatry meeting, Adelaide, May 2009

Genetics of cognition Bouchard Festschrift Symposium, Minneapolis, USA, Jun 2009

GWAS for personality Behaviour Genetics Association, Minneapolis, USA, Jun 2008

DR SARAH MEDLAND

1. Introduction to Mx

2. Linkage and association analysis using Mx

3. Linkage analysis, MERLIN

4. Multivariate association

Invited Faculty : 22nd International Workshop on Methodology of Twin

and Family Studies, Boulder, USA, Mar 2009

MS ANGELA MIKA

Scabies mite serpins Inaugural Scabies Workshop, Darwin, Aug 2008

PROF GRANT MONTGOMERY

Genetic architecture of common complex diseases MMRI Mucosal Disease Symposium, Mater Hospital, Australia, Oct 2008

Genomics and genetic architecture in common complex diseases Institute of Molecular Biosciences, University of Queensland Brisbane,

Oct 2008

Genetic architecture of common complex diseases Children’s Medical Research Institute, The Children’s Hospital at

Westmead, Mar 2009

New genetic technologies and twin research Australian Twin Registry Workshop, Sydney, Apr 2009

MR BRIAN MORRISON

Characteristics of breast cancer stem cells. Australian Health and Medical Research Congress – Epithelial

Development and Differentiation Symposium, Brisbane, Nov 2008

DR MIRIAM MOSING

Lecture : Available Australian Twin Data Faculty Mayo Clinic – Wellbeing Consortium Meeting, Rochester, MN, Feb 2009

PROF BRYAN MOWRY

Plenary speaker International Conference on Schizophrenia Research Chennai, India, Oct 2008


2008-2009 CONTINUED


MS MICHELLE NELLER

Ex vivo analysis of effective T cell responses against advanced

melanoma

EMBO Advanced cytometry and cell sorting training course, Berlin,

Germany, Jul 2008

DR JAMIE NOURSE

EBV microRNAs in PTLD European Haematology Association, PTLD meeting, Berlin, Germany, Jun 2009

DR DALE NYHOLT

Selected participant for 2008 Theo Murphy High Flyers Think Tank

on Preventative Health

Convened by Australian Academy of Science 2008, Sydney, Nov 2008

DR COLLEEN OLIVE

Expression of dendritic cell maturation markers in response to

lipid-core peptide group A streptococcal vaccines

Sixth World Congress on Vaccines, Immunisation and Immunotherapy,

Milan, Italy, Sep 2008

PROF LAWRIE POWELL

Haemochromatosis - 2008 Update Czech Hepatology Society, Prague, Czech Republic, Aug 2008

Iron overload in the Asia-Pacifi c region Asia-Pacifi c Association for the Study of the Liver, Hong Kong, China, Feb

2009

ASSOC PROF GRANT RAMM

Plenary Session Chair on Haemochromatosis BioIron 2009: World Congress on Iron Metabolism, Porto, Portugal, Jun 2009

Research as a career for physician scientists – career planning,

mentoring choices and funding opportunities

National Scientifi c Conference of Gastroenterological Society of Australia,

Brisbane, Oct 2008

Stem cells in liver development and HCC Schering-Plough AASLD 2008 Meeting, Brisbane, Nov 2008

Lymphotoxin-beta signalling in stellate cells: relationship to

infl ammation, regeneration and progenitor cells

Opportunities in Liver Infl ammation and Cancer Symposium, Centenary

Institute, Sydney, Jun 2009

MS SIMONE REYNOLDS

Scabies mite inactivated protease paralogues Inaugural Scabies Workshop, Darwin, Aug 2008

DR CHRIS SCHMIDT

Stage IV melanoma patients responding clinically to DC

immunotherapy mount T cell responses against multiple tumour

epitopes

Australian Health and Medical Research Congress, Brisbane, Dec 2008

Enabling melanoma research with validated cell lines Australasian Biospecimen Network, Sydney, Nov 2008

MR HARAN SIVAKUMARAN

Arginine methyaltion increases the stability of HIV-1 Tat Retroviruses Meeting, Cold Spring Harbor, USA, May 2009

DR TINA SKINNER-ADAMS

HIV and malaria co-infection: interactions and consequences of

chemotherapy

La Trobe University, Melbourne, Jul 2008

High-throughput screening in Parasitology: The Plasmodium

falciparum aminopeptidases

The Australian Health and Medical Research Congress, Brisbane, Sept 2008

DR KEVIN SPRING

CpG Island methylator phenotype in serrated polyps of the

colorectrum

Peter MacCallum Symposium – Cancer Epigenetics, Wilson’s

Promontory, Victoria, Oct 2008

DR AMANDA SPURDLE

Role of bioinformatic analysis for prediction of splicing aberrations IARC Unclassifi ed Variants in Mismatch Repair Genes Workshop, Lyon,

France, Feb 2009


Evaluation of mismatch repair gene unclassifi ed sequence variants Queensland Clinical Genetics Service Inservice Training Meeting,

Brisbane, Nov 2008

Breast cancer genetics – current state of the fi eld Australian Health and Medical Research Congress 2008, Nov 2008

PROF KADABA SRIPRAKASH

Group A Streptococcus – can horizontal gene transfers explain

changes in epidemiology?

Society for Pediatric Infectious Diseases Meeting, Brussels, Belgium,

11 Jun 2009

DR AMANDA STANLEY

Important roles for liver APC and LIGHT during experimental

visceral leishmaniasis

University of York, York and University of Manchester, Manchester, UK,

Dec 2008

ASSOC PROF ANDREAS SUHRBIER

A clinical trial and 12 year follow up of a peptide-based vaccine for

Epstein Barr virus-induced glandular fever

Australian Society for Microbiology Conference, Melbourne, Jul 2008

Commercial contract research for the real world QUT Research Boot Camp Program, Brisbane, Aug 2008

Ticks associated with Macquarie Island penguins carry arboviruses

from four genera

8th Mosquito Control Association of Australia International Conference,

Coffs Harbour, Sep 2008

DR KATHARINE TRENHOLME

Sex in Plasmodium : A sign of commitment Institute for the Biotechnology of Infectious Diseases, Sydney, Nov 2008

Starving malaria parasites to death : Aminopeptidase enzymes as

potential targets for the development of antimalarial drugs

Rotary against Malaria Conference, Caboolture, May 2009

DR PATRICIA VALERY

High prevalence of metabolic syndrome among youth of the Torres

Strait Islands of Australia

Brisbane Winter Endocrine Symposium, Brisbane, Jul 2008

PROF PETER VISSCHER

Prediction of individual genetic risk to disease Lorne Genome, Lorne, Feb 2009

GWAS for schizophrenia ANU, Canberra, Mar 2009

Statistical aspects of the prediction of risk to disease from marker data University of Alabama, Birmingham, USA, Jun 2009

DR MEAGAN WALSH

The role of host factors in non-response to antiviral therapy in

patients with chronic Hepatitis C

Australian Society for Medical Research, Student Conference, Brisbane,

May 2009

DR MICHAEL WALSH

Does expression of the gastric mucin MUC6 help identify

advanced serrated colorectal polyps?

Clinicians, Auckland Hospital, Auckland, NZ, Apr 2009

DR DAVID WARRILOW

A host cell factor may stabilize the HIV reverse transcription complex Retroviruses Meeting, Cold Spring Harbor, USA, May 2009

ASSOC PROF PENNY WEBB

Ethical issues surrounding informed consent and the use of

biospecimens for future unspecifi ed analyses

45 and Up Study Workshop, Sydney, Jul 2008

Confounding Postgraduate Epidemiology Program, Brisbane, Aug 2008

Epidemiology Panel member Greater Metropolitan Clinical Taskforce: Clinical Forum on ovarian cancer,

Sydney, Oct 2008


2008-2009 CONTINUED


DR VICKI WHITEHALL

Pathways of colorectal tumourigenesis AHMRC, Brisbane, Nov 2008

Bowel cancer: prevention to cure Rotary BowelScan Launch, Brisbane, Feb 2009

PROF EMMA WHITELAW

A screen for modifi ers of epigenetic reprogramming Queenstown Molecular Biology Meeting, Queenstown, New Zealand,

Sept 2008

Epigenetics and human health NHMRC Spring Council Dinner, Canberra, Sept 2008

Cancer Epigenetics Peter MacCullum Cancer Centre workshop, Wilsons Promontory, Oct, 2008

Epigenetic reprogramming in development IMB Institute seminar, Brisbane, Nov 2008

Epigenetics and disease Australian Pediatrics and Endocrinology annual meeting, Canberra,

Nov 2008

Epigenetics and obesity Australian Health and Medical Research Congress, Brisbane, Nov 2008

and Keystone Symposia on obesity, Banff, Canada, Jan 2009

The role of epigenetics in development Hanson Institute seminar, Adelaide, Apr 2009

Intangible variation 7th Gene mappers conference, Katoomba, Apr 2009

Genetics to Epigenetics James Cook University, Townsville, Apr 2009

Intangible variation in mammals John Curtin School of Medicine, ANU, Canberra, May 2009

An ENU screen for modifi ers of epigenetic reprogramming MRC Human Genetics Unit, Edinburgh, UK, May 2009

Epigenetics in development Epigenetics and Development, Gotteborg, Sweden, May 2009

An ENU screen for modifi ers of epigenetic reprogramming Japanese Society of Developmental Biology, Niigata, Japan, May 2009

and RIKEN Institute seminar, Yokohama, Japan, Jun 2009

Epigenetics and the innate/acquired distinction International Society for History, Philosophy and Social Studies of Biology,

University of Queensland, Brisbane, Jul 2009

ASSOC PROF DAVID WHITEMAN

Man and cancer Cancer Council WA, Perth, Jul 2008

Upper gastrointestinal cancers Clinical Oncological Society, Sydney, Nov 2008

Obesity and cancer AHMRC, Brisbane, Nov 2008

Men and cancer Queensland Department of Tourism, Mt Isa, Nov 2008

Is melanoma caused by genes or environment? World Congress of Melanoma, Vienna, Austria, May 2009

DR JOHN WHITFIELD

Genotyping in common metabolic dieases and toxicology 18th IFCC-FESCC European Congress of Clinical Chemistry and

Laboratory Medicine, Innsbruck, Austria, Jun 2009

DR DANIEL WORTHLEY

DNA methylation throughout the human colorectum: person, place

and pathology.

AHMRC, Brisbane, Nov 2008

Donor determined mannose-binding lectin defi ciency increases the

likelihood of clinically signifi cant infection after liver transplantation.

Invited speaker at the Royal Australasian College of Surgeons, Annual

Scientifi c Congress, Brisbane, May 2009

DR NAOMI WRAY

The race to fi nd genes for anxiety and depression QIMR retreat, Queensland, Sep 2008 and Orygen Research Centre,

Melbourne, Sep 2008


The impact of co-morbidity between anxiety and depression

disorders on the analysis of genome-wide association studies

Symposium of the World Congress of Psychiatric Genetics, Osaka,

Japan, Oct 2008

Selected Participant : 2008 Theo Murphy High Flyers Think Tank

on Preventative Health

Convened by Australian Academy of Science, Sydney, Nov 2008

Towards an understanding of the genetic architecture of psychiatric

disorders

Brain and Mind Research Institute, Sydney, Dec 2008

From Genome-wide Association Studies to Prediction of Genetic Risk Griffi th Medical Research College, Brisbane, Apr 2009

Genetic evidence for a shared etiology of affective and psychotic

disorders

Eli Lilly Cutting Edge Symposium, Melbourne, May 2009

DR MARGIE WRIGHT

Optimism and its link to health in older Australian twins International College of Geriatric Psychoneuropharmacology, Sydney, 5

Sept 08

A genetics primer for geriatric psychiatry – beginning the era of

personalised medicine

AAGP 2009 Annual Meeting Honolulu, Hawaii, USA, Mar 09.

ASSOC PROF JOANNE YOUNG

Serrated polyposis Colorectal Cancer Summit, Cleveland, Ohio, USA, Sept 2008

Heterogeneity in hyperplastic polyposis may have a genetic basis Peter Macallum Cancer Epigenetics Workshop, Tidal River, Australia,

Nov 2008

Serrated neoplasia: genetics and environment AHMR Congress, Brisbane, Nov 2008

Importance of stratifi cation in colorectal cancer gene discovery GWAS Working Group Colon CFR, Santa Monica, California, USA,

Jan 2009

Serrated neoplasia families Memorial University of Newfoundland Discipline of Genetics, St John’s,

Canada, Mar 2009

DR WENBAO ZHANG

Control of echinococcosis in China Workshop on Current Diagnosis, Treatment and Control of Cystic

Echinococcosis, University of Peru, Lima, Peru, Mar 2009


2008-2009 CONTINUED


DIRECTOR

M F Good AO BSc(Med) MBBS(Hons)

PhD MD DSc FASM FAFPHM

FRACP(HON) FAIM

DEPUTY DIRECTOR

A C Green MBBS MSc PhD AC

GENERAL MANAGER

J Tarr BA JD LLM PhD

CHIEF COMMERCIAL MANAGER

D Hancock BComm MBA

ASSISTANT DIRECTORS

A W Boyd (UQ) BMedSc(Hons) MBBS PhD

FRACP

M F Lavin (UQ) BSc(Hons) PhD

EXECUTIVE SECRETARY TO DIRECTOR

J Black

Administrative Support to Director

T Checkley

EXECUTIVE OFFICER

N Karger BSc MBA (to Feb 09)


Division Chair: E Whitelaw

A Green MBBS MSc PhD AC

T Ahmed MBBS MPH (to Aug 08)

L Braatvedt BSc MSpeechPath

R Cicero BA

T Corish RN

J Doecke BSc(Hons) PhD (to Sep 08)

P Fahey BSc(Stats) MMedStats

L Gordon BEcon MPhil PhD

R Grealy BBiomedSc(Hons)

L Green RN

N Hirst BEcon BCom

M Hughes BS MMedSc

L Jackman BSc(BusAdmin)

J Jetann BNursing

T Lawton

V Logan

T Luong AssocDipArts/Photograghy

K Mallitt BSc(Hons)

L Marquart BSc BEcon

F Millar BNursing

R Neale BVSc PhD

P O’Rourke BSc(Hons) BA(Hons) PhD GCEd

P Parmar BSc MSc

D Simmonds BNurs MPH

V Siskind BSc PhD

P Valery MD MPH PhD

J Van der pols BSc MSc PhD

B Waters BAppSc MPhil

INDIGENOUS HEALTH RESEARCH

G Garvey Bed MEd

E Anderson

W Anderson

S Anderson

J Cavanagh CertEducationSupport BTheology

V Clements MAppEpi

V Harrhy BSc

C Jacka

R Mobbs BA(Hons) (to Sep 08)

C Suey (to Feb 09)

CANCER CONTROL

D Whiteman BMedSc MBBS(Hons) PhD

A Antonsson MBBS(Hons) PhD

C Baxter BA

H Carroll MBBS MPH

M Davis MD MPH

K Harrap BInfoTech

C Hill BN

J Mayhew RN (to Dec 08)

A McMurtrie BNursing

S O’Brien BNursing MPH

C Olsen BSc(Hons) PhD

N Pandeya BSc GradDipAppSc MMedSc

S Perry BAppScNurs MEnvirCommHlth

BEnvirHlthSc

B Ranieri

CANCER GENETICS

G Trench BSc(Hons) PhD

J Arnold BSc(Hons) PhD (to Aug 08)

J Beesley BSc(Hons) PhD

X Chen BMed

S Healey BSc DipEd BAppSc

H Holland BHlthSc(Hons)

J Jayanthan BSc(Hons) (to Mar 09)

S Johnatty MSc PhD

C Johnstone BSc(Hons) PhD (to Jan 09)

S Kugler

A Marsh BSc(Hons)

N Waddell BSc(Hons) PhD

EPIGENETICS

E Whitelaw BSc(Hons) PhD

A Ahola MSc

A Apedaile BSc(Hons) MSc PhD

A Ashe BSc(Hons) PhD (to Mar 09)

S Chong BAppSc(Hons) PhD

T Epp BSc(Hons) MSc PhD

E Lambley BSc(Hons)

D Morgan BSc(Hons)

S Young BAppSc(Hons)

N Youngson BSc(Hons) PhD


QIMR STAFF 2008-2009

FAMILIAL CANCER

J Young GradDipBiotech MAppSc PhD

S Arnold BSc(Hons) (to Nov 08)

D Buchanan BSc(Hons)

M Clendenning BSc(Hons) PhD

M Mckeone (to May 09)

D Mckeone AssocDipLabTech

E Pavluk BSc DipEd GradDipZoo

S Pearson AssocDipBioLabTech

A Roberts BSc(Hons)

M Walsh BAppSc

R Walters BAppSc

L Young (to May 09)

GENETIC EPIDEMIOLOGY

N Martin BSc(Hons) PhD FASSA FAA

J Atherton (to Aug 08)

H Beeby BSc(Hons)

L Boettcher (to Dec 08)

J Brodie (to Dec 08)

M Caffrey

J Cochrane BBus(HRM&IndRel)

M De Nooyer BPsych(Hons)

A Dormer AssocDipArts

D Duffy MBBS PhD

T Dumenil BAppSc MAppSc

G Dwyer BHlthSc

A Eldridge RN

J Evans AssocDipBus

M Ferreira PhD

S Fox BSc

M Ferguson

N Garden BSc(Psych)(Hons)

N Gillespie BA(Hons) PhD (to Feb 09)

S Gordon BEng(Hons) PhD

M Grace RN

L Grey BSc

M Grimmer Bsc(Psych)(Hons) MSc(OccPsych)

(to Mar 09)

T Gunasekera BSc(Biotech)(Hons) (to Apr 09)

H Handoko BSc MSc PhD

K Hanigan BSc(Pub Health)

N Hansell BSc(Hons) PhD

D Hickey AssocDipArts

N Huang BAgSc MAppSc

L Hume BA MA PhD

F Husband (to Aug 08)

T Hyam AdvDipAppSc CertHlthCareAss

(to May 09)

M Ikonomopoulou BSc(Hons) MSc PhD

S Jamali BA BBusMgt BHealthSc

M James BSc(Hons) MSc PhD

C Jaremczuk BA(Psych) GradDipProfPsych

K Krishnaprasad BEngineer

C Laizans

A Lin BMedSc

E Mallon

K McAloney BCommerce

S McCoombe

J Medhurst BBus DipHort

S Medland BA(Psych)(Hons) PhD

R Middelberg BSc(Hons) PhD

E Miller BBehavSc(Hons)

N Moghbelpour BSc(Psych) GradDipPsych

MInternatPubHlth

J Moir BSc BA

J Morrissey

L Nunn DipTeaching

H Park GradDipRehab MHumServs

D Park

R Parker BPsych(Hons)

C Pink

C Pretsel

L Rasmussen (to Aug 08)

C Redfern BA(Psych)(Hons) (to Aug 08)

S Rodda BSocSc MA

L Ryan BSc(Hons) (to Feb 09)

S Shekar BSc(Hons) PhD

P Shertock

L Simms BSc(Hons)

C Singer BA(Soc) MInfMgtSys

D Smyth BEngineer(Hons)

A Somerville BA

D Statham BA(Hons) MClinPsych

L Sullivan BA

H Taylor

A Toivanen BPsych(Hons)

K Watson

K White AdvCertArts

J Whitfi eld BSc(Hons) MSc PhD FRCPath FRACB

L Winkler

J Wood

N Wray BSc(Hons) MSc PhD

M Wright BSc(Hons) PhD

O Zheng DipInfoTech

G Zhu BSc(Med) MPH

GYNAECOLOGICAL CANCER

P Webb MA PhD

B Alexander RN BNursing

V Beesley BHlthSc(Hons) PhD

S Brown RN BA

J Griffi th

K Ibiebele BSc MPHSocialSc PhD

QIMR STAFF 2008-2009 CONTINUED


F Kolahdooz BSc MSc GradDipPubHlth

M Malt EN BBus

K Martin RN BHlthAdmin

C Nagle BAppSc PhD

D Roffe RN

J White RN

MOLECULAR CANCER EPIDEMIOLOGY

A Spurdle BSc MSc PhD

K Ferguson

F Lose BSc(Hons) PhD

M O’Brien

C Paterson BSc

P Schultz (to Dec 08)

B Thompson BSc(Hons)

L Walker BSc MSc PhD

S Webb BNursing

P Whiley BSc(Hons)

MOLECULAR EPIDEMIOLOGY

G Montgomery BAgSc(Hons) PhD

L Bowdler BAppSc

M Campbell BAppSc

N Campbell BSc MSc

A Caracella BSc

B Chapman BAppSc

S Crooks BSc GradDipClinMicrobiol

A Henders BSc(Hons)

L Le BSc(Hons) MSc (to Dec 08)

M Lin BMed MSc

P Lind BSc(Hons) PhD

J Painter BSc(Hons) PhD

K Patel BSc(Hons) GradCert Immunology

M Richter BAppSc

S Smith BBioSc(Hons)

S Thomas BSc

L Wallace BBiomedSc

GradDipGeneticCounsel

C Zhang BSc

Z Zhao MDentSc PhD

MOLECULAR PSYCHIATRY

C Lendon BSc(Hons) PhD

A Pritchard BMedSc(Hons) PhD

NEUROGENETICS

D Nyholt BSc(Hons) PhD

HUMAN GENETICS

N Hayward BSc MSc(Qual) PhD

L Aoude BA BEng

M Auret BSc(Hons) PhD

V Bonazzi PhD

K Loffl er BSc(Hons) PhD

D Nancarrow BSc MSc(Qual) PhD

L Packer BSc(Hons) PhD

J Palmer RN

E Planas Rigol BSc (to Aug 08)

M Stark BAppSc(Hons)

J Symmons BBus RN

S Tyagi MSc PhD

QUEENSLAND STATISTICAL GENETICS

P Visscher BSc MSc PhD

B Benyamin BAgrSc(Hons) MAgrSc PhD

H Lee Bagr MAgr PhD

S MacGregor BSc MSc PhD

B McEvoy BA(Hons) PhD

A McRae BSc(Hons) PhD

J Yang BSc PhD


Division Chair: G Anderson

DRUG DISCOVERY GROUP

P Parsons BSc(Hons) PhD

G Boyle BSc(Hons) PhD

J Johns BSc(Hons)

A Martyn BSc(Hons) (to Dec 08)

L Maslovskaya PhD

J Pedley BSc

C Pierce BBioMedSc(Hons)

J Shan BSc MEngineer PhD (to Dec 08)

HEPATIC FIBROSIS

G Ramm BSc(Hons) PhD

M Bertrand-Philippe MSc PhD

D Hoang-le BSc(Hons)

T Pereira BSc(Hons) PhD

L Ramm BSc

D Rowsell BSc(Hons)

R Ruddell BSc(Hons) PhD

M Walsh BSc(Hons) PhD

IRON METABOLISM

G Anderson BSc(Hons) MSc PhD

D Darshan MBBS MAppSc PhD

J Dixon RN BA(Hons) MPH

D Frazer BAppSc(Hons) PhD

J Ghazali BNursing

C McDermott BSc(Hons) PhD (to May 09)

L Powell AC FTSE MBBS MD PhD D

Univ(Griff) FRCP FRACP

L Rawlings

V Shaw

T Steele BSc(Hons)

A Sue tin (to Mar 09)

S Wilkins BSc(Hons)


LEUKAEMIA FOUNDATION

A Boyd BMedSc(Hons) MBBS PhD FRACP

S Charmsaz BBiotech MBiotech

K Chen BSc (to May 09)

B Day BAppSc BSc(Hons) PhD

C De Bock BSc MSc PhD

S Duffy BSc(Hons) PhD (to Jun 09)

K Ensbey BBehavSc BSc

N Herath BSc(Hons) PhD

P Jamieson BA BSc(Hons)

E Lau BSc GradDipSc

K Miller BSc

N Neijman DipMedBiol (to Jul 08)

F Smith BAppSc

M Spanevello BAppSc(Hons) PhD

S Stein BAppSc

B Stringer BMedSc MBBS PhD

T Yeadon BSc(Hons) PhD

MEMBRANE TRANSPORT

N Subramaniam BSc MSc PhD

E Crampton BSc(Hons) PhD (to Oct 08)

C McDonald BSc(Hons) PhD

L Summerville BSc GradDipClinBiochem

D Wallace BSc(Hons) MSc PhD

CCQ TRANSGENICS

G Kay BSc(Hons) PhD

D Carrie BSc

A Mould BSc(Hons) PhD

J Pang BBiotech MBiotech

I Tonks BSc(Hons) PhD

RADIATION BIOLOGY AND ONCOLOGY

M Lavin BSc(Hons) PhD

O Becherel BSc MSc PhD

G Birrell CertBioTech MMedSc PhD

(to Nov 08)

M Buck DipMedTech

P Chen BSc MSc PhD

J Cullen BSc(Hons) PhD

S Earl BBiotech(Hons) PhD

A Farrell NCEA CertAppSc

M Gatei BSc PhD

A Kijas BBiotech(Hons) PhD

S Kozlov MSc PhD

J Luff CertVetNurs/AnimalCare

T Roberts BSc(Hons) PhD

R Stirling BSc(Hons) PhD

A Suraweera BSc(Hons) PhD

M Trabi BSc(Hons) PhD

RBWH GASTROENTEROLOGY

B Leggett MBBS (Hons) MD FRACP

K Banducci BAppSc(Hons)

W Fernando BTech MMolecBiol

S Greco BSc

S Nayler BAppSc(Hons)

I Ramsnes BBusInfoSys BSc (to Jan 09)

C Rickman BSc(Hons)

J Robinson BSc(Hons) PhD

K Spring BSc PhD

SIGNAL TRANSDUCTION

K Khanna BSc MSc PhD

E Bolderson BSc(Hons) PhD

D Boucher DipHlth MRadBiol PhD

K Hobson BSc(Hons) (to Dec 08)

J Jeffery BSc(Hons) PhD

S Miles AssocDipAppBiol

J Pagan BSc(Hons) PhD (to Oct 08)

L Papp BSc(Hons)PhD

M Parish

D Richard BSc(Hons) PhD

M Shariff BSc(Hons) MPhil (to Dec 08)

W Shi BMed MSc PhD

A Urquhart BSc(Hons) PhD

A Van der Horst BBioMedSc PhD

SKIN CANCER CARCINOGENESIS

G Walker BSc MSc(Qual) PhD

B Ferguson BSc

IMMUNOLOGY DIVISION

Division Chair: G Hill

BONE MARROW TRANSPLANTATION

G Hill BHB MBChB FRCPA FRACP MD

T Banovic MD MMedSc

P Bunn

A Don BSc(Hons)

M Koyama MD PhD

R Kuns BSc(Hons)

K Macdonald BSc(Hons) MSc PhD

S Olver BSc(Hons)

N Raffelt BSc(Hons)

A Varelias BAppSc PhD

Y Wilson BAppSc(Hons)

CANCER IMMUNOTHERAPY

C Schmidt BSc(Hons) PhD

K Ellem BSc(Med) MBBS PhD AO

X Huang BMed PhD

C Lanagan BBiomedSc(Hons)

L O’connor AssocDegAppSc

CELLULAR IMMUNOLOGY

S Burrows BSc PhD

M Bell BSc(Hons)

J Burrows BSc GradDipTeaching

J Miles BSc(Hons) PhD



M Neller BAppSc

S Silins BSc(Hons) PhD

CLINICAL IMMUNOHAEMATOLOGY

M Gandhi MBChB FRACP FRCP FRCPath PhD

P Crooks BSc(Hons)

E Han BMed MMed

K Jones BSc(Hons)

J Nourse BSc DipSc MSc PhD

S Singh BSc MSc(Qual) (to Jun 09)

F Vari BSc(Hons) PhD

DENDRITIC CELLS AND CANCER

A Lopez MD

EBV BIOLOGY

D Moss BSc PhD

P Crooks BSc(Hons)

J Johns BSc(Hons)

V Lutzky MSS PhD

M Martinez DipAppSc

L Morrison CBLT

N Stevens BScBiotech

IMMUNOLOGY AND INFECTION

C Engwerda BAgrSc(Hons) PhD

F Amante BSc(Hons) PhD

F De Labastida Rivera BSc(Biotech) GradDipBiotech

MBiotech

K Evans BMedChem PhD

A Haque BA(Hons) PhD

L Randall BSc(Hons) (to Sep 08)

A Stanley BSc(Hons) PhD (to Apr 09)

IMMUNOVIROLOGY

A Suhrbier BA(Hons) PhD

I Anraku BSc(Hons) PhD

S Cozzi BAppSc(Hons) PhD

J Gardner BAppSc

C James BBiotech MA

T Le BAppSc GradDipBiotech

L Major BAppSc(Hons)

W Schroder BSc(Hons) PhD

MOLECULAR IMMUNOLOGY

M Good BSc(Med) MBBS(Hons) PhD MD

DSc FASM FAFPHM FRACP(Hon)

FAIM

R Anderson

A Caudron BSc MPhil (to Dec 08)

S Cavaignac MSc PhD (to Apr 09)

V Kienzle BSc(Hons)

X Liu BMed MMedSc

V McPhun BSc MSc

D Mitchell BSc(Hons)

C Olive BSc(Hons) PhD

A Pinzon-Charry MD PhD

M Wykes BSc(Hons) PhD

M Yong BBiotech(Hons) (to Jan 09)

MOLECULAR VACCINOLOGY

D Doolan BSc(Hons) MPhil PhD

S Apte BSc(Hons) PhD

K Buttigieg BBioTech

F Caldas Cardoso BSc MSc PhD

P Day

P Groves BAppSc

A Trieu BBiotech(Hons) PhD

TUMOUR IMMUNOLOGY

R Khanna BSc MSc PhD

L Beagley BSc

T Crough BSc(Hons) PhD

D Elhassen BSc MSc PhD

L Heslop BBiomedSc(Hons)

D Hoang-le BSc(Hons)

L Jones

J Peet BAppSc(Hons)

M Rist BSc(Hons) PhD (to Dec 08)

C Smith BSc(Hons) PhD

F Soldevila Casals BBiotech/BBiochem (to Aug 08)

N Tellam

J Tellam BSc(Hons) MSc PhD

S Walker BAppSc (to Nov 08)

K Wynn BSc(Hons) (to Mar 09)

J Zhong BSc PhD


Division Chair: J McCarthy

BACTERIAL PATHOGENESIS

K Sriprakash BPharm MPharm PhD

B Duell BSc(Hons) (to May 09)

M Georgousakis BSc(Hons) PhD

D McMillan BSc(Hons) PhD

N Rosenzweig BBioSc (to Apr 09)

J Shera BSc(Hons)

T Vu BAppSc(Hons)

BACTERIAL VACCINES

M Batzloff BSc(Hons) PhD

J Cox BSc GradDipBiotech MAppSc

(to Mar 09)

J Hartas BAppSc

G Magor BSc(Hons)

J Malcolm BSc(Hons)

M Pandey BSc MSc PhD

S Sekuloski BSc(Hons) PhD


CLINICAL TROPICAL MEDICINE

J McCarthy MBBS FRACP MD

K Andrews BSc(Hons) PhD (to Dec 08)

A Butterworth BSc(Hons)

M Ho BSc(Hons)

D Jones BAppSc(Nursing)

M Kuwahata BA BAppSc MSc

L Melville BA BSc

C Pasay BS MSc PhD

A Robertson BSc(Hons)

E Siu BSc BA (to Aug 08)

L Tran BSc(Hons)

HELMINTH BIOLOGY

A Loukas BSc(Hons) PhD

A Aziz

L Cooper ADCLT BAppSc

S Gaze BSc MSc PhD

P Giacomantonio BSc (Hons) (to Feb 09)

H McSorley MSc PhD

M Meuleman

J Mulvenna BSc(Hons) PhD

M Pearson BSc MSc PhD

D Pickering BAppSc(Hons)

N Ranjit BBiotech(Hons) (to Aug 08)

D Smyth BSc(Hons) PhD

L St Pierre BAppSc(Hons) PhD

M Tran BSc GradDipClinBiochem PhD

L Tribolet BAppSc GradDipBiotech

HIV MOLECULAR VIROLOGY

D Harrich BSc PhD

A Apolloni BSc PhD

H Sivakumaran BSc(Hons) PhD

D Warrilow BSc(Hons) PhD

T Wei BAgrSc MAgrSc PhD

MALARIA BIOLOGY

D Gardiner BAppSc PhD

K Anderson CBLT

T Skinner-adams BSc(Hons) PhD

K Trenholme BSc MSc PhD

MALARIA DRUG RESISTANCE AND CHEMOTHERAPY

Q Cheng BMed MMed PhD

L Bain BSc

A Codd BE(Hons) MSc(Hons) PhD

(to Jun 09)

M Gatton BSc(Hons) PhD

K Gresty BSc(Hons)

A Pelecanos BBioinformatics BSc(Hons)

W Sharrock BSc(Hons)

F Teuscher BPharm PhD

N Walpole Cert3 Bus AdminCert3 Animal Serv

MOLECULAR GENETICS

P Upcroft BSc(Hons) PhD

A Burgess BSc MSc(Hons) PhD

L Dunn BSc(Hons) PhD

K Krauer BSc PhD

J Upcroft BSc(Hons) PhD

MOLECULAR

PARASITOLOGY

D McManus BSc(Hons) PhD DSc

M Duke AssDipFarmMgt

M Ellis BSc(Hons) MSc PhD

G Gobert BSc(Hons) PhD

D Gray BSc MSc GradCertPublicHlth PhD

Y Li MD PhD

J Li BPharm PhD

L Moertel BBiomedSc(Hons) PhD

W Zhang BSc PhD

MOSQUITO CONTROL

P Ryan BSc(Hons) PhD

C Cheah BBiotech(Hons) (to Mar 09)

J Darbro BA MS PhD

P Fraley

L Hugo BSc(Hons) PhD

T Hurst BSc(Hons) PhD

J Jeffery BSc(Hons) PhD

B Kay BSc(Hons) PhD AM FAA

G Lu BAgrSc MAgrSc MVetSc PhD

L Maddock BSc MEntomology (to Apr 09)

K Marshall

J Monkman BSc(Hons)

B Trewin BSc(Hons)

PARASITE CELL BIOLOGY

M Jones BSc(Hons) PhD

E Lovas BAppSc(Hons)

PROTEIN DISCOVERY CENTRE

J Gorman BSc PhD

J Chicher BSc MSc

K Dave BSc(Hons) MSc

A Diseberg BSc(Hons)

H Goswami BSc(Hons) (to Jul 08)

B Hamilton BSc(Hons) PhD (to Jul 08)

M Hastie BAppSc(Hons) PhD

M Headlam BSc PhD

H Jiang BSc MSc PhD

N Patel BPharm (to Feb 09)

M Plan BAgrSc GradDipAgrStud PhD

E Redhead BSc(Hons)

C Wright BSc(Hons)

Scabies

D Kemp BSc(Hons) PhD FAA



K Fischer PhD

M Johnstone BSc(Hons) PhD

A Mika BSc MSc PhD

Y Zhou BMed DipAppSc

MENTAL HEALTH RESEARCH DIVISION

M Breakspear BSc(Med) BA(Hons) MBBS(Hons)

PhD

N Quirk

Q-GEN

J Youngson BSc PhD

K Aliabadi zadeh DVM PhD (to Oct 08)

M Bleasdale BSc(Hons) (to Feb 09)

K Bouyer BAppSc (to Jan 09)

B Butcher DipElect CertBiomedEngTech

(to Feb 09)

G Butterworth BSc(Hons) (to Mar 09)

W Chung BSc(Hons) PhD (to May 09)

S Collett BAppSc(Hons) (to Mar 09)

J Crowley RN (to Dec 08)

T Dex BBiotech(Hons) (to Mar 09)

A Evans BSc(Hons) (to Mar 09)

M Gerometta BAppSc(Hons) PhD (to Mar 09)

S Johnson RN (to Nov 08)

A Jordan BAppSc (to Jan 09)

P Kearns BAppSc(Hons) PhD (to Feb 09)

F Khan BA BSc MSc (to Sep 08)

M Leaf (to Aug 08)

N Martinez BSc(Hons) PhD (to Aug 08)

M Mcintyre AssocDipAppSc (to Mar 09)

A McLean BAppSc(Hons) GAICD (to Aug 08)

M Muroa (to Sep 08)

J Ridgewell (to Jan 09)

M Sheridan BSc (to Aug 08)

R Sinha BBiomedSc MAppSc (to Mar 09)

P Toh BSc

A Tolstoff BAppSc (to Sep 08)

J Uksanovic-Barnjak DipVetFoodSc DipLabTech

J Williamson (to Nov 08)

L Wilson (to Oct 08)

K Windle BBiotech(Hons) (to Sep 08)

ACITH (JOINT WITH UQ)

B H Kay BSc(Hons) PhD AM FAA

P Fraley

CORPORATE DIVISION

GENERAL MANAGER

J Tarr BA JD LLM PhD

CHIEF COMMERCIAL MANAGER

D Hancock BComm MBA

ASSISTANT SECRETARY

N Fox

EXECUTIVE SECRETARY TO GM

B Wanrooy

ADMINISTRATION

C Green CertBus

D Gunn

S Hunting

T Laing BA

D Meaclem

R Meaclem CertBus (to Sep 08)

M Randle CertAdminFinance

DipBasicOperations DipBasicMgt

G Sriprakash

P Verso BBus DipConservLandMgt

BUSINESS DEVELOPMENT

G Haaima BSc(Hons) PhD MBA

J Fox BSc PhD

FINANCE

G Cunningham BBus(Acc)

M Cornell BBus (to Jun 09)

L Lin BLit MComm GradDipMgt

Y Marcinkus (to Oct 08)

C McNally

K Moran

M Stromberg

A Valentine

GRANTS

L Casey BSc GDTh

K Dry DipMgt

B Dunphy BBus(Acc)

D Evans

J Whybird BBus(Acc) GradDipAdult Voc Ed

HUMAN RESOURCES

T Greenaway BComm GradDipPsych

M Anderson CertBus

P Buratowski

N Green BBus(HRM) MBA (to Sep 08)

E Horsfi eld DipBus

L Lane

P Pekhu

M Weaver AdvDipBus(Acct)

PURCHASING

S Wood CertTransportWarhouseDistrib

M Eaton CertTransportWarhouseDistrib

RECORDS AND INFORMATION SERVICES

N Kremko

O Griffi ths BA

L O’Mahoney

REGULATORY AFFAIRS

A Mitchell BSc(Hons) PhD

J Chow BA BSc MPH


R Lacey

B Rosser BAppSc BA MHlthSc (to May 09)

SCIENTIFIC SERVICES

J A Cooper BSc MSc PhD GCertMgt

A Allester

D Bain (to Mar 09)

J Bonnily (to Feb 09)

J Canning CertLabAnCare (to Nov 08)

J Carter (to Mar 09)

S Cassidy CLabAnCare CertTrainAsses

A Dorrington

G Chapman BSc MSc PhD

G Chojnowski BAppSc

P Collins BSc(Hons)

R Collins CertBioLabTech

A Cross CertAnimalServ

C Cross

G Cuthbert BNurs CertTrainAsses

C Dickfos CertLabCare AssDipAppSc

M Edmundson BSc MSc

N Felder

B Fewster

A Girle CertTransportWarhouseDistrib

S Gregg CertAnimalTech

C Groennou CertAnimalTech

A Hale

P Hall BSc

S James Cert Companion Animal Services

Cert Childrens Services

T Kent

V Matthews

M McDade CertTransportWarhouseDistrib

M McInnes CertAnimalCare (to Feb 09)

D McNeilly CerLAnimalTech

A O’Regan Cert Companion Animal Services

S H Park DipClinPath

H Platt Cert Companion Animal Services

(to May 09)

G Rees CertDiagnosticCytology

AssDipClinLabTechniques

DipOccHlthSfty

T Scown CertAnimalTech

I Shiels BVSc MACSVSc PhD

A Smith BAppScNur (to Aug 08)

J Sutton CertCompanionAnimalServices

L Thompson

S Watkins

C Winterford AssDipAppBiol

BUILDING AND SECURITY

A Stockman HND (Elec Eng) HTC (Plant)

M Bugden TradeCert(Refrig)

J P Fahrner CKennel/CatPrac

G Madders ElectricMechanic/Fitter

A McKee AssocDipElectEngineer

D Patrick AssocDipElecEngineer

R Tyrrell EngFitter

SAFETY

H Leonard BSc MSc PhD WHSO RSO

M Richards BSc GradDipSc WHSO RSO

INFORMATION TECHNOLOGY

C Ward ADAB GradDipCommComp MACS

M Creevey BEng

M Feodoroff BInf MCSE HP AIS

D James

S Jaremczuk BBiolSc MBA MInfSys

P Kaim BAppSc

X Lin GradDipIT BEng MEng PhD

V Mar COBC CCSA CSA HP-UX

A Nutley-Govaerts BAppSc MCP

A Orreal CertBusAdmin DipITNetwork

(to Feb 09)

A Stevens

L Ward BInfoTech

EXTERNAL RELATIONS

V Johnson GradCertMktg MBus BA

H Astbury GradCertBus

F Beltran BBusMktPR (to Dec 08)

E Carroll CertTextilesClothing (to Sep 08)

S Cross BSc(Hons) DipEd MSc

G D’Adam GradCertBus (to Sep 08)

A Dignan

M Gampbell (to Nov 08)

J Gill BComm

A Hall Bbus

M Kersting BFA Medical Illustration

H Matthews BA CertPhotography

A McGaw

M O’Hara

J O’Keefe BAppSc DipBusComm

M Quince DipBus

T Scanlan

J Stockman

S Tennant BAdvSc(Hons) GradDipScComm

GradDipSecEd MEnvSc&Law

V Torres CertBus

A Van Der Beek BBusComm

VISITING SCIENTISTS


R Arden BA(Hons)

R Ataee Pharm D

C Bain BSc MBBS MPH MS

T Bates BA MA PhD



J Batra BSc MSc PhD

W Coventry BAgrSc GradDipSocSc BA(Psych)

(Hons)

E Fearnley BEnvHlth PhD MAppEpi

C Filippich BAppSc

J Flanagan BSc(Hons) PhD

T Flatscher-Bader BSc(Hons) PhD

N Gillespie BA(Hons) PhD

D Goldgar BA MD PhD

J Gratten BSc(Hons) PhD

E Hacker BSc MSc PhD

A Hadley BMed(Hons)

P Hatemi BS BA MA PhD

A Heath BA PhD

A Hewitt BSc(Hons) DipSc

E Holliday BSc(Hons)

K Holohan BSc(Hons)

S Jordan MBBS(Hons)

N Kaminen-Ahola MSc PhD

J Keith BMath(Hons) PhD

M Larsson BSocSc PhD

M Lynskey BSc(Hons) MSc(Psych) PhD

D Mackey MBBS MD FRACS FRANZCO

P Madden BS MS PhD

S Manning

G Miller BA PhD

B Mowry MBBS BA(Hons) FRANZP MD

E Nelson BA MD

G Radford-Smith BA MBBCh MRCP FRACP PhD

H Rangappa MBBS MPH

V Relan BSc MSc PhD

J Riley

S Sadeghi MD GradDipPubHlth PhD

W Slutske BA (Psych) BSc(Psych) PhD

H Smith BSc

J Stirling MPrimHlthCare

R Sturm BSc(Hons) PhD

D Tam MBBS BPhar

S Treloar BSocStud MSc MSocWk PhD


R Aizawa MD

J Aylward BSc MSc PhD

G Beadle MBBS FRACP FRACR

R Buttenshaw CertChem

V Catts BSc(Hons) PhD

D Chin MBBCh FRCSI PhD

R Clarke BSc(Hons) PhD

M Coulthard MBBS FRACP FJFICM PhD

M Cummings MBBS FRCPA PhD FIAC

L Da silva MD

L Fletcher BSc(Hons) PhD

F Gardiner MBBS FRCS FRACS MD

A Hallahan BSc MBBS DipPaed

M Heritage BBiomedSc(Hons) PhD

W Ingram BSc(Hons) PhD

T Ishii MBBS PhD

L Jaskowski ADCLT

J Jayanthan BSc(Hons)

P Keith BSc MPhil

S Lakhani BSc(Hons) MBBS MRCP MD FRCP

P Lewindon MBBS MRCP FRACP

P Li BSc

C Loo BMedSc MBBS PhD

G Macdonald MBBS(Hons) FRACP

P Masci BSc MQual MBiochem

T Murphy BSc MSc

R Murray BBioSc MAppSc

S Ogbourne BSc(Hons) PhD

P Pakkiri MBChB(Hons) MMedPath

C Peng MMed

S Reece MBBS FRACS FRCS MD FRACGP

L Reid BSc MSc(Qual)

R Shepherd MBBS MRCP MD FRACP

P Simpson BSc PhD

C Smart BSc(Hons) PhD

J Smith BSc PhD

L Teng BSc(Hons)

A Umapathy BSc(Hons) Mbiotech

S Vuckovic BSc MSc PhD

D Walker BMedSc MBBS(Hons)

V Whitehall BSc(Hons) PhD

K Zhao BSc MSc PhD


PHD SCHOLARS

QIMR

SUPERVISOR

A Abdel-Aal BSc MSc M Batzloff

N Abdul Murad BSc MMSc M Lavin

B Appleyard BSc(Hons) MPH J McCarthy

S Arabshahi

BSc MSPh

GradDipPubHlth A Green

L Bain BSc(Hons) K Khanna

J Balen BSc (Hons) D McManus

G Blokland MSc N Martin

C Bond BPhysio MSc B Leggett

R Brennan BSc(Hons) S Burrows

M Burke BBiomedSc D McManus

E Byrne BA(Hons) P Visscher

T Chuah BMedSc MBBS M Lavin

V Dasari BSc MSc R Khanna

P Driguez BSc(Hons) D McManus

K Dutton-Regester BAppSc(Hons) N Hayward

L Fernandez BAppSc(Hons) J McCarthy

I Gillions BAppSc(Hons) A Lopez

A Glanfi eld BSc(Hons) M Jones

D Hall BSc(Hons) MBBS P Parsons

J Hancock BAppSc(Hons) M Lavin

J Hansen BSc(Hons) N Martin

C Jekimovs BAppSc(Hons) K Khanna

J Johnson BSc(Hons) G Trench

M Jones BSc(Hons) K Khanna

M Kvaskoff MPH D Whiteman

S Lane MBBS(Hons) A Boyd

E Leddy BAppSc(Hons) N Subramaniam

PHD SCHOLARS

QIMR

SUPERVISOR

N Lee BBiotech(Hons) J McCarthy

Y Lim BSc(Hons) M Lavin

Y Lu BEcon(Hons) MSc P Visscher

K Markey BEng(Chem)(Hons) G Hill

Nico Martin BSc MSc N Martin

P McBride BMedSc MBBS A Green

J McCarron BAppSc(Hons) A Boyd

N McDougall BAppSc(Hons) P Parsons

L Meredith BSc(Hons) D Harrich

S Moore BHlthSc MPH A Green

B Morrison BABiology MSc A Lopez

M Mosing BPsych Mpsych N Martin

D Muslim BSc(Hons) N Subramaniam

S Nawaratna MBBS(Hons) MPhil M Jones

P Nguyen BMed MPH P Ryan

N Pandeya

BSc GradDipAppSc

MMedSc D Whiteman

C Peatey BSc(Hons) D Gardiner

K Phillipps BBiotech(Hons) M Good

A Redmond MBBS D Doolan

M Reiter BSc(Hons) C Schmidt

S Reynolds BSc(Hons) A Loukas

N Richmond BAppSc(Hons) A Green

R Robb BSc(Hons) G Hill

A Roberts BBiomedSc(Hons) E Whitelaw

M Rubinov MBBS BMedSc M Breakspear

M Sa’Ariwijaya BSc(Hons) MSc M Lavin

M Sheel BSc(Biotech) M Batzloff

RESEARCH STUDENTS AT

QIMR AS AT JUNE 2009

Left to right: Jacinta Simmons, Ken Dutton-Regester,

Rebekah Brennan, Sally Mujaj, Michelle Neller, Denny

Muslim, Jatin Patel, Imogen Gillions, Julie Johnson


PHD SCHOLARS

QIMR

SUPERVISOR

J Simmons BBiotech(Hons) K Khanna

K Smith MBChB D Whiteman

M Smout BSc(Hons) A Loukas

S Tey

MBBS(Hons) FRACP

FRCPA R Khanna

P Tran BMed MPH P Ryan

T Tran BSc(Hons) J McCarthy

C Verweij BPsych MSc N Martin

K Warren BMedSc(Hons) D Harrich

N Wayte BSc(Hons) G Trench

N Whitelaw BSc(Hons) E Whitelaw

M Wood MBBS RACP G Ramm

D Worthley MBBS(Hons) B Leggett

H You BSc MSc D McManus

B Zietsch BPsychSc(Hons) N Martin

MASTERS SCHOLARS

QIMR

SUPERVISOR

S Anderson BBioSc MBBS P Parsons

R Barr BEcon BAppSc MBBS P Parsons

P Faleiro BSc M Good

B Jayakody

Arachchige BSc J Gorman

B Kendall MBBS D Whiteman

D Menon

BSc GradDip

MicrobialBiotech K Khanna

M Miranda BSc B Leggett

S Ratnakar BTech MSBiotech J McCarthy

K Thelakkat BSc M Lavin

M Tomasella BHlthSc MPH G Garvey

M Vinod BSc K Khanna

L Whop BAppSc G Garvey

HONOURS STUDENTS

QIMR

SUPERVISOR

M Bauer BBiotech K Sriprakash

J Chaplin BMath BSc G Montgomery

W Fernandes BSc A Loukas

I Ferriera BSc A Loukas

R Foale BAppSc P Parsons

T Hanrahan BSc D Harrich

T Harding BAppSc K Sriprakash

H Lim BSc J McCarthy

J Liu BEcon BSc P Visscher

L McGarvey BSc D McManus

S Morgan BBiomedSc K Sriprakash

D Pattinson BSc D Doolan

M Perumalpillai-

McGarryBSc M Jones

J Rami BBiotech A Loukas

N Ross BAppSc M Gandhi

B Rutherford BAppSc P Ryan

L Schulte BSc M Jones

R Stewart BBiomedSc M Lavin

L Yong Ming BBiotech A Loukas


AASLD American Association

for the Study of Liver Diseases

ACITH Australian Centre for

International and Tropical Health

ACVD Australian Centre for

Vaccine Development

AHMRC Aboriginal Health and


AIDS Acquired Immune

Defi ciency Syndrome

AMATA Australasian Microarray

and Associated Technologies

Association

ANU Australian National

University

AOA1 Ataxia with oculomotor

apraxia type 1

AOCS Australian Ovarian

Cancer Study

APC Antigen presenting cells

APHA Australian Private

Hospitals Association

API Antiretroviral protease

inhibitors

ARC Australian Research

Council

ASARCO American Smelting

and Refi ning Company

ASIP Agouti signalling protein

A-T Ataxia-telangiectasia

ATM Ataxia-telangiectasia

mutated

BCC Basal cell carcinoma

BRCA Breast cancer gene

CDKN2A Cyclin-dependent

kinase inhibitor 2A

CF Cystic fi brosis

CMR Centre for Magnetic

Resonance

CRCAH Cooperative Research

Centre for Aboriginal Health

CSIRO Commonwealth

Scientifi c and Industrial

Research Organisation

CSLD Chronic suppurative lung

disease

CT Computed axial tomography

CTL Cytotoxic T lymphocyte

CVD Cardiovascular disease

DC Dendritic cells

DNA Deoxyribonucleic acid

EBV Epstein-Barr virus

ENU N-ethyl-N-nitrosourea

EVC Emory Vaccine Centre

FACS Fluorescence-activated

cell sorter

FAS Fetal alcohol syndrome

Fd Ferrodoxin

GAS Group A streptococcus

GC Germinal cell

G-CSF Granulocyte colony

stimulating factor

GFP Green fl uorescent protein

GGS Group G streptococcus

GITR Glucocorticoid-induced

tumor necrosis factor receptor

GMP Good manufacturing

practice

GMRC Griffi th Medical

Research College

GU Griffi th University

GVHD Graft-versus-host

disease

GVL Graft-versus-leukaemia

GWAS Genome-wide

association study

HCC Hepatocellular carcinoma

HCMV Human cytomegalovirus

HDC Higher Degrees

Committee

HGSA Human Genetics Society

of Australasia

HIF Hypoxia inducible factor

HIV Human immunodefi ciency

virus

HL Hodgkin’s lymphoma

HLA Human leukocyte antigen

HPS Hyperplastic polyposis

syndrome

IL-2 Interleukin 2

IMB Institute of Molecular

Bioscience

JCC Joint Consultative

Committee

JCU James Cook University

LAW cohort Longitudinal

Ageing Women’s cohort

LDRL Liver Disease Review

Letters

MALVAC Malaria Vaccine

Advisory Committee

MBL Mannose-binding lectin

MCP-1 Monocyte chemotaxis

protein-1

MDR Multi-drug resistant

MEGA Epidemiology Molecular,

Environmental, Genetic &

Analytic Epidemiology

MGE Mobile genetic elements

MHC Major histocompatibility

complex

MIC-1 Macrophage inhibitory

cytokine 1

MLPA Multiplex ligation-

dependent probe amplifi cation

MLST Multilocus sequence

typing

MRC Medical Research Council

mRNA Messenger ribonucleic

acid

MS Multiple sclerosis

MYH MutY homologue

NCI National Cancer Institute

NCRIS National Collaborative

Research Infrastructure

Strategy

NHMRC National Health and


NIAID National Institute of

Allergy and Infectious Disease

NIH National Institute of Health

NKT-cell Natural Killer T-cell

NPC Nasopharyngeal

carcinoma

PACMISC Pacifi c Malaria

Initiative Support Centre

PCA3 Prostate cancer gene 3

PDC Protein discovery centre

PET Positron emission

tomography

PFOR Pyruvate ferredoxin

oxidoreductase

PHERP Public Health

Education and Research

Program

PTEN Phosphatase and tensin

homologue

PTLD Post-transplant

lymphoproliferative disease

QTL Quantitative trait locus

QUT Queensland University of

Technology

RBWH Royal Brisbane and

Women’s Hospital

RDT Rapid diagnostic test

RISS Research Infrastructure

Support Services

RNA Ribonucleic acid

RSV Respiratory synctival virus

RT-PCR Reverse transcription

polymerase chain reaction

SCC Squamous cell carcinoma

SMIPP Scabies mite inactivated

protease paralogue

SNP Single nucleotide

polymorphisms

SPH School of Population

Health

TCR T-cell receptor

TLR Toll-like receptor

TNF Tumour necrosis factor

UK The United Kingdom

UNESCO United Nations

Educational, Scientifi c and

Cultural Organization

UQ The University of

Queensland

UVR Ultra violet radiation

VIPBG Virginia Institute for

Psychiatric and Behavioural

Genetics

WEHI Walter and Eliza Hall

Institute

WHO World Health

Organisation

YSA Young Scientist of

Australia

ACRONYMS


QIMR - Annual Report 2008-2009 QIMR - Annual Report 2008-2009

AbOUT UsQIMR is one of Australia’s largest and most successful medical research institutes. Our researchers are investigating the genetic and environmental causes of more than 40 diseases as well as developing new diagnostics, better treatments and prevention strategies. The Institute’s diverse research program extends from tropical diseases to cancers to Indigenous health, mental health, obesity, HIV and asthma.

OUR VIsION better health through medical research.

OUR MIssION To prevent and cure disease through research.

OUR PHILOsOPHy QIMR supports scientists who perform world-class ethical medical research aimed at improving the health and well-being of all people.

OUR LOgO The QIMR logo is comprised of superimposed benzene rings which symbolise one of the fundamental molecular arrangements of the chemicals which make up living things.

Director – Professor Michael good AO

Deputy Director – Professor Adèle green AC

www.qimr.edu.au | [email protected]

1800 993 000

Cover Image: Close up of neuron network

Inside Cover Image: Rebekah Brennan, PhD student Cellular Immunology Laboratory - Immunology Division

300 Herston Road, Herston QLD 4006, AustraliaT: 1800 993 000 E: [email protected] www.qimr.edu.au

Project Manager sarah Tennant

Compilation Jann O’Keefe Editing sarah-Jane Matthews

Design Rowland

Graphic Support Mimi Kersting

Photography Heather Matthews Tony Phillips

Published October 2009

Copies can be obtained by phoning 1800 993 000 or [email protected]

Online version available at www.qimr.edu.au

ANNUAL REPORT

2008-09300 Herston Road, Herston QLD 4006, Australia

P: (+61) 7 3362 0222 F: (+61) 7 3362 0111 www.qimr.edu.au [email protected]

ANNUAL REPORT

2008-09

QIM

R A

NN

UA

L RE

PO

RT 2008-09

ANNUAL REPORT 2008-09 - parliament.qld.gov.au · ANNUAL REPORT 2008-09 300 Herston Road, Herston...

Documents

Transcript of ANNUAL REPORT 2008-09 - parliament.qld.gov.au · ANNUAL REPORT 2008-09 300 Herston Road, Herston...